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1. Introduction 
1.1 Epidemiology  
Myasthenia gravis (MG) is a rare neuromuscular autoimmune disease the cause of 
which remains unknown [87]. However, what is well established is the role of 
pathogenetic circulating antibodies targeting the nicotinic acetylcholine receptor. 
Occurring in all races, in both genders of all ages MG has developed from being a 
severe disease with a mortality of 70% [60], to being, in most cases, a disease that can 
be effectively treated. As a result of optimal treatment, the disease can be managed 
satisfactorily in most instances with a good long-term prognosis and a normal life 
expectancy [135, 175]. 
A large number of MG epidemiological studies have been performed worldwide over 
the past 60 years. Norway has contributed to this research from the first nationwide 
Norwegian published paper on MG epidemiology in 1966 to recent studies [9, 72, 183, 
184, 195]. Even though studies from all continents are represented, there is a 
preponderance of European studies, in particular from Scandinavia, the UK and Italy.  
1.1.1 Prevalence and incidence 
Reported MG prevalence has increased over time from 15 per million in 1951 [183] to 
240 per million in 2012 [123]. Despite variations, there is a clear trend towards an 
increase in MG prevalence over time.  This increase can in part be explained by 
increased survival for MG patients, in part by population cohorts with more elderly 
people and less children. In Norway, two recently published studies reported 
prevalence of 131 and 145 per million respectively [9, 72], and with good concordance 
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between the two databases used [10]. For publications during the last five years, the 
MG prevalence has ranged between 117 and 240 per million [27, 41, 54, 123, 137].  
Reported annual MG incidence has also increased from 4.0 in the period 1951-1981 
[184], to a report of 24.9 per million in 2012 [54]. Published MG incidence during the 
last five years has ranged between 14.8 and 24.9 per million [54, 100, 137]. When 
AChR-antibody assays were introduced in 1976, one could expect the heterogeneity in 
MG incidence to be reduced, but there is no evidence for this. However, the MG 
incidence rates increased significantly with approximately a doubling after the 
introduction of this assay [25].  
The increase in MG incidence can partly be explained by improved diagnostics and 
case ascertainment and the change in demographics with an ageing population and 
lower birth rates. Nevertheless, it is probably also a genuine increase in MG incidence 
due to environmental and genetic factors. In Italy, two studies were carried out within 
the same region and with a similar study design over a twenty-year interval, and found 
an increase in both incidence and prevalence from 7.4 to 14.8 per million and 82.0 to 
129.0 respectively [48, 137]. In two studies from UK [205] and Greece [147], with 
identical study design and over the same time of period, there was a marked difference 
in incidence; from 4.8 per million in the Greek study and 18.0 per million in the UK 
study. The difference might point to genetic and/or environmental causative factors, 
although medical practice and access to specialist examinations probably also differed 
between the two countries. 
1.1.2 Gender Characteristics 
The MG incidence was for many years described with a peak in the 2nd and 3rd decade 
for women, and peaking in the 6th and 7th decade for men [39, 147].  In recent years, 
some studies have demonstrated a two-peaked MG incidence for women, and with a 
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ratio close to 1:1 in the 6th and 7th decade [9, 72, 137], some studies have not identified 
any early peak for women [54, 100] but a steady increase in MG incidence and a peak 
for both genders in the 6th and 7th decade. In a systematic review of epidemiological 
studies of MG, the bimodal pattern for women was observed in 5 of 14 studies [25]. 
Particularly, this was found in studies from Scandinavia, the UK and Italy. The 
frequency of older individuals with MG is probably greater than previously thought for 
both genders [62, 180, 205].  
Age at first-time positive AChR-antibody test in the total population, females and males. 
Heldal, A.T, 2009; Seropositive myasthenia gravis: a nationwide epidemiologic study [72] 
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1.2 Diagnosis of MG 
1.2.1 Clinical features 
The most frequent initial MG symptoms are ptosis or diplopia. The disease becomes 
generalised in a various proportion of the patients, depending on the population. 
Predominantly, MG affects oropharyngeal and/or respiratory muscles or limb and/or 
axial muscles, the latter being the most common [60, 120]. Patients with MG also 
often describe pathological fatigue, differentiated from normal fatigue because it does 
not subside with rest [94]. Pathological fatigue is also well documented in patients 
with other autoimmune diseases, such as multiple sclerosis [151]  and rheumatoid 
arthritis [202]. There are a number of differential diagnoses, including brain stem 
pathology, amyotrophic lateral sclerosis, multiple sclerosis, polymyositis, muscular 
dystrophy, mitochondrial myopathies and general fatigue. Especially in very old 
patients, MG can be overlooked or misdiagnosed. Symptoms such as slurred speech, 
difficulty in swallowing and dysphagia, have many potential explanations in elderly 
people [43, 107, 122, 205]. In addition, elderly patients have more comorbidity than 
younger patients, which can make the symptoms more difficult to identify. Moreover, 
ocular symptoms as ptosis and diplopia are common clinical signs at MG onset, and 
are easier to detect in a more youthful appearance. Ptosis can be difficult to spot 
because of a decrease in the total eyelid area with sagging of the lower eyelids, as a 
result of ageing. Macular degeneration or cataract formation can impede the detection 
of diplopia [2].  Pure ocular symptoms may be due to ocular myopathies or 
neuropathies as neuromyelitis optica [208]. In younger patients, MG could be 
misinterpreted as multiple sclerosis, brain stem infarction, psychiatric conditions or 
general fatigue. Other neuromuscular diseases should also be considered, such as 
Lambert Eaton myasthenic syndrome and genetic myasthenic syndromes. 
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The most important tool in clinical examination is the patient history and the 
identification of any fluctuations over the course of the day. A ptosis test may reveal 
ocular weakness (ability to maintain gaze fixed upwards or laterally for up to 30 
seconds). Axial muscles should be tested specifically. A simple test to reveal weakness 
in proximal limb musculature is by holding an arm stretched out for a defined period 
of time. Bulbar manifestations including speech and swallowing should be examined. 
Weight loss can be a sign of bulbar affection. Symptoms of respiratory insufficiency 
represent severe MG with increased risk for the development of a myasthenic crisis. 
1.2.2 AChR-antibody testing 
The presence of AChR-antibodies is specific for MG, with some rare exceptions as 
explained in the section above. MG with a positive AChR-antibody test is in this thesis 
called anti-AChR MG. AChR-antibody measurements should always be undertaken 
when MG is suspected. The most common immunological test measures the amount of 
antibodies in serum that precipitates AChRs. This is detected by radioimmunoassay 
with 125I-a-bungarotoxin-labeled AChR. Further aspects of the AChR-antibodies and 
the method of testing will be discussed under the “Pathophysiology of anti-AChR 
MG” and “AChR database” sections, page 31 and 44 respectively. 
1.2.3 Pharmacology 
A suspected case of MG can be tested by response to the oral administration of an 
acetylcholinesterase inhibiting (ACh-I) drug (pyridostigmine). If a marked objective 
improvement occurs, this will be a rather specific and significant proof of MG. This is 
diagnostically most important in cases in which no antibodies are detected. 
Intravenous administration of the ACh-I edrophonium, Tensilon-test [134], was 
previously an integrated part of the diagnostic procedure, but has recently been phased 
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out in many clinics as the drug is not easily available, the test is time-consuming, and 
other methods of equal efficacy are employed, antibody- testing in particular. 
1.2.4 Neurophysiology 
Neurophysiological tests in the diagnosis of MG include repetitive nerve stimulation 
(RNS) and single fiber electromyography (SFEMG). In MG, the safety factor (defined 
as the difference between the end plate potential (EPP) and the threshold potential to 
initiate an action potential) is reduced, and during RNS, some EPPs may not reach 
threshold resulting in no action potential to occur. This results in the decrement in 
amplitude of the compound muscle action potential, thus being the basis for the 
decremental response in RNS. A positive RNS test is defined as a >10 % decremental 
response having the patient contract the muscle maximally for 10 to 60 seconds or by 
delivering a high-frequency train of stimuli with 3-5 Hz repetitive stimulation [78]. 
The maximal decrease in ACh release occurs after the first four stimuli. RNS is a 
technically difficult procedure, and the sensitivity and specificity will depend on the 
operator and the number of muscles tested. However, when affected muscles are 
tested, and the test properly conducted, the specificity of RNS is approximately 95% 
for both generalized and ocular MG. The sensitivity is reported as less than 30% in 
ocular MG and approximately 80% in generalised MG [78]. 
SFEMG is based on simultaneous recording of two muscle fiber action potentials 
generated by a single motor neuron. The difference between the firing of one muscle 
fiber action potential compared to the other in time is termed neuromuscular jitter. The 
jitter is increased in MG patients. SFEMG is considered as the most sensitive 
diagnostic test for detecting pathological neuromuscular transmission. For generalised 
MG, the sensitivity and specificity of SFEMG have been reported as 79% and 97% 
respectively. In ocular MG, sensitivity has been reported as 29% and specificity 94% 
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[17, 78]. As for RNS, the sensitivity and specificity will depend on the muscles tested, 
and how thoroughly the neurophysiological examination is conducted.
1.2.5 Imaging 
Thymus pathology is typical for MG, and rarely linked to other autoimmune diseases 
[26]. All patients diagnosed with MG or suspected to have the disease, should undergo 
radiological examination of the anterior chest cavity to look for thymus pathology. 
Most important is it to differentiate thymic hyperplasia (lymphoid hyperplasia) and 
especially thymoma from the normal thymus.  The thymus gland is diffusely enlarged 
with the tissue similar to normal thymic tissue at both computer tomography (CT)-scan 
and magnetic resonance imaging (MRI). A normal-sized thymus gland on CT-scan 
does not exclude hyperplasia, and hyperplasia is difficult, often impossible, to 
diagnose by imaging. Thymoma is seen as a homogeneous lobulated soft-tissue mass 
in the anterior mediastinum. It can be difficult to distinguish between thymic 
hyperplasia and a thymoma. Contrast-enhanced CT-scan is the modality of choice for 
evaluation of thymomas [116]. The sensitivity of mediastinal CT for undifferentiated 
thymic pathology is approximately 90%. The sensitivity and specificity of CT-scan for 
thymus hyperplasia is reported as 36% and 95% respectively. The sensitivity for 
thymoma is reported as 89-100% and with a specificity of 77% [142, 212]. 
MRI can give useful additional information if suspicion of tumor spread with local 
infiltration of surrounding organs, if equivocal information first has been examined on 
CT [116, 167, 196].  
1.3 Subgroups of MG 
MG should be separated into several subgroups, reflecting pathogenesis and different 
considerations prior to therapeutic choices. The subgroups early-onset MG, late-onset 
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MG, MG with thymoma and ocular MG are relevant for this thesis, as these groups all 
have AChR-antibodies. The other subgroups either have pathogenetic antibodies 
against other muscle antigens or no detectable antibodies.  These subgroups will be 
discussed separately in the “MG with low-affinity AChR-antibodies and with non 
AChR-antibodies”-section, page 33. 
1.3.1 Early-onset MG 
Up to 1990, the cut off between early- and late-onset MG was set at 35-40 years of 
age. Based on more precise studies this delineation was increased to 50 years of age 
[180]. However, there are still studies that argue for early-onset MG to be defined as 
occurring prior to age 40 years [33, 168]. Our data support onset before or after 50 
years of age as the best distinction between the two subgroups early- and late-onset 
MG [9, 72, 137, 147, 205]. In Scandinavia, there is a preponderance of females in the 
early-onset MG group [72], however this preponderance has not been recognised in all 
studies (see “Gender characteristics”- section, page 12).  
Thymus hyperplasia with enlarged thymus is most common for early-onset MG with 
the occurrence of intrathymic lymphoid follicles and germinal centers [118, 155]. 
Early thymectomy is recommended as treatment, especially if thymus hyperplasia has 
been identified on their mediastinal CT-scan [61, 98, 175]. Approximately 90% of 
early-onset MG patients have AChR-antibodies, whereas titin-antibodies are detected 
only in 10% of such patients. Ryanodine receptor (RyR)-antibodies are seldom found 
[159].    
The main risk allele for early-onset MG is HLA-*B*08 [117], but also HLA class II 
region DRB1*16 is positively associated with early-onset MG. HLA class II 
DRB1*0701 is negatively associated with early-onset MG [213].  
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1.3.2 Late-onset MG 
This group is defined as patients with MG onset after 50 years of age. Alternatively, 
this subgroup is defined as onset after 40 years of age, as discussed in the early-onset 
section above. Late-onset MG has an equal gender distribution. Thymus is most often 
normal. Thymectomy is usually not recommended for this group, but may be 
recommended in patients with thymus hyperplasia [55]. Most often the patients have 
AChR-antibodies, approximately 60% of whom have titin-antibodies detected, and 
RyR-antibodies are detected in about 15% of the patients [159]. Late-onset MG is 
associated with HLA DRB1*15:01[117].  
The age limit to distinguish between early- and late-onset MG has implications for 
sensitivity and specificity for the two subgroups. It has also been suggested a cut-of at 
60 years of age for late-onset MG. There is a “grey-zone” in clinical, immunological 
and pathological terms between 40 and 60 years of age [118]. Age for cut-off is crucial 
when analysing and comparing data.  
1.3.4 MG with thymoma 
Thymomas are neoplasms derived from thymic epithelial cells, and these cells are 
mixed with non-neoplastic T-cells. MG is the most common thymoma-associated 
autoimmune disease, affecting 30-50% of patients with thymoma [93, 125, 155]. 10-
15% of  all MG patients have a thymoma [51]. Moreover, an additional 25% of 
patients with thymoma and no clinical symptoms of MG have circulating AChR-
antibodies in their serum [51]. Titin-antibodies are found in up to 95% of MG patients 
with thymoma, and antibodies against RyRs in 50-60% [118]. There is no typical onset 
age for MG-thymoma, but it is rarely diagnosed during the two first decades of life.   
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1.3.5 Ocular MG 
Approximately 10-20 % of MG patients have ocular MG, the remaining have a 
generalised form of MG [53, 60]. Ocular MG is a localised form of MG affecting the 
ocular and periocular muscles, thereby causing ptosis and diplopia. MG is defined as 
ocular if no non-ocular symptoms have appeared during the first two years after onset 
[175]. 30-70% of the patients with ocular symptoms as their debut, develop 
generalised symptoms during this period [60, 99, 178, 203]. It has been discussed 
whether there are clinical features at onset which can predict whether an individual 
patient`s ocular symptoms will convert to a generalised form. Some studies have found 
that the ocular MG patients usually are below age 65 years, and with milder symptoms 
than those with conversion to a generalised MG [60, 178]. This is an important issue 
because of the emerging evidence that early corticosteroid treatment may have a risk-
modifying effect. These studies are, however, flawed by suboptimal designs [210].  
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1.4 Treatment of MG 
1.4.1 Symptomatic treatment 
The initial treatment of MG is oral ACh-I. Such drugs inhibit the breakdown of ACh at 
the NMJ, increasing the amount of available ACh and thereby reducing the muscle 
weakness. Pyridostigmine is the most commonly used drug, but also neostigmine, and 
to a lesser degree ambenonium is used. Pyridostigmine has a higher bioavailability, 
slower onset, longer duration and produces fewer side-effects compared to equipotent 
doses of neostigmine [12]. This treatment is purely symptomatic and usually well-
tolerated at standard doses of up to 60 mg five times per day [175]. As the ACh-Is 
cause increased concentration of ACh at both nicotinic and muscarinic NMJs, typical 
side-effects occur frequently. These are dose-dependent. Muscarinic side effects are 
stomach cramps, diarrhea, increased sweating, superfluous respiratory and 
gastrointestinal secretions [144]. The main nicotinic side effects are muscle 
fasciculations and cramps [148].  Optimal dosage should be balanced between the 
clinical improvement of the muscle strength and the degree of side-effects [175].  
1.4.2 Immunosuppressive treatment 
Corticosteroids: For most patients, pyridostigmine alone is insufficient to reduce the 
symptoms, and immunosuppressive treatment is needed. The first-line drug of 
immunosuppressive treatment is prednisolone [175]. To induce remission, it is often 
required a relatively high-dose (60-80 mg on alternate days) which is slowly tapered to 
the dose required to maintain the state of remission [175]. High doses every day with 
prednisolone are given in critically ill patients, in addition to plasma exchange or IVIG 
to overcome the acute worsening [175]. There is a risk of a temporary worsening at 
high doses of prednisolone (steroid dip), and close observation of the patient is 
therefore needed. Steroids are efficient treatment of MG [164] by its 
immunosuppressive effects, however, the effects are complex and not completely 
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understood.  It is suggested that the therapeutic effect is due to several mechanisms, 
such as influencing the distribution and trafficking of leukocytes, inhibiting 
recruitment and migration of lymphocytes to areas of inflammation, and blockade of 
several functional properties of T-cells [38]. Steroids have in addition a direct effect on 
the muscle by increasing the number of AChRs on the cell membrane resulting in 
increased AChR function and improved synaptic transmission [152].  
Long-term treatment of prednisolone carries a risk for side-effects and serious health 
problems. These are reduced glucose tolerance, osteoporosis, increased blood pressure, 
weight gain, fluid retention and peptic ulcer disease. 
While prednisolone is used in most European centers, prednisone is the standard 
steroid for oral use in the USA, and represents a therapeutically equivalent on weight 
basis to prednisolone [164]. High-dose parenteral corticosteroids can be given in 
severe MG and in acute situations in addition to PE or IVIG [129, 175]. 
Azathioprine: Azathioprine is a first-choice drug for long-term immunosuppressive 
therapy in MG. It is usually recommended in combination with prednisolone [175]. It 
inhibits DNA and RNA synthesis and interferes with T-cell function. A main 
disadvantage of this drug is the delayed onset of action with a maximum effect 
obtained after 6-24 months. Often azathioprine is therefore started combined with 
prednisolone to achieve also a more rapid therapeutic effect. Subsequently 
prednisolone is tapered off over a prolonged time after the clinical effect of 
azathioprine is achieved. The formal evidence of this is weak even though its extensive 
use [67]. However, a well-conducted double-blind prospective study showed the long-
term superiority of the combination prednisolone and azathioprine as compared with 
prednisolone alone [136]. Azathioprine is usually well tolerated, but flu-like symptoms 
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or gastrointestinal disturbances, pancreatitis included, occur in 10%, usually within the 
first days of treatment. Leukopenia and hepatotoxicity are potential adverse effects, 
and careful ongoing blood monitoring during the first few months is required. Dosage 
should be adjusted according to blood cell count and liver enzymes. These adverse 
effects usually respond to drug withdrawal.   
Mycophenolate mofetil (MMF): This drug blocks purine synthesis by selectively 
inhibiting proliferation of activated B- and T-lymphocytes [4]. MMF has been shown 
to be safe and beneficial in inflammatory conditions such as psoriasis and systemic 
lupus erythematosus [171]. Two recent randomized double-blind trials comparing 
MMF plus prednisone with prednisone alone, failed to prove the benefit of MMF over 
prednisone in treatment of MG [126, 165]. However, both trials had a short duration of 
time and may not have taken enough consideration to the great benefit of prednisone, 
thus masking the additionally and steroid-sparing effect of MMF [166]. In 2010, a 
retrospective study reviewing 116 MG patients treated with MMF was conducted [70]. 
When followed for 2-3 years, the authors concluded that MMF was beneficial both 
with prednisone and as monotherapy, and the effect appeared after 6 months in both 
groups. MMF is reported to have less side-effects than cyclophosphamide and 
ciclosporin. The most commonly observed are nausea, headache and diarrhea [119]. 
Opportunistic infections have been reported [193]. According to the European 
Federation of Neurological Societies (EFNS) guidelines, MMF should be tried in 
patients intolerant or unresponsive to azathioprine [175].  
Rituximab (Anti-CD20): Rituximab has been reported as a promising agent in MG 
treatment, especially for the MG subgroup with antibodies to muscle-specific tyrosine 
kinase (anti-MuSK) MG patients [37, 91, 133]. The efficacy of rituximab in this 
subgroup may be explained by the disease being mediated by IgG4 antibodies [46]. 
Patients with anti-MuSK MG have in general a poorer response to standard therapies 
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than anti-AChR MG patients [138]. In one study from 2012, 17 patients with anti-
AChR MG and anti-MuSK MG were treated by rituximab (mean follow-up time 31 
months), and compared [37]. Both groups benefited from the treatment, but the effect 
was dramatically better and longer-lasting in the anti-MuSK MG group. Moreover, the 
antibody titers in the latter group declined significantly during follow-up. In the anti-
AChR MG group, the concentration of AChR-antibodies did not change significantly. 
Rituximab has, based on the promising studies reported, been proposed as an early 
therapeutic option especially in anti-MuSK MG patients without response to steroids 
[37]. The side-effects were minor and related to the infusion of the drug (facial 
flushing and generalised skin rush). However, there are reports on development of 
progressive multifocal leukoencephalopathy in patients treated with rituximab, so the 
patients need to be thoroughly tested and monitored [92, 112, 113]. 
Ciclosporin: Ciclosporin inhibits T-cell function and is mainly used when azathioprine 
does not provide sufficient effect. The positive steroid-sparing effect on MG is well 
documented [30, 130, 131]. However, common adverse effects are nephrotoxicity and 
hypertension. The drug should therefore only be considered in patients intolerant or 
unresponsive to azathioprine [175]. 
Methotrexate: Methotrexate is a structural analogue of folic acid and exerts an anti-
proliferative effect on immune cells by inhibiting DNA synthesis. Both safety and 
efficacy of this drug is well documented in other autoimmune diseases such as 
rheumatoid arthritis, but poorly investigated in MG [69]. According to the EFNS 
guidelines, methotrexate should be considered in MG patients who do not respond to 
first choice immunosuppressive drugs [175]. 
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Cyclophosphamide: Cyclophosphamide is used in severe MG. It adds an alkyl group 
to the guanine base of DNA, and thereby interferes with DNA replication. It is a strong 
suppressor of B-cell activity and antibody synthesis, and at high doses it also affects T-
cells. The effect on MG is well-documented [35, 40] but with a risk of toxicity leading 
to bone-marrow suppression, opportunistic infections, bladder toxicity, sterility and 
neoplasms. The medication should therefore be limited to those patients with MG 
intolerant or unresponsive to steroids plus azathioprine, methotrexate, cyclosporine 
and/or mycophenolate mofetil [175]  
Tacrolimus (FK506): This agent inhibits proliferation of activated T-cells via the 
calcium-calcineurin pathway. It potentiates excitation-contraction coupling in skeletal 
muscle [80]. Tacrolimus may have an additional effect in RyR-antibody positive 
patients through enhancing RyR-related sarcoplasmic calcium release that in theory 
might be blocked by RyR-antibodies, hence inducing symptom relief [82, 175]. 
Tacrolimus is recommended for MG patients with poorly controlled disease, and 
especially in RyR-antibody positive patients [175].
Eculizumab: Eculizumab is a recombinant humanised monoclonal IgG2/4 antibody that 
blocks the formation of complement complex. A double-blind, placebo controlled 
crossover trial of anti-AChR MG patients with severe refractory disease, has recently 
been reported [79]. In this study they found a significant improvement of the patients 
on eculizumab. The trial demonstrated a promising result with a possible new 
approach for the management of severe and refractory MG.  
There are other emerging therapy options acting on various elements of the immune 
system, such as etanercept, bortezomib, belimumab and granulocyte-macrophage 
colony-stimulating factor. Some of these drugs are approved for treatment for other 
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autoimmune diseases but not validated for use in MG, and should therefore be used 
only as part of open studies. Establishing treatment with new and more selective 
immunoactive drugs, and a more tailored treatment for the different MG subgroups 
and even individual patients should be aimed for in the coming years. 
Plasma exchange (PE) and intravenous immunoglobulin (IVIG): During PE, AChR-
antibodies are removed from sera by membrane filtration or centrifugation.  IVIG 
affects the function and/or the production of antibodies by complex mechanisms that 
are not entirely understood. It acts on the immune system through various ways 
including suppressing antibody production and by anti-idiotypic autoantibodies 
neutralizing the autoantibodies [34]. Both PE and IVIG have a rapid effect, occurring 
after a couple of days and lasting for 1-3 months. Both are short-term treatments. They 
are used in severe cases to induce remission, as a lifesaving procedure in myasthenic 
crisis, and as a preoperative preparation [175]. PE and IVIG have been shown to be 
equally effective [13, 42, 52]. PE has a higher frequency of severe side effects, and 
represents a more complicated procedure. For that reason, IVIG treatment is the 
preferred option in most centers [52, 56]. A report from the American Academy of 
Neurology concluded that evidence is insufficient to distinguish between IVIG and 
plasmapheresis regarding efficiency in treating MG [139].  
1.4.3 Thymectomy  
Thymectomy is an integral part of MG treatment. Data from several class III 
observational studies show that thymectomy is beneficial in MG for non-thymomatous 
MG patients. Moreover, early thymectomy in the course of MG improves the chance 
of remission. Thymectomy is therefore a recommended treatment for MG, and an early 
intervention is preferred compared to later in the course of MG [175, 177, 181, 192].  
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Thymectomy can be performed either transsternally or by a video-assisted 
thoracoscopic (VATS) approach. One review from 2011 concluded VATS to be the 
preferred method because of better cosmetic result, reduced need for postoperative 
medication and equivalent disease resolution [214]. The effect of thymectomy is 
expected to occur within two years. Immunotherapy is often started before 
thymectomy and continued and tapered off as the effect of surgery appears. 
Indication for thymectomy is related to subgroup of MG: 
Early-onset MG: Thymus in these patients is enlarged, and is probably the site where 
the autoimmune response develops and arises [26]. Thymectomy should be undertaken 
early, before disease-specific T-cells seed in the periphery [55]. Most centers will 
recommend early thymectomy in all early-onset MG cases without full clinical 
remission on ACh-I treatment [55, 156, 174, 175].  Surgery is usually uncomplicated. 
Late-onset MG: Thymectomy is not recommended for late-onset MG with an atrophic 
thymus. A proportion of late-onset MG patients have, however, a hyperplastic thymus, 
usually those with an early-onset within this group. Late-onset MG patients with 
hyperplastic thymus most probably have a positive effect of thymectomy [57]. Patients 
with titin- or RyR-antibodies are believed to be less likely to benefit from a 
thymectomy than those without such antibodies [157].  
Thymoma-MG: Thymectomy is the mainstay treatment for all thymoma-MG patients 
aiming to remove a potentially infiltrating tumor [175]. Surgical removal is sufficient 
for non-invasive thymomas. If not possible with surgical removal, chemotherapy and 
radiotherapy are also effective treatment for a thymoma [55, 96]. 
Ocular MG: There is no evidence for a better clinical outcome after thymectomy. 
Thymectomy is not recommended for this group [29, 57]. 
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Treatment flowchart. Meriggioli, M.N, 2009; Autoimmune myasthenia gravis [120]
1.4.4 Supplementary treatment 
Respiratory muscle training has been shown to improve lung function and respiratory 
muscle strength and/or endurance in MG patients [150]. Physical training can be 
carried out safely in MG and produces some improvement in muscle force [175]. 
Weight reducing or -control, training and other life style modifications are suggested 
as important, but there is no solid scientific evidence to support these 
recommendations [175]. Seasonal flu vaccination should be recommended in MG 
patients. Aggressive treatment of infections is recommended. 
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1.4.5 MG and giving birth 
MG represents a risk factor for pregnancy and delivery. Several pregnancy 
complications occur with slightly increased frequency, and also operative interventions 
during delivery are undertaken more often than expected [77]. Women with MG 
should be followed up by a neurologist during a pregnancy, and an active cooperation 
between obstetrician, neurologist and pediatrician is recommended. 10-20% of the 
children born to mothers who have MG develop transient neonatal MG because of 
transplacental transmission of IgG antibodies. The antibodies diminish naturally 
postpartum with clearance. The symptoms include weak sucking, dysphagia, weak cry, 
hypotonia, and more rarely, respiratory problems. The symptoms are usually evident 
within the two first days of life and can last for two to four weeks [45, 76]. 
Arthrogryposis multiplex congenita (AMC) is defined as nonprogressive congenital 
contractures that generally results from lack of fetal movement in utero [145]. 
Maternal MG can be a rare cause of AMC. There is no correlation between the 
severity of maternal disease and the occurrence of neonatal MG or AMC [64, 75]. 
Pregnancy does not worsen the long term outcome of MG, and women should 
therefore not be discouraged from conceiving [175]. Breast feeding should be 
encouraged [132]. 
1.4.6 Treatment myasthenic crisis 
Approximately 15-20% of MG patients experience a myasthenic crisis during lifetime 
[7]. Myasthenic crisis is defined as weakness severe enough to necessitate intubation 
or delayed extubation following surgery [16, 90]. Approximately 70% of myasthenic 
crisis are precipitated by infections [194]. Surgery and administration of different 
medications are other risk factors. In many cases, there is no obvious cause which led 
to crisis.  In patients with a confirmed MG-disease, deterioration to a myasthenic crisis 
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is easy to identify. Sometimes MG can start with severe respiratory failure, requiring 
an extended diagnostic work-up. 
The life-saving treatment of a myasthenic crisis is promptly to recognise it and to 
establish adequate mechanic respiratory support, either by non-invasive positive 
pressure ventilation or intubation [162]. ACh-Is are discontinued as this medication 
increases bronchial secretion, the patient has often used high doses during the MG 
worsening leading to the crisis [55]. PE and IVIG are comparable in terms of efficacy 
on the basis of clinical evidence preceding controlled trials [19, 52, 149, 175]. 
However, PE is probably slightly more effective than IVIG in myasthenic crisis. There 
is a general agreement that PE or IVIG should be combined with high doses of steroids 
during recovery from myasthenic crisis, and the treatment is required for several 
weeks [28, 85]. The mortality rate of myasthenic crisis has improved greatly from 
above 40% in the 1960s to less than 5% today [31, 209].  
Long term immunosuppressive treatment is recommended to maintain the effect of PE 
or IVIG [175]. Gradually tapered dose of prednisolone combined with azathioprine is 
usually chosen. Ach-Is should be introduced again. 
1.4.7 MG and the heart 
Nearly 50% of all MG patients and approximately 97% of all MG thymoma patients 
have antibodies against titin and RyR, autoantibodies targeting both proteins in striated 
and cardiac muscle [127]. Antibodies targeting adrenergic ß-receptors [211], 
muscarinic AChRs [191] and voltage-gated K+ channel (anti-Kv1.4) [186] has later 
been identified. That myocardial pathology may occur in association with thymoma 
MG, is established knowledge [198]. This is possibly due to thymoma infiltration and 
invasion of the pericardium, myocardium, large vessels and other local structures, and 
thereby a possible alteration of the cardiac function. Myocarditis is the heart condition 
most often thought to be related to MG [189]. This is a potentially lethal disorder in 
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which symptoms such as shortness of breath, exercise intolerance or fatigue can be 
misinterpreted as myasthenic symptoms [189]. Findings of electrocardiography (ECG) 
and conventional ultrasound echocardiography are unspecific [1].  
Anti-Kv1.4 antibodies have been reported as a possible marker for cardiac 
involvement [185, 190]. One study from 2013 found patients with antibodies against 
anti-Kv1.4 in 70 of 650 MG patients. Of these, 60% had abnormal ECG findings with 
high frequencies of T-wave abnormality and QT-prolongation. Clinically suspected 
myocarditis was found in eight MG patients, and none in the MG patients without anti-
Kv1.4 antibodies [185]. Heart examination is necessary in MG patients with antibodies 
to RyR, titin or anti-Kv1.4.  
1.5 Pathophysiology of anti-AChR MG 
The NMJ consists of three main parts: the presynaptic nerve terminal where 
acetylcholine is made, stored and released; the synaptic space, and the postsynaptic 
membrane. When a nerve action potential enters the nerve terminal, it triggers an 
exocytosis of synaptic vesicles containing ACh. The ACh diffuses across the synaptic 
cleft and interacts with the AChRs clustered on the ridges of the postsynaptic folds of 
the muscle membrane. This leads to depolarization of the membrane, and a muscle 
action potential is induced. 
In approximately 85% of cases, MG is caused by AChR-antibodies with affinity for 
the nicotinic AChRs in skeletal muscle [111, 206]. These antibodies were first 
discovered in 1976 [111]. AChR-antibodies are polyclonal, mainly immunoglobulin G 
(IgG), which in humans consist of four isotypes. These isotypes (IgG 1-4) have similar 
amino acid sequences, but differ in their ability to activate complement. IgG 1 and IgG 
3 are effective complement activators, IgG 2 activates poorly and IgG 4 does not 
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activate complement at all. In anti-AChR MG, the isotypes IgG 1 and IgG 3 
predominate, and IgG 1 and IgG 4 are present only in low concentrations [59, 153].  
The AChR is an oligomeric membrane protein composed of five subunits. In the fetal 
form, the receptor consists of two alphas, one beta, one gamma and one delta subunit. 
In the adult form, the gamma is substituted with an epsilon unit [84]. This switch is 
accompanied by a decrease in channel opening time and a longer receptor half-life 
[74]. AChR-antibodies can bind to both fetal and adult types of the receptors, but often 
with different affinity. Most AChR-antibodies bind to the main immunogenic region at 
the alpha1-subunit [115].  
There are three main mechanisms by which the AChR-antibodies reduce the number 
of functional receptors: 
1. Complement-mediated lysis of the postsynaptic membrane resulting in 
distortion [44, 158] 
2. Cross-linking of adjacent AChRs resulting in their accelerated internalisation 
and degradation[110]  
3. Direct blocking of the acetylcholine binding site, this being less important than 
mechanisms 1. and 2. [24] 
AChR-antibodies are very specific antibodies for MG. They are not detected in healthy 
individuals, and rarely in patients with other neuromuscular or autoimmune disorders.  
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1.6 MG with low-affinity AChR-antibodies and with non 
AChR-antibodies 
1.6.1 Low-affinity AChR-antibodies 
These antibodies are identified in approximately 60% of patients negative for both 
AChR- and MuSK-antibodies in radioimmunoprecipitation assays (RIAs). The 
antibodies do not have the high affinity required to bind to AChRs in solution, but bind 
divalently to adjacent AChRs expressed in dense clusters, and can be detected using 
cell-based assays and direct immunofluorescence [207]. These methods have 
unfortunately not yet become commercially introduced. The antibodies are still likely 
to be pathogenic because of the high density of AChRs at the NMJ, and because the 
antibodies are of the IgG1 class and activate complement [104]. Patients with low-
affinity AChR MG have the same pathogenesis, treatment and treatment response as 
patients with ordinary AChR-antibodies. They have, as expected, in general a good 
response to therapy, to ACh-I as well as to immunosuppressive treatment. It is 
suggested that early-onset MG without AChR- and MuSK-antibodies should have 
thymectomy as recommended for MG with AChR-antibodies, especially if they have 
an enlarged thymus on imaging [175].   
1.6.2 Anti-MuSK antibodies 
 In Europe, anti-MuSK MG patients are most frequently found between the latitudes 
30° and 50° N [204]. Up to 64% of non-AChR MG patients in Italy have a detectable 
concentration of MuSK-antibodies [172]. In contrast, there have been few reports of 
anti-MuSK MG patients in northern countries such as Norway (unpublished). An 
association between MuSK-antibody concentration and disease severity has been 
found according to a study from Italy [14]. 
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MuSK is a NMJ protein co-localised with AChR at the postsynaptic membrane. The 
protein is important in the maintenance of the normal functionality of the NMJ by 
mediating clustering of AChRs [120]. MuSK-antibodies are not detected in AChR- 
antibody positive patients [63]. While complement activation plays a major role in 
anti-AChR MG, this is not the case in anti-MuSK MG. These antibodies are of IgG-4 
type which does not activate complement. In anti-MuSK MG, a correlation between 
titer of IgG4 subclass and disease severity was found [143]. It is suggested that the 
myasthenogenic effect of these antibodies is through a decrease in postsynaptic AChR 
density [102]. There has been reported low-affinity MuSK-antibodies detected by cell-
based assays only [218]. The full understanding of the pathological mechanisms in 
anti-MuSK MG remains elusive.  
Clinically, anti-MuSK MG differs from anti-AChR MG by predominantly cranial- and 
bulbar involvement and a higher risk of respiratory crisis. Maximum disease severity 
is usually seen a short time after disease onset [163]. The response to ACh-Is is poorer 
than in anti-AChR MG. The effect of immunosuppressive drugs is usually favourable 
[170]. Rituximab has been recommended as an early therapeutic option if no response 
to corticosteroids [106].  In general, no thymic pathology is observed in this MG group 
[47, 105], and therefore no expected effect of thymectomy. 
1.6.3 Anti-LRP4 antibodies 
 LRP4-antibodies were initially found in 8% of the patients with no antibodies to 
MuSK or AChR. One large study screened approximately 800 MG sera from 10 
countries, and identified LRP4-antibody positive patients among those negative for 
AChR- and MuSK antibodies varying between 7% (Norway) to 32.7% (Poland) [219]. 
LRP4 antibodies were surprisingly also found in some sera positive for AChR-
antibodies or MuSK-antibodies in the same study. LRP4 is a NMJ transmembrane 
35 
protein localised at the postsynaptic membrane where it binds to agrin-receptor in 
skeletal muscle [215]. LRP4 interacts with MuSK and plays a role both in the 
clustering AChR and in other synaptic tasks to maintain the formation of the 
membrane [216]. The majority of anti-LRP4 MG patients have a mild ocular or 
generalised MG, milder than most patients positive to AChR- or MuSK-antibodies. 
Bulbar symptoms are more frequent at onset than limb or axial muscle-affection [18, 
219]. The role of thymus in this MG subgroup is still unknown. 
1.6.4 Ryanodine receptor (RyR)-antibodies 
RyR-antibodies in MG were first identified by Mygland et. al in 1992 [128]. The 
receptor is a Ca2+ -release channel located intracellularly in the sarcoplasmic 
reticulum. RyR-antibodies have an essential role in excitation-contraction (EC)-
coupling in striated muscle. A pathogenic role for striational antibodies has not been 
proven in vivo. One recent study found that an impaired EC-coupling contributed to 
muscle weakness in patients with MG [82], but another study by the same authors 
could not reproduce this finding [81]. RyR-antibodies serve as a marker for a more 
severe and prolonged disease, and indicate the presence of a thymoma [154].  
1.6.5 Titin-antibodies 
Titin-antibodies were first discovered by Aarli et. al in 1990 [3]. Titin is a giant muscle 
protein, and one of the largest components of the skeletal and cardiac sarcomere [160]. 
Titin-antibodies are associated with late-onset MG patients and thymoma. In late-onset 
MG, titin-antibodies are detected in 30-50% of the patients, and most frequently found 
in patients older than 60 years of age [157, 187]. These antibodies are very uncommon 
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in early-onset MG, and absent or borderline in patients without AChR- or MuSK-
antibodies and in healthy controls [23]. 95% of patients with thymoma-MG have titin-
antibodies [159]. Testing for RyR- and titin-antibodies combined gives a 95% 
sensitivity and specificity, and a 70% positive predictive value for a thymoma in MG 
[159]. Presence of titin-antibodies correlates with MG severity [176]. RyR- and titin 
antibodies can be detected by enzyme-linked immunosorbent assay (ELISA) or 
immunoblot.  
1.6.6 Voltage-gated potassium channel (VGKC) Kv1.4 antibodies 
Kv 1.4 is a transmembrane protein, located mainly in the brain, peripheral nerves and 
skeletal- and heart muscles. Kv1.4 antibody is a marker for the potential development 
of severe autoimmune myocarditis and response to calcineurin inhibitors (see 
“Myasthenia gravis and the heart”-section [185, 188]. Kv1.4 antibodies can be 
detected by an immunoprecipitation assay using 35S-labeled rhabdomyosarcoma 
cellular extract as the antigen source [185]. 
37 
1.7 MG and epidemiological research 
MG is a rare disease, in Europe defined as “not more than 5 in 10 000 persons”[32] . 
Epidemiological research seeks to: “1) describe health status by measuring disease 
frequency, distribution and trends; 2) know who becomes ill, what are the specific 
characteristics of cases, where and when these cases occur; 3) explain disease etiology; 
and 4) control the spread of specific diseases and their effects, by setting up preventive 
measures, improving prognosis and/or quality of life, and reducing mortality and other 
devastating complications” [36]. In my research, all points have been applied: I have 
measured disease frequency by calculating prevalence and incidence of MG, I have 
studied the distribution of the disease and trends of incidence over decades, and 
thereby tried to contribute to explain its etiology. I have also studied specific 
characteristics of MG patients and especially studied whether AChR-antibody test can 
be used as a biomarker to support the clinical assessments. 
Two concepts are essential in epidemiological research as well as in my research; 
prevalence and incidence:  
Prevalence: Prevalence can be defined as “the probability that an individual in a 
population will be a case at time t” [73]. A more practical definition of prevalence, the 
proportion of the population that has a disease at a set time point, point prevalence, has 
been applied in my research. Prevalence is a crucial estimator to gain an understanding 
of how many patients live with MG at a given time, and enables comparing frequency 
of a disease among regions or countries. To know the prevalence of a certain disease is 
also useful for long-range health care planning, organising health services for the 
disease, and for how to distribute research- and clinical competence of the disease.   
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Incidence:  Incidence can be expressed as a rate providing a measure of the occurrence 
of new disease cases per person-time unit [73]. Another incidence measure, which was 
implied in my research, is the incidence proportion, which gives the proportion of the 
population that develops the disease during a specific period of time. Incidence per 
year is the most common way to refer to time when studying MG either as a rate or as 
a proportion. A reason for that is that life-expectancy in MG is now approximately the 
same as in the general population in Norway [146]. Thus the denominator, which for 
the incidence rate is the number of persons under surveillance multiplied by one (1 
year), equals the general population resulting in the incidence rate and incidence 
proportion being two concepts measuring the same number of new incident cases. 
Prevalence-incidence ratio is interesting to study over time because it can reveal a 
change in the disease dynamics: if incidence is high relative to prevalence of a disease, 
it tells us that this disease has a low survival rate or the patients are cured. If incidence 
is low compared to the prevalence, it tells us that the survival rate is high, or it can be a 
result of improved detection of the disease. For MG, the latter is the case, having a 
high prevalence and a low incidence. The prevalence-incidence ratio has increased 
[25] over the last decades, suggesting an improving MG treatment and survival with 
subsequently increasing life-expectancy. The other explanation is the improved 
detection; it is likely that case-ascertainment has improved in the recent epidemiologic 
studies conducted in Norway. Moreover, there have been demographic changes in 
most western countries with an ageing population and lower birth rates. 
It requires robust methods and high-quality data to make accurate epidemiological 
estimates of MG-incidence. Accurate estimates of MG-incidence allow studying the 
actual occurrence of MG, capturing the dynamic of the disease over time and also the 
geographical distribution of MG. Accurate estimates are necessary to compare 
incidences of MG between populations and thereby provide clues to the etiology of the 
disease.  
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An important way of creating robust methods and good-quality data is to develop large 
population-based registries. In Norway, several national health registries have been 
established. National health registries provide an opportunity to conduct 
epidemiological research on a complete, nationwide population. The Norwegian 
Prescription Database is one example of a national health register from which we have 
obtained data in paper III. The AChR-database is not a registered national health 
register. It is not obliged by law to take an AChR-antibody test for all suspected MG 
cases, as it is for the pharmacies to register all prescription medications dispensed. 
However, we believe that AChR-antibody status is investigated in every suspected 
new MG-case in Norway. Thus, the AChR-antibody database should serve as a 
nationwide and specific proxy to identify new cases of MG.  
The health care registries are regulated by the Personal Health Data Filing System Act 
(2002). The importance of an individual´s right to privacy is emphasised, and access to 
the registries presupposes an approval from the Regional Ethics Committee.   
Clinical epidemiology is a term derived from two parent disciplines: clinical medicine 
and epidemiology. It is clinical as it endeavors to answer clinical questions and support 
clinical and therapeutic decisions. The methodology to answer the clinical questions is 
epidemiologic.  The purpose of clinical epidemiology is to develop and apply sound 
methodology to validate conclusions based on clinical observations and thereby 
avoiding systematic errors. It is an important approach to guide doctors in making the 
best available decisions for the patients [50].   
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1.7.1 Myasthenia gravis Foundation of America Clinical Classification   
Myasthenia gravis Foundation of America (MGFA) Clinical Classification was 
designed to classify patients with MG with similar clinical features and severity of the 
disease, enabling comparative analysis of the various therapeutic interventions for 
MG. It may be hard to classify patients with MG because of the fluctuations and the 
variable predominance of affected muscle groups, thus even more important to 
develop universally accepted standards to grade patients and methods to evaluate 
patients undergoing MG-treatment. The Medical Scientific Advisory Board of MGFA 
thus formed a Task Force in May 1997 to address these issues [86]. Existing 
classifications at that time was mostly Osserman´s classification from 1958 or 
modifications of it [134].  
  
41 
MGFA Clinical Classification 
Class I Any ocular muscle weakness; may have weakness of eye closure. All other 
muscle strength is normal. 
Class II Mild weakness affecting muscles other than ocular muscles; may also have 
ocular muscle weakness of any severity. 
 IIa. Predominantly affecting limb, axial muscles, or both. May also have lesser 
involvement of oropharyngeal muscles. 
 IIb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May 
also have lesser or equal involvement of limb, axial muscles or both. 
Class III Moderate weakness affecting muscles other than ocular muscles. May also have 
ocular muscle weakness of any severity. 
 IIa. Predominantly affecting limb, axial muscles, or both. May also have lesser 
involvement of oropharyngeal muscles. 
 IIb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May 
also have lesser or equal involvement of limb, axial muscles or both. 
Class IV Severe weakness affecting muscles other than ocular muscles. May also have 
ocular muscle weakness of any severity. 
 IIa. Predominantly affecting limb, axial muscles, or both. May also have lesser 
involvement of oropharyngeal muscles. 
 IIb. Predominantly affecting oropharyngeal, respiratory muscles, or both. May 
also have lesser or equal involvement of limb, axial muscles or both. 
Class V Defined as intubation, with or without mechanical ventilation, except when 
employed during routine postoperative management. The use of feeding tube 
without intubation places the patient in class IVb.
It is an inherent imprecision of classifying MG as with mild, moderate or severe 
weakness, as is done in the MGFA classification. What will be defined as mild by one 
doctor, can be defined as moderate by another. The grading will also depend on how 
the patient formulates his or her symptoms. The MGFA classification represents a 
subjective assessment with a lack of quantification. A standard classification is, 
however, needed to achieve a meaningful comparison of data. The Task Force 
recommends that the most severely affected muscles should define the score.  
A quantitative MG-scoring system (QMG-score) was developed by the same Task 
Force to more objectively evaluate therapeutic interventions of MG. This score is 
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recommended used in conjunction with the Clinical Classification and the Post 
intervention status, and should not primarily be used to compare severity between 
patients. QMG should be used in all prospective studies of MG therapy. This scoring 
system was not applicable for our study as it was retrospective and the scores being 
based on free text medical notes. To reduce parts of the imprecision in the MGFA 
Clinical Classification, we validated the score by two independent observers, as 
explained in the statistical methods-section. 
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2. Aims of study 
i. To determine the prevalence and incidence of anti-AChR MG in Norway. 
ii. To study anti-AChR MG incidence in the different geographical regions in 
Norway, and thereby identify factors that may contribute to the development of 
MG. 
iii. To compare incidence and prevalence data from the AChR database and the 
national prescription database to evaluate the two nationwide registries and find 
correct estimates. 
iv. To examine the association between MG clinical severity and concentration of 
AChR-antibodies in individual patients over time to evaluate if repeated AChR-
antibody measurements have a value for therapeutic decisions.  
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3. Materials and methods 
3.1 AChR database 
In 1974, AChR-antibodies were discovered to be present in the majority of MG 
patients [5, 6]. Subsequently, an assay to quantify the AChR-antibody concentration 
was developed [108]. The method was based on extracts containing human AChRs 
prepared from amputated legs. The receptors were labeled with 125I-Į-bungarotoxin. 
Concentration of AChR was estimated by measuring 125I-Į-bungarotoxin binding to 
AChRs. The toxin-receptor complex was then precipitated with a possible myasthenic 
serum.  Different preparations of AChR from human muscle could vary in the capacity 
to bind both the 125I-Į-bungarotoxin and the receptor antibody. To adjust for this, the 
concentration of AChR-antibodies was measured in arbitrary units/L. The patient 
sample was compared with a healthy serum, and values above a 95% confidence limit, 
was considered as abnormal.  A standard positive patient serum with a known AChR-
antibody concentration was also added. By extrapolating from this information, all 
new positive sera got their AChR-antibody concentration. This method was used at the 
laboratory of Haukeland University Hospital from 1983 to 1994 as the only laboratory 
in Norway offering this analysis. From 1994, the laboratory incorporated a commercial 
kit (IBL-Hamburg GmbH, Germany) for the method to analyse concentration of 
AChR-antibodies. Using a radio-receptor assay for the in-vitro-diagnostic semi-
quantitative determination of AChR-antibodies in serum ensured high sensitivity and 
reproducibility.  In this method, ACh from human muscle is used as antigen. The 
receptors are prelabelled with 125I-Į-bungarotoxin. This snake venom binds to the 
receptors specifically and almost irreversibly. Autoantibodies present in the patient´s 
serum attach to the labelled receptors. The resulting immune complexes are 
precipitated with anti-human IgG. The amount of radioactivity of the sediment is 
proportional to the AChR-antibody concentration in the sample. AChR-antibody 
concentration is measured in nmol/L with a cut- off value set to 0.5 nmol/L, in line 
with literature recommandations [147, 179] and “instruction for use” from the 
45 
producer. Four times a year, the laboratory participates in a control trial assessment to 
ensure the analytic quality. These assessments have confirmed a high analytical 
quality, further explained in the “internal validity”-section, page 64. 
Sensitivity and specificity of the AChR-antibody test is of clinical importance. The 
AChR-antibody test measured by RIA technique is nearly 100 % specific as a 
diagnostic test for MG [49]. Even though the antibodies are very specific for MG, they 
may very rarely be detected in patients with celiac disease [21], systemic lupus 
erythematosus [21], rheumatoid arthritis on penicillamine [124], in allogeneic bone 
marrow transplantation patients who develop graft-versus-host disease [103], in 
patients with thymoma without MG, and in neuromyelitis optica [207]. The sensitivity 
of the RIA is difficult to quantify because it depends on the gold-standard used. The 
producer of the test claims a 100% sensitivity using a predicat RIA method as a 
comparison. This is highly questionable, and the producer has certainly not taken into 
account the presence of low-affinity AChR-antibodies.  
From 1983, name of patient, date of birth, date of sample- acquisition and name of 
referring doctor/hospital have been registered at the Haukeland University Hospital 
laboratory. All samples from the whole of Norway were sent to this laboratory. In the 
first years, the information was handwritten in books, resulting in some information 
being missed. From 1995 and onwards, all information was computerised and regarded 
as complete. From 1983 to 2008, approximately 12 000 samples were analysed with an 
annual increase from 47 in 1983 to more than 1000 tests in 2008. From 2008, a 
laboratory at Oslo University Hospital has offered analysing AChR-antibody 
concentration.  
The three first papers in the present thesis were based on the AChR-antibody tests for 
the period 1983-2008. This was the fundament for a nationwide calculation on 
prevalence, incidence and geographical distribution of anti-AChR MG. In the fourth 
paper, tests from the period 2008-2013 were also included. 
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3.2 Norwegian Prescription database  
All pharmacies in Norway register all prescription medication dispensed. They have 
been obliged by law to do so since 2004. The Norwegian prescription database 
(NorPD) contains thus information on drug consumption for the entire Norwegian 
population. Individual patients are anonymous, but can be identified by a unique 
person identifier. For MG and other chronic conditions with a confirmed diagnosis, 
medication is reimbursed, and the reimbursement code for MG served as a proxy for 
the MG diagnosis in paper III. 
The inclusion criteria for the study population drawn from the NorPD were as follows: 
Minimum two prescriptions of pyridostigmine during the study period (January 1st, 
2004 - December 31st, 2007), a prescription from a specialist in neurology, or 
prescription for MG as specified in NorPD. Patient’s age, gender and county of 
residence were identified for each prescription. Drug information included the 
Anatomical Therapeutic Chemical code (N07AA02) and date of expedition. 
3.3 Population and health regions of Norway 
On January 1st, 1995, Norway had a population of 4,348,410, increasing to 4,737,171 
on January 1st, 2008. In the same period the number of first or second generation of 
immigrants roughly doubled from approximately 200,000 (4.6%) to 460,000 (9.7%) 
(Statistics Norway - SSB, www.ssb.no). Norway has been a rather homogenous 
population, the one exception being the Sami population in the northern region. All 
prevalence and incidence calculations for the first two papers were based on the entire 
Norwegian population.  
In the period 1995-2007, the Norwegian Healthcare System was divided into five 
geographical health regions: east-, south-, west, mid- and north region. The 
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geographical distribution of anti-AChR MG examined in paper II, was based on the 
differences in incidence of anti-AChR MG between these five health regions. The 
number of inhabitants in the different health regions varied from 470 000 (north) to 
1 600 000 (south). Geographically, the northern region constitutes the largest area in 
Norway. 
3.4 Western Norway 
Paper IV was based on the population in western Norway. Western Norway constitutes 
the counties of Sogn and Fjordane, Hordaland, and Rogaland, comprising 
approximately 1 000 000 people in 2011 (Statistics Norway - SSB, www.ssb.no). In 
this study we used the AChR database to identify all patients from western Norway 
with two or more AChR-antibody tests taken. Then we compared the AChR-antibody 
concentrations with the MGFA scores to evaluate if there was an association between 
the antibody concentration and clinical severity derived from the score.  
3.5 Study populations in the four papers 
Paper I: The study population was obtained from 1983 to 2008 and comprised 11 926 
assays registered in the AChR database. The data obtained was used to calculate the 
prevalence. Incidence calculations were based on assays from 1995 to 2008 
comprising 8 742 samples. The Norwegian National Registry was used to determine 
whether the patients were alive at the prevalence day.  
Paper II: The study population comprised 419 individuals with first time positive 
AChR-antibody tests from 1995 to 2007 obtained from the AChR database. The total 
population, counted by gender and age in each health region, was recorded per year 
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from 1995 to 2007 to calculate annual incidence in each of the five geographical 
regions. 
Paper III: For the AChR database, the population was identical to the population in 
paper I and II. For NorPD, prevalence calculation was based on the number of patients 
who had received prescriptions of pyridostigmine according to the inclusion criteria 
and were residents in Norway on prevalence day. 677 (94%) out of the 723 with 
prescription of pyridostigmine met the criteria for being included in the prescription 
database. The selected prevalence day was January 1st 2008, the same as the 
prevalence day in paper I. Incidence of MG was defined as new users of 
pyridostigmine, with no prescription of pyridostigmine dispensed during the years of 
the study period preceding 2007.  
Paper IV: 185 patients from western Norway had two or more AChR-antibody tests 
taken. Eighty-five of these were deceased, and 98 patients were alive at study start 
(November 1st 2012). Two patients were impossible to trace. The patients alive were 
sent written information about the study and a request to participate. We received 
signed consent from 82 patients (positive response rate 84%). The final inclusion 
comprised the deceased patients and those with a signed consent form.  24 of the 
deceased and 43 of those alive had two or more AChR-antibody tests combined with a 
medical note including a possible MGFA score.  
3.6 Statistical methods 
Paper I: Incidence and prevalence were calculated per 1 million inhabitants per 
January 1st each year 1995–2008. 95% CIs were calculated assuming the Poisson 
distribution. Statistical software SPSS (15.0) and StatXact 7 were used for statistical 
analysis. 
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Paper II: The odds ratio with 95% CI was estimated to quantify relative risk for a 
positive AChR-antibody test in the patients over 50 years of age relative to patients 
younger than 50 years of age. To assess variation in incidence, Multiple Poisson 
regression analysis was used. This was done using the GENLIN procedure of SPSS 
with a logarithmic link-function and population size as an offset.  
Paper III: MG patients receive symptomatic treatment with pyridostigmine regardless 
of AChR-antibody. In Caucasian populations, 85% of the MG patients are regarded to 
be AChR-antibody positive [109, 206]. Thus a 15% stipulated share of AChR-
antibody negative patients was included in the calculations from the AChR database to 
compare the two databases.  
Age and sex specific incidence rates among MG patients were determined by 
calculating the standardised incidence ratios (SIRs) of observed number of patients 
identified in NorPD compared to the number of MG patients calculated from the 
numbers in the AChR database. 95% CIs were calculated assuming a Poisson’s 
distribution. All statistical analyses were performed in Microsoft Excel (2010). 
Paper IV: Two observers independently classified the first medical note of 33 
randomly picked included patients to validate the MGFA score. Inter-examiner 
agreement achieved was Kappa (K) 0.84 (almost perfect agreement). Time since first 
test was analysed both as a continuous variable and by dividing tests into four quartiles 
for each patient to adjust for the AChR-antibody measurements having been 
performed at irregular time intervals. The 1st quartile comprised 0.24 years (0-3 
months), the 2nd quartile comprised 0.24-1.85 years (3-19 months), the 3rd quartile 
comprised 1.85-4.93 years (19-37 months), and the 4th quartile comprised the rest of 
the time period (37 months-21 years). Correcting for repeated measures in the same 
individuals, multiple ordinal logistic regression using generalised estimating equations 
was used to estimate a possible predictive effect of AChR-antibody concentration and 
time since onset on MGFA score. We also investigated if the effect of AChR-antibody 
concentration on MGFA score depended on longer time since onset (test of time × 
AChR-antibody concentration interaction) using the Generalised Linear Model option 
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in SPSS 21. Results were reported as odds ratios (OR) and 95% CI. SPSS 21 was also 
used for all other statistical analyses. 
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4. Summary of results 
4.1 Seropositive myasthenia gravis: a nationwide 
epidemiologic study (Paper I) 
In this study, comprising data on AChR-antibody tests taken 1983-2008, we 
investigated incidence and prevalence of AChR-antibody positive MG patients for a 
nationwide population spanning over decades. The number of assays taken increased 
from 47 in 1983 to 1007 in 2007. The number of individual patients tested was 8628, 
5521 females and 3100 males (female:male ratio 1.8). We identified 898 AChR-
antibody positive MG patients: 543 females and 350 males (female:male ratio 1.6). Of 
these patients, 308 (34.2%) had their first-time positive AChR-antibody test before age 
50 years and 525 (58.4%) at age 50 years or later. For 65 (7.2%) patients, this age was 
unknown. 420 new AChR-antibody positive MG patients were identified 1995-2008. 
The total crude yearly incidence for 1995–2007 was 7.2 per million (95% CI: 6.5, 7.9). 
The prevalence of AChR-antibody positive MG was 115.5 per million (95% CI: 106.1, 
125.7). On January 1st, 2008, 547 of the 898 AChR-antibody positive MG patients 
were alive, 274 were dead, and the status of 77 patients was unknown. Presuming the 
same survival ratio among these 77 patients as in the rest of our MG population 
(66.6%), the prevalence of AChR-antibody positive MG would be 126.2 per million.  
4.2 Geographical distribution of a seropositive myasthenia 
gravis population (Paper II) 
In this study, we examined the geographical distribution of MG in Norway. Norway 
was divided according to the five previous health regions, and all calculations were 
based on this. 419 first-time AChR-antibody positive patients were identified (231 
females, 188 males), numbers varying between 80 and 212 in the five geographical 
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regions. Unadjusted average incidence per million inhabitants per year ranged from 
5.96 (north) to 9.05 (mid-Norway). Average annual incidence for all five regions 
combined was 7.04, ranging from <1 to 14 per million in the various regions.  
The main finding in this study was that the average incidence per million inhabitants 
did not vary significantly between the five regions (P = 0.091). There was no 
significant linear change in annual MG incidence in the period from 1995 to 2007 (P = 
0.308) adjusted for gender, region and age.  
Overall, it was a slightly higher probability to develop MG for females than for males 
(female: male ratio 1.32). In contrast, the odds of being late-onset was 2.25 times 
higher for a male than for a female (95% CI: 1.45, 3.48), and this did not vary between 
the regions. 
138 first-time AChR-antibody positive patients were 50 years or younger, while 278 
were over 50 years of age. Mean age at first positive AChR-antibody test in the early-
onset group varied from 30.2 years (north) to 36.1 years (west) with an average of 32.5 
years in all regions combined. In the late-onset group, mean age at first positive 
AChR-antibody test varied from 69.0 years (south) to 71.3 years (west) with an 
average of 70.2 years. 
4.3 Myasthenia gravis epidemiology in a national cohort; 
combining multiple disease registries (Paper III)
In this study, we compared prevalence and incidence calculated from the NorPD and 
the AChR database. While the AChR-antibody test provided an opportunity to monitor 
all tests taken in the study period and thereby identify all incident and prevalent cases 
of MG, NorPD provided the same opportunity by monitoring individual drug use of 
pyridostigmine.  
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Both a positive AChR-antibody test and the use of pyridostigmine are regarded as 
specific markers for MG. Prevalence January 1st 2008 was 131 per million by using 
the NorPD database, and 145 per million by using the AChR database (an estimated 
15% share of AChR-antibody negative patients was added). 
Analysing prevalence data, we found no significant difference between the NorPD and 
AChR databases (SIR 1.1; 95% CI 1.0, 1.2). Moreover, there was no difference in the 
number of females in the two cohorts. However, more men were found in the NorPD. 
The number of early-onset MG patients did not differ between the two cohorts, while 
in the late-onset groups more male patients were identified through NorPD compared 
to the AChR database.  
The incidence rate based on NorPD data was 16.0 per million in 2007, compared to 8.8 
per million per year in the AChR database, calculated as mean annual rates. This 
means a doubled incidence for the NorPD group compared to the AChR group (SIR 
1.8; 95% CI 1.4, 2.3). Nearly a threefold more female MG patients was found in the 
NorPD compared to the patients from the AChR-antibody database, while no 
differences in the number of male MG patients. Analysing the incidence rates 
according to early- and late-onset MG subgroups, the number of patients was doubled 
for the early-onset group in the NorPD compared to the AChR database. For females, 
twice as many were identified through the NorPD, while no differences for males 
between the NorPD and AChR database. There was an approximately doubling in the 
MG incidence rate for the late-onset group in the NorPD compared to AChR database. 
A threefold more females were identified through NorPD compared to AChR 
database, while the number of new male MG patients did not differ significantly in the 
two cohorts.  
54 
4.4 Acetylcholine receptor antibody concentration and 
association to myasthenia gravis development (Paper IV) 
This retrospective clinical study was based on patients from western Norway with two 
or more AChR-antibody tests and with corresponding medical notes. The study 
population was divided into those treated with immunosuppressive drugs 
(immunosuppressed MG group), and those treated with pyridostigmine only 
(pyridostigmine MG group). In total, 67 patients were included with 309 
measurements of AChR-antibodies. The immunosuppressed MG group constituted 56 
of the 67 patients, with 272 AChR-antibody measurements with a corresponding 
MGFA score. The pyridostigmine MG group constituted 11 patients with 37 AChR-
antibody measurements with a corresponding MGFA score.     
The concentration of AChR-antibodies was associated with the longitudinal 
development of clinical severity in individual patients treated with immunosuppressive 
drugs. This showed an effect of AChR-antibody concentration on the MGFA score for 
the whole study period in this group, though not significant for the last quartile (37 
months to 21 years). In the pyridostigmine group, this association was weakened 
considerably, and no longer significant. We found a diminished effect of AChR-
antibody concentration on MGFA score after the first three months. In the last quartile, 
the effect seemed to be the opposite of what was expected. The results of this study 
indicate that AChR-antibody measurements may be a valuable tool in the follow-up 
for the MG group treated with immunosuppressive drugs, and that an increase or 
decrease should influence therapeutic decisions. 
55 
5. General Discussion 
We found the annual incidence of AChR-antibody positive MG patients in Norway 
1995-2008 to be 7.2 per million. The point prevalence was 126.2 per million January 
1st 2008. In 1984, the total MG incidence and prevalence in Norway was reported as 
4.0 and 90 per million per year respectively [184]. Our study demonstrates an increase 
in both incidence and prevalence in Norway compared with the study from 1984. 
The increasing incidence can be explained by several factors. First, case-finding has 
probably improved due to the advent of the AChR-antibody assay. Worldwide, the 
MG incidence doubled after 1976, when the first version of the modern AChR-
antibody assay was described and introduced [25]. Our data were obtained from a 
national database, with a positive AChR-antibody test as a proxy measurement for 
anti-AChR MG. The epidemiological data from 1984 was based on data sent from 
neurological departments and practising neurologists in Norway. Furthermore, the 
healthcare system and neurological services have improved greatly from the study 
period of the 1984 study (inclusion period 1912-1981) and to our study (inclusion 
period 1983-2013). This has probably led to a lower threshold for neurological 
examinations and a subsequent increased case ascertainment.  
There is evidence for MG having been underdiagnosed in the elderly in particular. The 
clinical signs in MG are more difficult to assess correctly in this group, as explained in 
the “Clinical features”- section, page 14 [2]. More patients are diagnosed with MG 
today than previously because of enhanced awareness of MG in the elderly [2, 205].  
With an ageing population, an increase in new MG cases is expected as this group are 
at higher risk of acquiring MG. In our studies, twice as many patients had their first-
time positive AChR-antibody test after 50 years of age. In the Norwegian study from 
1984, calculations based on incidence rates demonstrated a higher rate for those with 
onset before 50 years versus those with onset after 50 years of age (2.9 per million 
versus 1.1 per million) [184].  The higher incidence among the elderly in recent years 
clearly shown in two epidemiological studies from Italy conducted within the same 
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region, with a similar study design and with a twenty years interval between the 
studies. The increase in incidence was mainly because of an increase of male patients 
with MG onset after age 50 years [137]. Therefore, enhanced awareness about late-
onset MG and increased longevity in the general population with more MG patients 
diagnosed in the elderly are causes of the increased MG incidence [71, 72, 137, 140, 
141, 205].  
It is a striking observation that in several studies the MG incidence peaks in the 70-80 
year old, and then fall off abruptly [9, 72, 147, 205]. This can partly be explained by 
underdiagnosing in the very elderly. In addition, Vincent (2003) discusses two other 
explanations: The peak can be a cohort effect, where people represented in the peak 
has been exposed to a particular environmental exposure, increasing their risk for 
developing MG. However, this explanation requires a very short time of duration of 
susceptibility of the exposure and a very long fixed duration from exposure to MG 
development. This explanation fits poorly as the short time of rise and fall for the 
incidence peak happens in several populations. It could also be that the steep fall in the 
incidence represents a competing risk for those patients at risk for developing MG. It 
could be that these patients are at higher risk than the general population for 
developing some other fatal disease. This is unlikely as it has to be very strongly 
associated with the risk of developing MG and a risk strictly limited to the very elderly 
[205].     
It could also be that there has been a genuine general increase in incident cases of MG 
from 1984 to 2008 caused by unknown environmental triggers. However, there is no 
evidence for an increase in MG incidence in Norway1995-2008 based on the AChR-
antibody database [71].  
The increase in MG incidence demonstrated in other studies are mainly caused by an 
increase in the proportion of patients with onset after 50 years of age [25]. The 
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immunological differences between early- and late-onset MG, suggest that these 
subgroups are different disease entities. The majority of early-onset anti-AChR MG 
patients have hyperplastic thymus with lymphocytic infiltrates and germinal centres 
similar to those found in lymph nodes. The thymuses contain all components 
necessary for a development of an immune response, supporting an intrathymic 
pathogenesis involved in the immune response in early-onset MG [95]. Late-onset MG 
usually lacks the thymic abnormalities, and therefore, the mechanisms of 
autosensitisation to AChRs in this subgroup are unclear. Their HLA-profile differs, 
and titres of circulating AChR-antibodies are lower in late-onset MG than in early-
onset MG. Antibodies to striated muscles are more often found in late-onset MG, 
while autoimmune comorbidity is more uncommon in this subgroup [120]. These 
aspects may explain why a genuine increase in late-onset MG may occur even if this is 
not true for early-onset MG.    
The MG incidence in our study was in the lower range compared to what was found in 
8 other studies on anti-AChR MG from other populations. The range in these studies 
spanned from 4.3 to 18.0 per million per year [25]. The observed heterogeneity may be 
explained by either biological and environmental factors, that incidence actually vary 
in different populations, or that the variation is due to methodological problems and 
study quality. There is a trend towards decreasing heterogeneity with increasing study 
quality [25]. A genuine geographical difference in anti-AChR MG epidemiology 
remains to conclude on. One exception is childhood onset MG in Asian populations 
appearing to be much higher compared to Caucasian populations [217].   
There was a marked variety in the prevalence found in previous studies, ranging from 
70 per million to 163 per million. There is linear trend of increasing prevalence with 
year of study [25]. The increased prevalence is for a large part related to longer life 
spans due to improved MG treatment [42]. An increased prevalence- incidence ratio 
has been demonstrated over time, reflecting the reduced MG mortality.  
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Our study was based on a nationwide population, a time period spanning over decades, 
very specific inclusion criteria, and the belief that we included nearly all cases of 
AChR-antibody positive MG patients in the study population through the study period. 
Accurate epidemiological analysis of low frequency diseases such as MG requires a 
large population to identify sufficient numbers of affected people to disclose patterns 
of the disease. The majority of published studies are limited in geographical scope, 
typically yielding small samples where estimates of incidence and prevalence cannot 
always be generalised beyond the study population. We have a sufficiently large 
population to draw realistic conclusions about the incidence and prevalence of anti-
AChR MG in Norway. Selection bias is a concern in most studies, but the risk of this 
type of bias should be low in our population. 
In paper III we evaluated the AChR database as a tool for epidemiological studies by 
comparing the results with those obtained through the NorPD database. We found a 
good concordance for the prevalences in the two databases, but the incidence 
calculated from the NorPD database was much higher. However, the incidence from 
NorPD was calculated only for 2007, while the incidences for data obtained from the 
AChR database were calculated annually from 1995 to 2007. The higher MG 
incidence found in NorPD can be explained by the inclusion of relapsing cases of MG 
because of a short inclusion period for this registry. If so, we will expect to find a 
lower incidence in future studies in NorPD. It is also unknown to what degree 
pyridostigmine have been prescribed as ex juvantibus treatment or how frequent 
prescribing practice without proper reimbursement coding occurs. There is a 
possibility that pyridostigmine prescriptions for other purposes than reducing MG 
symptoms in some cases have been included. An effect of pyridostigmine for 
diagnoses, such as gastrointestinal dysmotility in idiopathic pseudo-obstruction, has 
been inconclusive [182].  
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To be able to compare the two databases, a stipulated 15% share of MG patients 
without AChR-antibodies was added to the population from the AChR database. Even 
though there is a consensus about the anti-AChR MG constituting 85% of the total MG 
population, we have to consider whether this assumption is correct. Most studies 
performed to calculate this 85% proportion were conducted in the early 1980s. This 
proportion may have changed during the decades. There is also a possibility that not 
every diagnosed MG case actually has taken the AChR-antibody test, especially for 
the first years after the test was introduced in Norway in 1983. This would lower the 
incidence based on the AChR database. Norway has a public welfare system which is 
mainly free of charge for the patient, and the AChR-antibody test is of no extra cost. 
The test is well-known for its very high specificity, and regarded as a first diagnostic 
step to confirm a suspected MG case.  
The incidence for anti-AChR MG did not differ significantly between the five 
geographical regions of Norway (paper II). However, it tended to be lower in the 
northern region. We hypothesised that one reason for this tendency could be the 
existence of the Sami population in the north. It is known that multiple sclerosis (MS) 
occurs less frequently in this population, perhaps as a result of a different HLA profile 
[65, 66]. However, there is no official Sami registry, which hampers an estimation of 
the actual Sami population. We have not been able to disclose any epidemiological 
differences between the Norwegian and Sami population in our study.  
Another explanation for the trend towards a lower incidence in northern Norway could 
be the lower sun exposure and subsequently lower concentrations of vitamin D in this 
population. Vitamin D deficiency has been associated with several autoimmune 
diseases [15]. On the other hand, it is known that the intake of vitamin D through the 
diet is higher in northern Norway compared to the southern regions, compensating for 
the lower sun exposure [22]. There is a high prevalence of vitamin D deficiency in the 
adult population of Norway in general, and it is associated with season, body mass 
index and lifestyle. Body mass index has increased markedly in the last decades in 
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Norway [11]. An increase in body mass index, and a changed lifestyle, with lower 
intake of cod fish liver, could affect the prevalence of vitamin D deficiency, and 
should be a topic for future studies. However, there is no evidence to support a higher 
frequency of vitamin D deficiency in northern Norway compared to southern parts [89, 
101]. For MS, it has been found an effect of month and season of birth for disease risk. 
In the northern hemisphere, patients born in the spring have a higher risk for 
developing MS than those born in the autumn. The suggested reason for this is the 
lower concentration of vitamin D in the winter season, thus being an environmental 
factor in the intrauterine period affecting the MS susceptibility [197]. This effect 
seems to be more prominent in high-risk areas for MS, especially in areas where 
exposure to sun is low. Recently, it was revealed that after controlling for vitamin D 
concentration, decreased sunlight exposure still remained significantly associated with 
MS. This implicated that vitamin D is not the only mediator of the beneficial influence 
of sunlight on MS [68, 114]. Melatonin is another hormone with immunomodulatory 
properties, and it is light-dependent. This hormone may be a potential mediator of the 
neuro-immunomodulatory effects of vitamin D in patients with MS [58]. This could 
explain why there is a lower incidence of MS in the north even though the vitamin D 
levels do not differ from levels in the southern part of Norway. The month of birth-
effect has not been investigated for MG, and should be a topic for a future study. 
A distinct geographical distributional pattern for MS-incidence worldwide has been 
defined, with a significantly higher incidence with increasing latitude [173]. So far, it 
has not been possible to identify any differences in epidemiology worldwide explained 
by environmental factors for anti-AChR MG, as discussed previously in the general 
discussion. In Norway, we did not identify any differences in anti-AChR MG 
incidence in the different regions. Numerous epidemiological studies on MS in 
Norway have been conducted, spanning over decades. These studies have revealed a 
lower incidence in the northern region, and persistently the highest MS incidence in 
the inland in southern Norway [121]. For MS, genes associated with the immune 
system play a major role in the pathogenesis [83]. But as for MG, environmental 
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factors are of significance. Smoking is thought to elevate the risk of MS, while factors 
as sun exposure and food high in vitamin D are thought to decrease the risk. Less 
smoking and people spending more time in sunny parts of the world during the winter, 
thus increasing the levels of vitamin D, should decrease the frequency of MS. It is still 
not known how a change in diet will influence this risk [121]. However, MS still tends 
to increase in frequency. This illustrates how complex the interaction between genes 
and environmental factors is on the individual level. Both MG and MS are 
immunoactive disorders with autoimmunity, but most etiological properties are 
thought to differ. Our study indicates that geographically-related factors are among 
those that differ.  
For the anti-MuSK MG subgroup, which was not examined in our study, prevalence 
clearly differs among populations. In Norway, there are five known cases of anti-
MuSK MG (unpublished), four of these being alive. This gives a prevalence of 
approximately 0.8 per million in Norway. The prevalence is also low in Poland [97] 
but high in Greece [201]. Why this MG subgroup shows so distinct differences in 
incidence and prevalence while the anti-AChR MG subgroup does not remains to be 
resolved.  
In paper IV, we showed that patients with and without immunosuppressive treatment 
differed significantly according to AChR-antibody concentration and longitudinal 
association to clinical severity. While the group treated with immunosuppressive drugs 
had a significant association, no association was found in those patients treated with 
pyridostigmine only. This latter group was, however, small, constituting only 11 
patients. This indicates that it will be valuable to monitor the patients treated with 
immunosuppressive drugs for AChR-antibody concentration. AChR-antibody 
concentration probably reflects the amount of drug response, and changes in this 
concentration may indicate further treatment regarding drug or drug dose. The effect 
immunosuppressive drugs has on the AChR-concentration can be due to a reduction of 
B-cell synthesis and for activation, acting directly, or indirectly through inhibiting T-
cell mechanisms. We did not monitor the effect of individual immunosuppressive 
62 
drugs. It could well be that the effects on AChR-antibody concentration vary for the 
different drugs. However, we adjusted for thymectomy in the analysis, and this did not 
change the results. This means that the effect of immunosuppressive drugs on the 
AChR-concentration appears regardless of whether the patient is thymectomised or 
not.  
Prior to this study, statistical power was calculated. We managed to achieve the 
minimum sample size required to detect an effect of AChR-concentration on clinical 
state. Nevertheless, it would have been feasible to imply more variables in the 
regression model if we had a larger sample size, including subgrouping according to 
the different immunosuppressive drugs. This could be obtained by a multicentre study. 
On the other hand, the results from a multicentre study could be biased by different 
treatment approaches and variation in documenting the clinical state. By having a 
single center study, fewer doctors were involved and the MGFA score from the 
clinical assessment in the medical notes more homogenous. Indications for treatment 
and treatment changes would also be similar.  To monitor the disease with AChR-
antibody tests does not seem to have any value for the patients treated with 
pyridostigmine only.   
No consistent association between concentration of AChR-antibodies and MG disease 
severity has previously been found in. Most studies were performed in the early 1980s. 
Our study was retrospective. All clinical assessments were based on structured and 
validated medical notes. A prospective design would have included direct MGFA-
scoring and regular intervals between the clinical assessments and the AChR-antibody 
tests taken. This was not possible in our study and represents a major weakness.  
Based on the results from this study, it may be helpful to monitor MG patients on 
immunosuppressive drugs with repeated AChR-antibody tests, and especially if they 
do not respond clinically.    
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6. Methodological considerations 
6.1 Study design 
The studies were all retrospective cohort studies, and based on the AChR database. 
The database contains patient information (Patient name, date of birth, data of sample 
acquisition, and name of referring doctor/hospital) for all AChR-tests taken from the 
very beginning of performing the analysis of AChR-antibody concentration. For paper 
I, II and III there was no clinical information available, while paper IV was based on 
clinical information from the anti-AChR MG cohort of western Norway. The inclusion 
criteria in Paper I, II and III were entirely based on a positive AChR-antibody test. 
Because of the high specificity of AChR-antibody test, it is regarded as a first 
diagnostic step for MG. Therefore there is reason to believe that case ascertainment 
approximated 100% in the three first studies. In paper IV, we included all AChR-
antibody tests up till 2013. In 2008, another Norwegian laboratory (in Oslo) started to 
offer AChR-antibody analysis. This means that some AChR positive MG cases may be 
missed in paper IV. However, in this study we only included patients treated at 
Haukeland University hospital. We believe that most AChR-antibody tests in this 
region were analysed at this regional hospital, not at a regional hospital in Oslo. In 
paper IV we did no epidemiological calculations.  
For MG being a rare disease, it is always a challenge to have a sample size large 
enough enabling to disclose detailed epidemiological patterns. One solution to this 
problem would have been to establish a multinational study. However, we prioritised a 
homogenous national population and a study based on one database to increase 
reliability and validity. There were also practical reasons for choosing a single center 
study.  
In all clinical studies, a researcher has two concerns: the internal and external validity 
of the study. The internal validity of epidemiological studies can be affected by 
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random and systematic errors. External validity describes to what extent of a study can 
be generalised to other populations than the one studied [161].  
6.2 Internal validity 
6.2.1 Random errors 
Random error reflects a problem of precision in assessing a given exposure-disease 
relationship and can be reduced, among others, by increasing the sample size [199]. 
Random errors may also occur as a result of measurements not performed according to 
the procedures, misreading of AChR-antibody results, and incorrect coding of patient 
data and/or AChR-antibody result when typing it into the database. The database 
contains data of 15 000 tests, and with such a large study size, the effect of random 
errors will be reduced [161], yielding a more precise result of the study. The 
commercial RIA was introduced in 1994, and the analytical technique has been used 
since then at Haukeland University Hospital. The laboratory has built up extensive 
experience in using this particular test. Four times a year, the laboratory participates in 
an external quality assessment to promote best practice. The result from the quality 
assessment is measured as an overall misclassification score (OMIS), with three 
categories of performance: good, adequate and poor. The laboratory at Haukeland 
University Hospital has always performed in the best category since they joined the 
quality assessment program. Both the large population size and the high quality of the 
analyses performed at the laboratory reduce the effect of random error.  
6.2.2 Systematic errors  
Systematic errors or bias arise as a result from the research methods used by the 
investigator, from factors affecting the study participation (selection bias) or from 
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systematic distortions when collecting information about exposures and outcomes 
(information bias) [169].  
6.2.2.1 Research methods 
P-value: A p-value expresses “the probability that results at least as extreme as those 
obtained in an analysis of sample data are due to chance”[20]. When our estimates 
included use of a p-value in the analysis, we used the common standard that the p-
value for our results had to be less than 0.05 (the significance level) to reject the null 
hypothesis. There is always a probability of error in this type of reasoning. The 
possibility that significant results can be due to chance, as for example sampling error, 
has to be taken into consideration, as for all statistical analysis. 0.05 is somehow an 
arbitrary choice of level; this has been some of the critics of p-value. A low p-value 
reduces the risk of rejecting a null hypothesis that is actually true (type 1 error). A p-
value set to 0.1 reduces the risk of a type II error (the failure to reject a false null 
hypothesis), but then again increases the risk of a type I error, considered to be more 
serious.  
Regression model: The concept of a regression model is to predict or explain a 
dependent variable (response variable) by using a set of independent variables 
(explanatory variables). In paper II and IV, regression models were used to study if the 
dependent variable was the function of one or more independent variables.  In paper II, 
incidence was defined as the response variable, and gender, onset age and health 
region were defined as explanatory variables. Our null hypothesis was that anti-AChR 
MG incidence did not vary between the regions. The null hypothesis was not rejected, 
as we found no significant differences between the regions. In paper IV, MGFA score 
was defined as a response variable, and AChR-antibody concentration and time since 
onset defined as explanatory variables. Our null hypothesis for this study was that 
there was no association between MGFA score and AChR-antibody concentration. 
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The null hypothesis was rejected, as we found an association between the two 
variables for the group treated with immunosuppressive drugs.  
As for most statistical procedures, linear regression makes certain assumptions about 
the data used in the analysis. The assumptions are data appropriateness, independence, 
linearity, distribution and homoscedasticity. In both paper II and paper IV these 
assumptions were met in an acceptable manner. If these assumptions are not met 
properly, it may reduce the validity of the studies [20].  
The theory associated with linear regression is well understood, and allows rather 
complex statistics to be easily interpretable. However, even if there is an association 
between the predictor and outcome, that is no proof for an underlying causal 
mechanism. In paper IV, we found an association between AChR-antibody 
concentration and MGFA score, but the model says nothing about why there is an 
association. Regression models are sensitive for outliers because outliers pull the 
regression line towards itself. This can result in a solution more accurate for the 
outlier, but less accurate for all other cases in the data set. As discussed above, we did 
not have any extreme outliers in our data set.  
A general thumb rule in multiple regression is that one should have at least 10 times as 
many observations as variables; otherwise the estimates of the regression line may be 
unstable and difficult to replicate [8]. In paper II, the number of anti-AChR MG cases 
was 419. With such a large number of cases, the estimates should be stable and 
reproducible. In paper IV, the number was 67 anti-AChR MG cases.  In this model, we 
had 6 independent variables, near the limit for the general rule.  
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Poisson regression, the method applied in paper II, assumes that the observed counts 
are generated from a Poisson distribution. This model is often used to model count 
when the events being counted are somewhat rare. The probability of disease 
occurrence was low relative to total population size. In paper IV, multiple ordinal 
logistic regression was applied by using generalised estimating equations. We 
corrected for repeated measures in the same individuals, by assuming an exchangeable 
correlation structure. In this way, we estimated a possible predictive effect of AChR-
antibody concentration and time since onset on MGFA score. 
In paper III we compared MG incidence and prevalence using two different 
Norwegian nationwide databases by calculating the standardised ratios. The two 
databases used different markers to identify MG cases. A positive AChR-antibody test 
was used as a marker in the one database, while prescription of pyridostigmine was 
used as a marker in the other (NorPD). These databases have different sensitivity and 
specificity which complicates the comparison. The AChR database has a high 
specificity, but lacks the capacity to identify MG patients without AChR-antibodies. 
Therefore, we had to estimate a 15% share of MG patients negative to AChR-
antibodies to enable comparison between the databases. This lowers the sensitivity of 
the AChR database. The MG diagnosis is not available in NorPD, but the indication 
for treatment with pyridostigmine covered by reimbursement regulations is exclusive 
for MG. However, pyridostigmine prescriptions can be reimbursed for other diagnosis, 
for example congenital myasthenic syndromes or Lambert-Eaton myasthenic 
syndrome. This renders a lower specificity for NorPD. Such differences between the 
databases have to be taken into consideration when comparing the data. Thus, the two 
databases should be complementary and together elucidate the true MG prevalence 
and incidence in Norway. Both databases are nationwide and the data were collected 
within the same period of time.    
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The choice of research method has implications for the results from the studies, and it 
is important to carefully consider the methods before the study process begins. This 
became evident when conducting paper IV. Initially, we found no association between 
AChR-antibody concentration and MGFA score because we did not distinguish 
between those treated by pyridostigmine only and those treated with 
immunosuppressive drugs. When we did so, the results and the subsequent conclusion 
changed.  
   
6.2.3 Selection bias  
The AChR-database is a nationwide database with an expected coverage of all tests 
performed from the whole country during the period 1983-2008. In 2008, the 
laboratory at Oslo University Hospital also started to offer analysing AChR-antibody 
concentration, but for the three first papers, the inclusion stopped December 31st 2007.  
It is possible that some samples were sent abroad to be tested during the study period, 
however, this is probably a very small number. It could also be that some patients are 
diagnosed without taking AChR-antibody test. This is especially a concern for those 
diagnosed during the first years after the introduction of the test in 1983. There has 
been a steady increase in number tests taken from 47 in 1983 to over 1000 tests 
annually analysed in the recent years. This illustrates how the test is incorporated as a 
diagnostic tool [88]. Our calculations of incidence had a starting point in 1995, 12 
years after the introduction of the test. This reduces the risk of missing patients 
diagnosed without an AChR-antibody test. Prevalence was calculated 1st January 2008, 
and included all anti-AChR MG patients diagnosed the past 25 years and alive. In 
paper I, II and III, the only inclusion criteria was a positive AChR-antibody test taken, 
with cut-off at 0.5 nmol/L. This very strict inclusion criteria and the nationwide 
inclusion, reduce the chances of selection bias significantly.  
In paper II, we studied the geographical distribution of MG in Norway. We did not 
have the precise address of the patients, but used the address of the referring hospital 
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or doctor as a marker of the health region the patient belonged to. Norway has a public 
health care system funded from the national budget and run by five (in the study 
period, now four regions) Regional Health Authorities.  Every health region has 
hospitals with high competence for neurological service. The citizens have free choice 
of hospital within Norway and citizens are eligible for treatment free of charge in the 
public health system. Therefore, it may be that some samples were sent from one 
region whereas the patient belonged to another region. However, only approximately 
1% of patients are treated by other hospitals than default hospital within their health 
region, one-third representing minor surgery. When conducting paper the IV study, 
this assumption was also confirmed as no patients belonging to Haukeland University 
Hospital had chosen other than default hospital.  
Another challenge of defining the patients’ health region was migration within 
Norway. The majority group of migration is those from 20 to 29 years of age. In paper 
II, we consistently defined the patient´s region based on the first positive AChR-
antibody test from the region of the referring hospital or doctor (defined as MG onset). 
If a patient has been exposed to a possible environmental exposure for developing 
MG, but is registered with a first positive test in another region than the region for the 
potential exposure, we miss the opportunity to eventually identify this mechanism.  
This could represent a selection bias for those developing the disease as early-onset 
MG, and the distribution can be biased because more patients can be registered with 
their first positive test in another region than the region for exposure. However, even if 
we had known the exact address and migration pattern of the patients, we still had had 
to define one health region as the belonging health region. In this study we were 
consequent in the definition, and we think that more information about young adults’ 
migration would not change the results substantially.  
In paper IV, the inclusion criteria were more complex because only patients from 
western Norway with two or more AChR-antibody tests and a medical note written by 
a neurologist corresponding in time to the AChR-antibody test were included. This 
introduces a bias because we do not know why some patients took more tests than 
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others. Some doctors take more AChR-antibody tests than others. Some patients have 
a more severe disease or a more fluctuating disease or some may have had relevant 
comorbidity. Gender and age are thought not to be determining factors. Most probably, 
those with two or more test taken, had a more severe disease than those without. We 
concluded in the study that repeated AChR-antibody measurements are valuable to 
monitor response to immunosuppressive treatment in individual MG patients.   
6.2.4 Information bias 
The most important type of information bias is the misclassification bias [199]. In this 
study, classification first of all depended of the accuracy of the diagnostic test (AChR-
antibody test). As discussed in other sections, the AChR-antibody test is very specific 
for MG, even without clinical information available. With a cut-off value at 0.5 
nmol/L, there is, however, still a small risk for false positive test. The risk of a false 
negative test is probably higher, but difficult to determine (as discussed in the “AChR 
database-section”, page 44). In this thesis, we have defined patients with low-affinity 
AChR-antibodies as a separate subgroup.  
This study is limited to one MG subgroup. We have not investigated MG with low-
affinity AChR-antibodies or other antibodies such as against MuSK or LRP4. As 
discussed in “Pathophysiology of anti-AChR MG”-section, the AChR-antibody 
subgroup constitutes about 85% of all MG cases in Norway. To include just one 
subgroup of MG is both strength and a weakness of the study. The study has a strict 
inclusion criteria and it is based on one database with tests performed with high 
quality. On the other hand, these results cannot be generalized to all patients with MG 
in Norway.     
Misclassifications can also be introduced by the observer (interviewer bias, biased 
follow up), or by the study participants (recall bias). In paper IV all clinical 
information was entirely based on what the neurologist reported in the structured 
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medical notes. Our MGFA score was depended on what the patient told the doctor 
(recall bias), and how the doctor obtained the answers from the patient (interviewer 
bias), and finally how the observation was formulated in the medical note. Even 
though all doctors were experienced doctors on MG, these biases represent the 
weakness of a retrospective clinical study. Another bias was introduced when the 
investigator evaluated the medical notes and scored them according to MGFA score. 
To minimise this bias, the first medical notes from 33 randomly selected patients were 
validated by two independent observers, and with very good agreement between the 
observers. This validation did not reduce the recall- or interviewer bias, but ensured 
the best possible score based on the medical notes.      
6.2.5 Confounding 
Confounding occurs when the relationship between a given exposure and a specific 
disease/outcome is misinterpreted because of  the influence of a third variable or group 
of variables that has not been taken into account (confounder) [200]. Controlling for 
confounders can be done both in the study design (as randomization, restriction and 
matching), and/or during data analysis. In the data analysis, the most effective way to 
controI confounders, is by stratification. 
In paper I, we calculated annual incidence of anti-AChR MG in the period 1995-2008 
based on a positive AChR-antibody test. We had no clinical information, except for 
age and gender. The test for homogeneity of rates, used to compare the annual number 
of new cases, was based on the assumption that this number followed an independent 
Poisson distribution. This test was performed to evaluate whether the variation in 
estimates from one stratum to another (age or gender) was compatible with the 
assumption that the dependent variable, incidence, was uniform independent of age or 
gender.  
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In Paper II, multiple Poisson regression analysis was used to assess variation in 
incidence depending on year, gender, onset age, and geographical region. Multiple 
Poisson regression analysis was used because the probability of disease occurrence 
was low relative to the total population size. All incidence analyses were adjusted for 
gender, region and age.   
In paper IV, we cannot be sure to have all relevant information about the patients 
included in the medical notes. It could be that the patient or the doctor leave out 
information relevant for the MGFA scoring. The information about medication could 
have been incomplete. This may have resulted in uncontrolled confounders. In paper 
IV, all calculations were adjusted for gender, thymectomy and subclass (early-onset 
MG, late-onset MG, ocular MG and thymoma MG).   
6.2.6 External validity 
Epidemiological MG studies report a wide variation in prevalence and incidence in 
various populations. Since we do not know whether the variation is due to study 
quality or actual biological differences, the results of paper I, II and III, cannot 
automatically be generalised to all other populations. However, we will argue that our 
calculated prevalence and incidence reflect accurate epidemiological data for MG in 
Norway since we expect our case ascertainment to be close to 100%, nationwide, and 
by one database. Our data can therefore be used as comparison for high quality 
epidemiological data from other populations. Such comparisons should hopefully 
elucidate genetic or environmental causative factors. 
We believe that the results for paper IV are generalisable.  This assumption is based on 
the pathogenesis of anti-AChR MG being the same independently of the population. 
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We conclude that AChR-antibody measurements should be included as a decision-
making tool, valuable to monitor response to immunosuppressive treatment.  
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7. Conclusions 
This study has provided important epidemiological clues to anti-AChR MG: a 
nationwide incidence, prevalence and gender characteristics. Moreover, the study has 
yielded knowledge of the association between clinical anti-AChR MG status and 
concentration of AChR-antibodies intra-individually over time.  
We found a total crude yearly anti-AChR MG incidence of 7.2 per million in the 
period 1995-2007, and a prevalence of 126.2 per million January 1st 2008.  
The incidence of anti-AChR MG in the five geographical regions of Norway did not 
differ significantly. This means that the incidence of anti-AChR MG is the same in the 
different regions of Norway. 
We validated the AChR-database using NorPD, and found good concordance for the 
prevalence calculated in the two databases. The prevalences were calculated as 145 
and 131 per million for the two databases respectively. However, the incidence for 
2007 was twice as high in NorPD than in the AChR-database, 16.0 and 8.8 per million 
respectively. This may be explained by a shorter study period for NorPD (2004-2007).  
We found an association between clinical MG state and concentration of AChR 
antibodies intra-individually over time in patients with immunosuppressive drug 
treatment. In the group treated with pyridostigmine only, such an association was not 
found. Repeated AChR-antibody tests in MG patients treated with immunosuppressive 
drugs have an additional value and can be a support for therapeutic decisions.      
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ƉŚǇƐŝĐĂůĂĐƚŝǀŝƚǇďĞŚĂǀŝŽƌĂŶĚƚŚĞĚĞǀĞůŽƉŵĞŶƚŽĨďŽĚǇŵĂƐƐŝŶĚĞǆĚƵƌŝŶŐƚŚĞůĂƐƚϯϬǇĞĂƌƐŝŶ
EŽƌǁĂǇ͘^ĐĂŶĚŝŶĂǀŝĂŶũŽƵƌŶĂůŽĨŵĞĚŝĐŝŶĞΘƐĐŝĞŶĐĞŝŶƐƉŽƌƚƐϭϴ͗ϯϬϵͲϯϭϳ
ϭϮ͘ ƋƵŝůŽŶŝƵƐ^D͕,ĂƌƚǀŝŐW;ϭϵϴϲͿůŝŶŝĐĂůƉŚĂƌŵĂĐŽŬŝŶĞƚŝĐƐŽĨĐŚŽůŝŶĞƐƚĞƌĂƐĞŝŶŚŝďŝƚŽƌƐ͘
ůŝŶŝĐĂůƉŚĂƌŵĂĐŽŬŝŶĞƚŝĐƐϭϭ͗ϮϯϲͲϮϰϵ
ϭϯ͘ ĂƌƚŚ͕EĂďĂǀŝEŽƵƌŝD͕EŐ͕EǁĞW͕ƌŝůs;ϮϬϭϭͿŽŵƉĂƌŝƐŽŶŽĨ/s/ŐĂŶĚW>yŝŶƉĂƚŝĞŶƚƐ
ǁŝƚŚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘EĞƵƌŽůŽŐǇϳϲ͗ϮϬϭϳͲϮϬϮϯ
ϭϰ͘ ĂƌƚŽĐĐŝŽŶŝ͕^ĐƵĚĞƌŝ&͕DŝŶŝĐƵĐŝ'D͕DĂƌŝŶŽD͕ŝĂƌĂĨĨĂ&͕ǀŽůŝ;ϮϬϬϲͿŶƚŝͲDƵ^<
ĂŶƚŝďŽĚŝĞƐ͗ĐŽƌƌĞůĂƚŝŽŶǁŝƚŚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐƐĞǀĞƌŝƚǇ͘EĞƵƌŽůŽŐǇϲϳ͗ϱϬϱͲϱϬϳ
ϭϱ͘ ĂƐŝƚ^;ϮϬϭϯͿsŝƚĂŵŝŶŝŶŚĞĂůƚŚĂŶĚĚŝƐĞĂƐĞ͗ĂůŝƚĞƌĂƚƵƌĞƌĞǀŝĞǁ͘ƌŝƚŝƐŚũŽƵƌŶĂůŽĨ
ďŝŽŵĞĚŝĐĂůƐĐŝĞŶĐĞϳϬ͗ϭϲϭͲϭϳϮ
ϭϲ͘ ĞĚůĂĐŬZ^͕^ĂŶĚĞƌƐ;ϮϬϬϮͿKŶƚŚĞĐŽŶĐĞƉƚŽĨŵǇĂƐƚŚĞŶŝĐĐƌŝƐŝƐ͘:ŽƵƌŶĂůŽĨĐůŝŶŝĐĂů
ŶĞƵƌŽŵƵƐĐƵůĂƌĚŝƐĞĂƐĞϰ͗ϰϬͲϰϮ
ϭϳ͘ ĞŶĂƚĂƌD;ϮϬϬϲͿƐǇƐƚĞŵĂƚŝĐƌĞǀŝĞǁŽĨĚŝĂŐŶŽƐƚŝĐƐƚƵĚŝĞƐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘
EĞƵƌŽŵƵƐĐƵůĂƌĚŝƐŽƌĚĞƌƐ͗EDϭϲ͗ϰϱϵͲϰϲϳ
ϭϴ͘ ĞƌƌŝŚͲŬŶŝŶ^͕>ĞWĂŶƐĞZ;ϮϬϭϰͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĐŽŵƉƌĞŚĞŶƐŝǀĞƌĞǀŝĞǁŽĨŝŵŵƵŶĞ
ĚǇƐƌĞŐƵůĂƚŝŽŶĂŶĚĞƚŝŽůŽŐŝĐĂůŵĞĐŚĂŶŝƐŵƐ͘:ŽƵƌŶĂůŽĨĂƵƚŽŝŵŵƵŶŝƚǇ
ϭϵ͘ ĞƌƌŽƵƐĐŚŽƚ:͕ĂƵŵĂŶŶ/͕<ĂůŝƐĐŚĞǁƐŬŝW͕^ƚĞƌŬĞƌD͕^ĐŚŶĞŝĚĞƌ;ϭϵϵϳͿdŚĞƌĂƉǇŽĨ
ŵǇĂƐƚŚĞŶŝĐĐƌŝƐŝƐ͘ƌŝƚŝĐĂůĐĂƌĞŵĞĚŝĐŝŶĞϮϱ͗ϭϮϮϴͲϭϮϯϱ
ϮϬ͘ ŽƐůĂƵŐŚ^;ϮϬϭϮͿ^ƚĂƚŝƐƚŝĐƐŝŶĂŶƵƚƐŚĞůů͘KΖZĞŝůůǇ͕&ĂƌŶŚĂŵ͕^ƵƌƌĞǇ͕ŶŐůĂŶĚ
Ϯϭ͘ ƌŝĂŶŝ͕ŽƌŝĂ͕ZƵŐŐĞƌŽ^͕dŽĨĨĂŶŝŶ͕>ƵĐĂD͕ůďĞƌŐŽŶŝDW͕ΖKĚŽƌŝĐŽ͕'ƌĂƐƐŝǀĂƌŽ&͕
>ƵĐĐŚĞƚƚĂD͕Ğ>ĂǌǌĂƌŝ&͕ĂůǌĂŶŝ/͕ĂƚƚŝƐƚŝŶ>͕sĞƌŶŝŶŽ^;ϮϬϬϴͿŶƚŝďŽĚŝĞƐƚŽŵƵƐĐůĞĂŶĚ
ŐĂŶŐůŝŽŶŝĐĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌƐ;ĐŚZͿŝŶĐĞůŝĂĐĚŝƐĞĂƐĞ͘ƵƚŽŝŵŵƵŶŝƚǇϰϭ͗ϭϬϬͲϭϬϰ
ϮϮ͘ ƌƵƐƚĂĚD͕^ĂŶĚĂŶŐĞƌd͕ŬƐŶĞƐ>͕>ƵŶĚ;ϮϬϬϰͿsŝƚĂŵŝŶƐƚĂƚƵƐŝŶĂƌƵƌĂůƉŽƉƵůĂƚŝŽŶŽĨ
ŶŽƌƚŚĞƌŶEŽƌǁĂǇǁŝƚŚŚŝŐŚĨŝƐŚůŝǀĞƌĐŽŶƐƵŵƉƚŝŽŶ͘WƵďůŝĐŚĞĂůƚŚŶƵƚƌŝƚŝŽŶϳ͗ϳϴϯͲϳϴϵ
Ϯϯ͘ ƵĐŬůĞǇ͕EĞǁƐŽŵͲĂǀŝƐ:͕tŝůůĐŽǆE͕sŝŶĐĞŶƚ;ϮϬϬϭͿŽƚŝƚŝŶĂŶĚĐǇƚŽŬŝŶĞĂŶƚŝďŽĚŝĞƐŝŶ
D'ƉĂƚŝĞŶƚƐƉƌĞĚŝĐƚƚŚǇŵŽŵĂŽƌƚŚǇŵŽŵĂƌĞĐƵƌƌĞŶĐĞ͍EĞƵƌŽůŽŐǇϱϳ͗ϭϱϳϵͲϭϱϴϮ
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Ϯϰ͘ ƵĨůĞƌ:͕WŝƚǌZ͕ǌĞƉD͕tŝĐŬD͕&ƌĂŶŬĞ;ϭϵϵϴͿWƵƌŝĨŝĞĚ/Ő'ĨƌŽŵƐĞƌŽƉŽƐŝƚŝǀĞĂŶĚ
ƐĞƌŽŶĞŐĂƚŝǀĞƉĂƚŝĞŶƚƐǁŝƚŚŵǇƐĂƐƚŚĞŶŝĂŐƌĂǀŝƐƌĞǀĞƌƐŝďůǇďůŽĐŬƐĐƵƌƌĞŶƚƐƚŚƌŽƵŐŚŶŝĐŽƚŝŶŝĐ
ĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌĐŚĂŶŶĞůƐ͘ŶŶĂůƐŽĨŶĞƵƌŽůŽŐǇϰϯ͗ϰϱϴͲϰϲϰ
Ϯϱ͘ Ăƌƌ^͕ĂƌĚǁĞůůZ͕DĐĂƌƌŽŶWK͕DĐŽŶǀŝůůĞ:;ϮϬϭϬͿƐǇƐƚĞŵĂƚŝĐƌĞǀŝĞǁŽĨƉŽƉƵůĂƚŝŽŶ
ďĂƐĞĚĞƉŝĚĞŵŝŽůŽŐŝĐĂůƐƚƵĚŝĞƐŝŶDǇĂƐƚŚĞŶŝĂ'ƌĂǀŝƐ͘DŶĞƵƌŽůŽŐǇϭϬ͗ϰϲ
Ϯϲ͘ ĂǀĂůĐĂŶƚĞW͕>ĞWĂŶƐĞZ͕ĞƌƌŝŚͲŬŶŝŶ^͕DĂŐŐŝ>͕ŶƚŽǌǌŝ͕ĂŐŐŝ&͕ĞƌŶĂƐĐŽŶŝW͕
DĂŶƚĞŐĂǌǌĂZ;ϮϬϭϭͿdŚĞƚŚǇŵƵƐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗^ŝƚĞŽĨΗŝŶŶĂƚĞĂƵƚŽŝŵŵƵŶŝƚǇΗ͍
DƵƐĐůĞΘŶĞƌǀĞϰϰ͗ϰϲϳͲϰϴϰ
Ϯϳ͘ ĞƚŝŶ,͕&ƵůŽƉ'͕ĂĐŚ,͕ƵĨĨ͕ŝŵƉƌŝĐŚ&;ϮϬϭϮͿƉŝĚĞŵŝŽůŽŐǇŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶ
ƵƐƚƌŝĂ͗ƌŝƐŝŶŐƉƌĞǀĂůĞŶĐĞŝŶĂŶĂŐĞŝŶŐƐŽĐŝĞƚǇ͘tŝĞŶĞƌŬůŝŶŝƐĐŚĞtŽĐŚĞŶƐĐŚƌŝĨƚϭϮϰ͗ϳϲϯͲϳϲϴ
Ϯϴ͘ ŚĂƵĚŚƵƌŝ͕ĞŚĂŶWK;ϮϬϬϵͿDǇĂƐƚŚĞŶŝĐĐƌŝƐŝƐ͘Y:D͗ŵŽŶƚŚůǇũŽƵƌŶĂůŽĨƚŚĞƐƐŽĐŝĂƚŝŽŶŽĨ
WŚǇƐŝĐŝĂŶƐϭϬϮ͗ϵϳͲϭϬϳ
Ϯϵ͘ ŚĂǀŝƐW^͕^ƚŝĐŬůĞƌ͕tĂůŬĞƌ;ϮϬϬϳͿ/ŵŵƵŶŽƐƵƉƉƌĞƐƐŝǀĞŽƌƐƵƌŐŝĐĂůƚƌĞĂƚŵĞŶƚĨŽƌŽĐƵůĂƌ
DǇĂƐƚŚĞŶŝĂ'ƌĂǀŝƐ͘ƌĐŚŝǀĞƐŽĨŶĞƵƌŽůŽŐǇϲϰ͗ϭϳϵϮͲϭϳϵϰ
ϯϬ͘ ŝĂĨĂůŽŶŝ͕EŝŬŚĂƌE<͕DĂƐƐĞǇ:D͕^ĂŶĚĞƌƐ;ϮϬϬϬͿZĞƚƌŽƐƉĞĐƚŝǀĞĂŶĂůǇƐŝƐŽĨƚŚĞƵƐĞŽĨ
ĐǇĐůŽƐƉŽƌŝŶĞŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘EĞƵƌŽůŽŐǇϱϱ͗ϰϰϴͲϰϱϬ
ϯϭ͘ ŽŚĞŶD^͕zŽƵŶŐĞƌ;ϭϵϴϭͿƐƉĞĐƚƐŽĨƚŚĞŶĂƚƵƌĂůŚŝƐƚŽƌǇŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĐƌŝƐŝƐĂŶĚ
ĚĞĂƚŚ͘ŶŶĂůƐŽĨƚŚĞEĞǁzŽƌŬĐĂĚĞŵǇŽĨ^ĐŝĞŶĐĞƐϯϳϳ͗ϲϳϬͲϲϳϳ
ϯϮ͘ ŽŵŵƵŶŝƚŝĞƐŽƚ;ϭϵϵϵͿĞƐĐŝƐŝŽŶEŽϭϮϵϱͬϭϵϵϵͬŽĨƚŚĞƵƌŽƉĞĂŶWĂƌůŝĂŵĞŶƚĂŶĚŽĨƚŚĞ
ŽƵŶĐŝůŽĨϮϵƉƌŝůϭϵϵϵĂĚŽƉƚŝŶŐĂƉƌŽŐƌĂŵŵĞŽĨŽŵŵƵŶŝƚǇĂĐƚŝŽŶŽŶƌĂƌĞĚŝƐĞĂƐĞƐǁŝƚŚŝŶ
ƚŚĞĨƌĂŵĞǁŽƌŬĨŽƌĂĐƚŝŽŶŝŶƚŚĞĨŝĞůĚŽĨƉƵďůŝĐŚĞĂůƚŚ;ϭϵϵϵͲϮϬϬϯͿ͘/Ŷ͗
ϯϯ͘ ŽŵƉƐƚŽŶ͕sŝŶĐĞŶƚ͕EĞǁƐŽŵͲĂǀŝƐ:͕ĂƚĐŚĞůŽƌ:Z;ϭϵϴϬͿůŝŶŝĐĂů͕ƉĂƚŚŽůŽŐŝĐĂů͕,>
ĂŶƚŝŐĞŶĂŶĚŝŵŵƵŶŽůŽŐŝĐĂůĞǀŝĚĞŶĐĞĨŽƌĚŝƐĞĂƐĞŚĞƚĞƌŽŐĞŶĞŝƚǇŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ƌĂŝŶ͗Ă
ũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇϭϬϯ͗ϱϳϵͲϲϬϭ
ϯϰ͘ ĂůĂŬĂƐD;ϭϵϵϵͿ/ŶƚƌĂǀĞŶŽƵƐŝŵŵƵŶŽŐůŽďƵůŝŶŝŶƚŚĞƚƌĞĂƚŵĞŶƚŽĨĂƵƚŽŝŵŵƵŶĞ
ŶĞƵƌŽŵƵƐĐƵůĂƌĚŝƐĞĂƐĞƐ͗ƉƌĞƐĞŶƚƐƚĂƚƵƐĂŶĚƉƌĂĐƚŝĐĂůƚŚĞƌĂƉĞƵƚŝĐŐƵŝĚĞůŝŶĞƐ͘DƵƐĐůĞΘŶĞƌǀĞ
ϮϮ͗ϭϰϳϵͲϭϰϵϳ
ϯϱ͘ Ğ&ĞŽ>'͕^ĐŚŽƚƚůĞŶĚĞƌ:͕DĂƌƚĞůůŝE͕DŽůĨŝŶŽE;ϮϬϬϮͿhƐĞŽĨŝŶƚƌĂǀĞŶŽƵƐƉƵůƐĞĚ
ĐǇĐůŽƉŚŽƐƉŚĂŵŝĚĞŝŶƐĞǀĞƌĞ͕ŐĞŶĞƌĂůŝǌĞĚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘DƵƐĐůĞΘŶĞƌǀĞϮϲ͗ϯϭͲϯϲ
ϯϲ͘ ĚĞůĂWĂǌDW͕sŝůůĂǀĞƌĚĞͲ,ƵĞƐŽ͕ůŽŶƐŽs͕:ĂŶŽƐ^͕ƵƌƌŝĂŐĂK͕WŽůůĂŶD͕ďĂŝƚƵĂͲŽƌĚĂ/
;ϮϬϭϬͿZĂƌĞĚŝƐĞĂƐĞƐĞƉŝĚĞŵŝŽůŽŐǇƌĞƐĞĂƌĐŚ͘ĚǀĂŶĐĞƐŝŶĞǆƉĞƌŝŵĞŶƚĂůŵĞĚŝĐŝŶĞĂŶĚďŝŽůŽŐǇ
ϲϴϲ͗ϭϳͲϯϵ
ϯϳ͘ ŝĂǌͲDĂŶĞƌĂ:͕DĂƌƚŝŶĞǌͲ,ĞƌŶĂŶĚĞǌ͕YƵĞƌŽů>͕<ůŽŽƐƚĞƌZ͕ZŽũĂƐͲ'ĂƌĐŝĂZ͕^ƵĂƌĞǌͲĂůǀĞƚy͕
DƵŶŽǌͲůĂŶĐŽ:>͕DĂǌŝĂ͕^ƚƌĂĂƐŚĞŝũŵ<Z͕'ĂůůĂƌĚŽ͕:ƵĂƌĞǌ͕sĞƌƐĐŚƵƵƌĞŶ::͕/ůůĂ/;ϮϬϭϮͿ
>ŽŶŐͲůĂƐƚŝŶŐƚƌĞĂƚŵĞŶƚĞĨĨĞĐƚŽĨƌŝƚƵǆŝŵĂďŝŶDƵ^<ŵǇĂƐƚŚĞŶŝĂ͘EĞƵƌŽůŽŐǇϳϴ͗ϭϴϵͲϭϵϯ
ϯϴ͘ ŝĂǌͲDĂŶĞƌĂ:͕ZŽũĂƐͲ'ĂƌĐŝĂZ͕/ůůĂ/;ϮϬϬϵͿdƌĞĂƚŵĞŶƚƐƚƌĂƚĞŐŝĞƐĨŽƌŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ǆƉĞƌƚ
ŽƉŝŶŝŽŶŽŶƉŚĂƌŵĂĐŽƚŚĞƌĂƉǇϭϬ͗ϭϯϮϵͲϭϯϰϮ
ϯϵ͘ ƌĂĐŚŵĂŶ;ϭϵϵϰͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘dŚĞEĞǁŶŐůĂŶĚũŽƵƌŶĂůŽĨŵĞĚŝĐŝŶĞϯϯϬ͗ϭϳϵϳͲ
ϭϴϭϬ
ϰϬ͘ ƌĂĐŚŵĂŶ͕ĚĂŵƐZE͕,ƵZ͕:ŽŶĞƐZ:͕ƌŽĚƐŬǇZ;ϮϬϬϴͿZĞďŽŽƚŝŶŐƚŚĞŝŵŵƵŶĞƐǇƐƚĞŵ
ǁŝƚŚŚŝŐŚͲĚŽƐĞĐǇĐůŽƉŚŽƐƉŚĂŵŝĚĞĨŽƌƚƌĞĂƚŵĞŶƚŽĨƌĞĨƌĂĐƚŽƌǇŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ŶŶĂůƐŽĨ
ƚŚĞEĞǁzŽƌŬĐĂĚĞŵǇŽĨ^ĐŝĞŶĐĞƐϭϭϯϮ͗ϯϬϱͲϯϭϰ
ϰϭ͘ ĂƚŽŶtt͕ZŽƐĞEZ͕<ĂůĂǇĚũŝĂŶ͕WĞĚĞƌƐĞŶD'͕DŽƌƚĞŶƐĞŶW;ϮϬϬϳͿƉŝĚĞŵŝŽůŽŐǇŽĨ
ĂƵƚŽŝŵŵƵŶĞĚŝƐĞĂƐĞƐŝŶĞŶŵĂƌŬ͘:ŽƵƌŶĂůŽĨĂƵƚŽŝŵŵƵŶŝƚǇϮϵ͗ϭͲϵ
ϰϮ͘ ďĂĚŝ,͕ĂƌƚŚ͕ƌŝůs;ϮϬϭϯͿ^ĂĨĞƚǇŽĨƉůĂƐŵĂĞǆĐŚĂŶŐĞƚŚĞƌĂƉǇŝŶƉĂƚŝĞŶƚƐǁŝƚŚ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘DƵƐĐůĞΘŶĞƌǀĞϰϳ͗ϱϭϬͲϱϭϰ
ϰϯ͘ ũŵĂD͕<ŽƐǌĞǁŝĐǌD͕WŽĚĞŵƐŬŝZ͕DĂƌŝĂŶƐŬĂ<͕ƵĚƌĞǁŝĐǌ^͕dƵƌĞŬd;ϮϬϭϭͿŶĂƚŽŵŝĐĂů
ǀĂƌŝĂƚŝŽŶŽĨƚŚĞǀĞƌƚĞďƌĂůĂƌƚĞƌǇĐůŝŶŝĐĂůůǇŵŝŵŝĐŬŝŶŐŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘EĞƵƌŽůŽŐŝĐĂůƐĐŝĞŶĐĞƐ
͗ŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞ/ƚĂůŝĂŶEĞƵƌŽůŽŐŝĐĂů^ŽĐŝĞƚǇĂŶĚŽĨƚŚĞ/ƚĂůŝĂŶ^ŽĐŝĞƚǇŽĨůŝŶŝĐĂů
EĞƵƌŽƉŚǇƐŝŽůŽŐǇϯϮ͗ϳϭϱͲϳϭϳ
77 
ϰϰ͘ ŶŐĞů';ϭϵϴϰͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐĂŶĚŵǇĂƐƚŚĞŶŝĐƐǇŶĚƌŽŵĞƐ͘ŶŶĂůƐŽĨŶĞƵƌŽůŽŐǇϭϲ͗ϱϭϵͲ
ϱϯϰ
ϰϱ͘ ǀŽůŝ;ϮϬϭϬͿĐƋƵŝƌĞĚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶĐŚŝůĚŚŽŽĚ͘ƵƌƌĞŶƚŽƉŝŶŝŽŶŝŶŶĞƵƌŽůŽŐǇϮϯ͗ϱϯϲͲ
ϱϰϬ
ϰϲ͘ ǀŽůŝ͕ůďŽŝŶŝW͕ŝƐŽŶŶŝ͕DĂƐƚƌŽƌŽƐĂ͕ĂƌƚŽĐĐŝŽŶŝ;ϮϬϭϮͿDĂŶĂŐĞŵĞŶƚĐŚĂůůĞŶŐĞƐŝŶ
ŵƵƐĐůĞͲƐƉĞĐŝĨŝĐƚǇƌŽƐŝŶĞŬŝŶĂƐĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ŶŶĂůƐŽĨƚŚĞEĞǁzŽƌŬĐĂĚĞŵǇŽĨ
^ĐŝĞŶĐĞƐϭϮϳϰ͗ϴϲͲϵϭ
ϰϳ͘ ǀŽůŝ͕dŽŶĂůŝW͕WĂĚƵĂ>͕DŽŶĂĐŽD>͕^ĐƵĚĞƌŝ&͕ĂƚŽĐĐŚŝW͕DĂƌŝŶŽD͕ĂƌƚŽĐĐŝŽŶŝ
;ϮϬϬϯͿůŝŶŝĐĂůĐŽƌƌĞůĂƚĞƐǁŝƚŚĂŶƚŝͲDƵ^<ĂŶƚŝďŽĚŝĞƐŝŶŐĞŶĞƌĂůŝǌĞĚƐĞƌŽŶĞŐĂƚŝǀĞŵǇĂƐƚŚĞŶŝĂ
ŐƌĂǀŝƐ͘ƌĂŝŶ͗ĂũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇϭϮϲ͗ϮϯϬϰͲϮϯϭϭ
ϰϴ͘ &ĞƌƌĂƌŝ'͕>ŽǀĂƐƚĞD';ϭϵϵϮͿƉŝĚĞŵŝŽůŽŐǇŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶƚŚĞƉƌŽǀŝŶĐĞŽĨdƌĞŶƚŽ
;ŶŽƌƚŚĞƌŶ/ƚĂůǇͿ͘EĞƵƌŽĞƉŝĚĞŵŝŽůŽŐǇϭϭ͗ϭϯϱͲϭϰϮ
ϰϵ͘ &ĞƌƌĞƌŽ͕ŝŵŽ'͕WĂŐŶŝZ͕ĞƌŐĂŵĂƐĐŽ͕ŽŶŐŝŽĂŶŶŝDZ͕ĞƌŐĂŵŝŶŝ>͕ƵƌĞůůŝ>;ϭϵϵϳͿ
DŽĚŝĨŝĞĚĂŶĚŝŵƉƌŽǀĞĚĂŶƚŝͲĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌ;ĐŚZͿĂŶƚŝďŽĚǇĂƐƐĂǇ͗ĐŽŵƉĂƌŝƐŽŶŽĨ
ĂŶĂůǇƚŝĐĂůĂŶĚĐůŝŶŝĐĂůƉĞƌĨŽƌŵĂŶĐĞǁŝƚŚĐŽŶǀĞŶƚŝŽŶĂůĂŶƚŝͲŚZĂŶƚŝďŽĚǇĂƐƐĂǇ͘ůŝŶŝĐĂů
ĐŚĞŵŝƐƚƌǇϰϯ͗ϴϮϰͲϴϯϭ
ϱϬ͘ &ůĞƚĐŚĞƌZ,͕&ůĞƚĐŚĞƌ^t;ϮϬϬϱͿůŝŶŝĐĂůĞƉŝĚĞŵŝŽůŽŐǇ͗ƚŚĞĞƐƐĞŶƚŝĂůƐ͘>ŝƉƉŝŶĐŽƚƚtŝůůŝĂŵƐΘ
tŝůŬŝŶƐ͕WŚŝůĂĚĞůƉŚŝĂ
ϱϭ͘ &Ƶũŝŝz;ϮϬϭϯͿdŚǇŵƵƐ͕ƚŚǇŵŽŵĂĂŶĚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘^ƵƌŐĞƌǇƚŽĚĂǇϰϯ͗ϰϲϭͲϰϲϲ
ϱϮ͘ 'ĂũĚŽƐW͕ŚĞǀƌĞƚ^͕ůĂŝƌ͕dƌĂŶĐŚĂŶƚ͕ŚĂƐƚĂŶŐ;ϭϵϵϳͿůŝŶŝĐĂůƚƌŝĂůŽĨƉůĂƐŵĂĞǆĐŚĂŶŐĞ
ĂŶĚŚŝŐŚͲĚŽƐĞŝŶƚƌĂǀĞŶŽƵƐŝŵŵƵŶŽŐůŽďƵůŝŶŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘DǇĂƐƚŚĞŶŝĂ'ƌĂǀŝƐůŝŶŝĐĂů
^ƚƵĚǇ'ƌŽƵƉ͘ŶŶĂůƐŽĨŶĞƵƌŽůŽŐǇϰϭ͗ϳϴϵͲϳϵϲ
ϱϯ͘ 'ĂƌůĞƉƉD:͕ĂǁŬŝŶƐZ>͕ŚƌŝƐƚŝĂŶƐĞŶ&d͕>ĂǁƚŽŶ:͕>ƵĐŝĂŶŝ'͕DĐ>ĞŽĚ:͕ƌĂĚůĞǇ:͕'ĞŶŬŝŶƐ'͕
dĞŶŐ^;ϭϵϴϭͿƵƚŽŝŵŵƵŶŝƚǇŝŶŽĐƵůĂƌĂŶĚŐĞŶĞƌĂůŝƐĞĚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘:ŽƵƌŶĂůŽĨ
ŶĞƵƌŽŝŵŵƵŶŽůŽŐǇϭ͗ϯϮϱͲϯϯϮ
ϱϰ͘ 'ĂƚƚĞůůĂƌŝD͕'ŽƵŵĂƐ͕tŽƌƚŚŝŶŐƚŽŶ:D;ϮϬϭϮͿŶĂƚŝŽŶĂůĞƉŝĚĞŵŝŽůŽŐŝĐĂůƐƚƵĚǇŽĨ
DǇĂƐƚŚĞŶŝĂ'ƌĂǀŝƐŝŶƵƐƚƌĂůŝĂ͘ƵƌŽƉĞĂŶũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͗ƚŚĞŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞ
ƵƌŽƉĞĂŶ&ĞĚĞƌĂƚŝŽŶŽĨEĞƵƌŽůŽŐŝĐĂů^ŽĐŝĞƚŝĞƐϭϵ͗ϭϰϭϯͲϭϰϮϬ
ϱϱ͘ 'ŝůŚƵƐE;ϮϬϬϵͿƵƚŽŝŵŵƵŶĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ǆƉĞƌƚƌĞǀŝĞǁŽĨŶĞƵƌŽƚŚĞƌĂƉĞƵƚŝĐƐϵ͗ϯϱϭͲ
ϯϱϴ
ϱϲ͘ 'ŝůŚƵƐE;ϮϬϭϭͿEĞƵƌŽŵƵƐĐƵůĂƌĚŝƐĞĂƐĞ͗ĂĐƵƚĞƚƌĞĂƚŵĞŶƚĨŽƌŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘EĂƚƵƌĞ
ƌĞǀŝĞǁƐEĞƵƌŽůŽŐǇϳ͗ϭϯϮͲϭϯϰ
ϱϳ͘ 'ŝůŚƵƐE͕KǁĞ:&͕,ŽĨĨ:D͕ZŽŵŝ&͕^ŬĞŝĞ'K͕Ăƌůŝ:;ϮϬϭϭͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĂƌĞǀŝĞǁŽĨ
ĂǀĂŝůĂďůĞƚƌĞĂƚŵĞŶƚĂƉƉƌŽĂĐŚĞƐ͘ƵƚŽŝŵŵƵŶĞĚŝƐĞĂƐĞƐϮϬϭϭ͗ϴϰϳϯϵϯ
ϱϴ͘ 'ŽůĂŶ͕^ƚĂƵŶͲZĂŵ͕'ůĂƐƐͲDĂƌŵŽƌ>͕>Ăǀŝ/͕ZŽǌĞŶďĞƌŐK͕ŝƐŚŽŶ^͕ĂƌĂŬD͕/ƐŚͲ^ŚĂůŽŵ^͕
DŝůůĞƌ;ϮϬϭϯͿdŚĞŝŶĨůƵĞŶĐĞŽĨǀŝƚĂŵŝŶƐƵƉƉůĞŵĞŶƚĂƚŝŽŶŽŶŵĞůĂƚŽŶŝŶƐƚĂƚƵƐŝŶƉĂƚŝĞŶƚƐ
ǁŝƚŚŵƵůƚŝƉůĞƐĐůĞƌŽƐŝƐ͘ƌĂŝŶ͕ďĞŚĂǀŝŽƌ͕ĂŶĚŝŵŵƵŶŝƚǇϯϮ͗ϭϴϬͲϭϴϱ
ϱϵ͘ 'ŽŵĞǌD͕sĂŶĞŶƌŽĞĐŬ:͕sƌŽůŝǆ<͕:ĂŶƐƐĞŶ^W͕>ĞŵŵĞŶƐD͕sĂŶĞƌƐĐŚ͕ƵŝŵĞů,͕
&ƌĞĚĞƌŝŬW͕DŽůĞŶĂĂƌW͕DĂƌƚŝŶĞǌͲDĂƌƚŝŶĞǌW͕ĞĂĞƚƐD,͕>ŽƐĞŶD;ϮϬϭϬͿŶƚŝďŽĚǇ
ĞĨĨĞĐƚŽƌŵĞĐŚĂŶŝƐŵƐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐͲƉĂƚŚŽŐĞŶĞƐŝƐĂƚƚŚĞŶĞƵƌŽŵƵƐĐƵůĂƌũƵŶĐƚŝŽŶ͘
ƵƚŽŝŵŵƵŶŝƚǇϰϯ͗ϯϱϯͲϯϳϬ
ϲϬ͘ 'ƌŽď͕ƌƵŶŶĞƌE͕EĂŵďĂd͕WĂŐĂůĂD;ϮϬϬϴͿ>ŝĨĞƚŝŵĞĐŽƵƌƐĞŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘DƵƐĐůĞ
ΘŶĞƌǀĞϯϳ͗ϭϰϭͲϭϰϵ
ϲϭ͘ 'ƌŽŶƐĞƚŚ'^͕ĂƌŽŚŶZ:;ϮϬϬϮͿdŚǇŵĞĐƚŽŵǇĨŽƌDǇĂƐƚŚĞŶŝĂ'ƌĂǀŝƐ͘ƵƌƌĞŶƚƚƌĞĂƚŵĞŶƚ
ŽƉƚŝŽŶƐŝŶŶĞƵƌŽůŽŐǇϰ͗ϮϬϯͲϮϬϵ
ϲϮ͘ 'ƵŝĚĞƚƚŝ͕^ĂďĂĚŝŶŝZ͕ŽŶĚĂǀĂůůŝD͕ĂǀĂůůĞƚƚŝ^͕>ŽĚĞƐĂŶŝD͕DĂŶƚĞŐĂǌǌĂZ͕ŽƐŝs͕^ŽůŝŵĞ&
;ϭϵϵϴͿƉŝĚĞŵŝŽůŽŐŝĐĂůƐƚƵĚǇŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶƚŚĞƉƌŽǀŝŶĐĞŽĨZĞŐŐŝŽŵŝůŝĂ͕/ƚĂůǇ͘
ƵƌŽƉĞĂŶũŽƵƌŶĂůŽĨĞƉŝĚĞŵŝŽůŽŐǇϭϰ͗ϯϴϭͲϯϴϳ
ϲϯ͘ 'ƵƉƚŝůů:d͕^ĂŶĚĞƌƐ͕ǀŽůŝ;ϮϬϭϭͿŶƚŝͲDƵ^<ĂŶƚŝďŽĚǇŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĐůŝŶŝĐĂůĨŝŶĚŝŶŐƐ
ĂŶĚƌĞƐƉŽŶƐĞƚŽƚƌĞĂƚŵĞŶƚŝŶƚǁŽůĂƌŐĞĐŽŚŽƌƚƐ͘DƵƐĐůĞΘŶĞƌǀĞϰϰ͗ϯϲͲϰϬ
78 
ϲϰ͘ 'ǀĞƌŝĐͲŚŵĞƚĂƐĞǀŝĐ^͕ŽůŝĐ͕ůǀĞĚũŝͲ'ĂƐƉĂƌŽǀŝĐs͕'ǀĞƌŝĐd͕sƵŬĞůŝĐs;ϮϬϬϴͿĂŶŶĞŽŶĂƚĂů
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐďĞƉƌĞĚŝĐƚĞĚ͍:ŽƵƌŶĂůŽĨƉĞƌŝŶĂƚĂůŵĞĚŝĐŝŶĞϯϲ͗ϱϬϯͲϱϬϲ
ϲϱ͘ ,ĂƌďŽ,&͕ZŝĐĐŝŽD͕>ŽƌĞŶƚǌĞŶZ͕hƚƐŝ͕DǇŚƌ<D͕DĞůůŐƌĞŶ^/͕&ůĂŵ^d͕dŚŽƌƐďǇ͕
^ĂŶĐŚĞǌͲDĂǌĂƐ͕>ŝĞ;ϮϬϭϬͿEŽƌǁĞŐŝĂŶ^ĂŵŝĚŝĨĨĞƌƐƐŝŐŶŝĨŝĐĂŶƚůǇĨƌŽŵŽƚŚĞƌEŽƌǁĞŐŝĂŶƐ
ĂĐĐŽƌĚŝŶŐƚŽƚŚĞŝƌ,>ƉƌŽĨŝůĞ͘dŝƐƐƵĞĂŶƚŝŐĞŶƐϳϱ͗ϮϬϳͲϮϭϳ
ϲϲ͘ ,ĂƌďŽ,&͕hƚƐŝ͕>ŽƌĞŶƚǌĞŶZ͕<ĂŵƉŵĂŶDd͕ĞůŝƵƐ'͕DǇŚƌ<D͕>ŝĞ͕DĞůůŐƌĞŶ^/͕
dŚŽƌƐďǇ;ϮϬϬϳͿ>ŽǁĨƌĞƋƵĞŶĐǇŽĨƚŚĞĚŝƐĞĂƐĞͲĂƐƐŽĐŝĂƚĞĚZϭΎϭϱͲYϭΎϬϲŚĂƉůŽƚǇƉĞŵĂǇ
ĐŽŶƚƌŝďƵƚĞƚŽƚŚĞůŽǁƉƌĞǀĂůĞŶĐĞŽĨŵƵůƚŝƉůĞƐĐůĞƌŽƐŝƐŝŶ^Ăŵŝ͘dŝƐƐƵĞĂŶƚŝŐĞŶƐϲϵ͗ϮϵϵͲϯϬϰ
ϲϳ͘ ,Ăƌƚ/<͕^ŚĂƌƐŚĂƌd͕^ĂƚŚĂƐŝǀĂŵ^;ϮϬϬϵͿ/ŵŵƵŶŽƐƵƉƉƌĞƐƐĂŶƚĚƌƵŐƐĨŽƌŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘
:ŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͕ŶĞƵƌŽƐƵƌŐĞƌǇ͕ĂŶĚƉƐǇĐŚŝĂƚƌǇϴϬ͗ϱͲϲ͖ĚŝƐĐƵƐƐŝŽŶϲ
ϲϴ͘ ,ĂƌƚW,͕'ŽƌŵĂŶ^͕&ŝŶůĂǇͲ:ŽŶĞƐ::;ϮϬϭϭͿDŽĚƵůĂƚŝŽŶŽĨƚŚĞŝŵŵƵŶĞƐǇƐƚĞŵďǇhsƌĂĚŝĂƚŝŽŶ͗
ŵŽƌĞƚŚĂŶũƵƐƚƚŚĞĞĨĨĞĐƚƐŽĨǀŝƚĂŵŝŶ͍EĂƚƵƌĞƌĞǀŝĞǁƐ/ŵŵƵŶŽůŽŐǇϭϭ͗ϱϴϰͲϱϵϲ
ϲϵ͘ ,ĞĐŬŵĂŶŶ:D͕ZĂǁŽŽƚ͕ĂƚĞŵĂŶ<͕ZĞŶŝƐŽŶZ͕ĂĚƌŝD;ϮϬϭϭͿƐŝŶŐůĞͲďůŝŶĚĞĚƚƌŝĂůŽĨ
ŵĞƚŚŽƚƌĞǆĂƚĞǀĞƌƐƵƐĂǌĂƚŚŝŽƉƌŝŶĞĂƐƐƚĞƌŽŝĚͲƐƉĂƌŝŶŐĂŐĞŶƚƐŝŶŐĞŶĞƌĂůŝǌĞĚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘
DŶĞƵƌŽůŽŐǇϭϭ͗ϵϳ
ϳϬ͘ ,ĞŚŝƌD<͕ƵƌŶƐdD͕ůƉĞƌƐ:͕ŽŶĂǁĂǇDZ͕^ĂǁĂD͕^ĂŶĚĞƌƐ;ϮϬϭϬͿDǇĐŽƉŚĞŶŽůĂƚĞ
ŵŽĨĞƚŝůŝŶŚZͲĂŶƚŝďŽĚǇͲƉŽƐŝƚŝǀĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ŽƵƚĐŽŵĞƐŝŶϭϬϮƉĂƚŝĞŶƚƐ͘DƵƐĐůĞΘ
ŶĞƌǀĞϰϭ͗ϱϵϯͲϱϵϴ
ϳϭ͘ ,ĞůĚĂůd͕ŝĚĞ'͕'ŝůŚƵƐE͕ZŽŵŝ&;ϮϬϭϮͿ'ĞŽŐƌĂƉŚŝĐĂůĚŝƐƚƌŝďƵƚŝŽŶŽĨĂƐĞƌŽƉŽƐŝƚŝǀĞ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐƉŽƉƵůĂƚŝŽŶ͘DƵƐĐůĞΘŶĞƌǀĞϰϱ͗ϴϭϱͲϴϭϵ
ϳϮ͘ ,ĞůĚĂůd͕KǁĞ:&͕'ŝůŚƵƐE͕ZŽŵŝ&;ϮϬϬϵͿ^ĞƌŽƉŽƐŝƚŝǀĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĂŶĂƚŝŽŶǁŝĚĞ
ĞƉŝĚĞŵŝŽůŽŐŝĐƐƚƵĚǇ͘EĞƵƌŽůŽŐǇϳϯ͗ϭϱϬͲϭϱϭ
ϳϯ͘ ,ĞŶŶĞŬĞŶƐ,͕ƵƌŝŶŐ:͕DĂǇƌĞŶƚ^>;ϭϵϴϳͿƉŝĚĞŵŝŽůŽŐǇŝŶŵĞĚŝĐŝŶĞ͘>ŝƚƚůĞ͕ƌŽǁŶ͕ŽƐƚŽŶ
ϳϰ͘ ,ŽĞĚĞŵĂĞŬĞƌƐ͕ǀĂŶƌĞĚĂsƌŝĞƐŵĂŶW:͕ĞĂĞƚƐD,;ϭϵϵϳͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐĂƐĂ
ƉƌŽƚŽƚǇƉĞĂƵƚŽŝŵŵƵŶĞƌĞĐĞƉƚŽƌĚŝƐĞĂƐĞ͘/ŵŵƵŶŽůŽŐŝĐƌĞƐĞĂƌĐŚϭϲ͗ϯϰϭͲϯϱϰ
ϳϱ͘ ,ŽĨĨ:D͕ĂůƚǀĞŝƚ<͕'ŝůŚƵƐE;ϮϬϬϰͿƐǇŵƉƚŽŵĂƚŝĐŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶĨůƵĞŶĐĞƐƉƌĞŐŶĂŶĐǇ
ĂŶĚďŝƌƚŚ͘ƵƌŽƉĞĂŶũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͗ƚŚĞŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞƵƌŽƉĞĂŶ&ĞĚĞƌĂƚŝŽŶŽĨ
EĞƵƌŽůŽŐŝĐĂů^ŽĐŝĞƚŝĞƐϭϭ͗ϱϱϵͲϱϲϮ
ϳϲ͘ ,ŽĨĨ:D͕ĂůƚǀĞŝƚ<͕'ŝůŚƵƐE;ϮϬϬϳͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶƉƌĞŐŶĂŶĐǇĂŶĚďŝƌƚŚ͗ŝĚĞŶƚŝĨǇŝŶŐ
ƌŝƐŬĨĂĐƚŽƌƐ͕ŽƉƚŝŵŝƐŝŶŐĐĂƌĞ͘ƵƌŽƉĞĂŶũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͗ƚŚĞŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞ
ƵƌŽƉĞĂŶ&ĞĚĞƌĂƚŝŽŶŽĨEĞƵƌŽůŽŐŝĐĂů^ŽĐŝĞƚŝĞƐϭϰ͗ϯϴͲϰϯ
ϳϳ͘ ,ŽĨĨ:D͕ĂůƚǀĞŝƚ<͕'ŝůŚƵƐE;ϮϬϬϯͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĐŽŶƐĞƋƵĞŶĐĞƐĨŽƌƉƌĞŐŶĂŶĐǇ͕
ĚĞůŝǀĞƌǇ͕ĂŶĚƚŚĞŶĞǁďŽƌŶ͘EĞƵƌŽůŽŐǇϲϭ͗ϭϯϲϮͲϭϯϲϲ
ϳϴ͘ ,ŽǁĂƌĚ:&͕:ƌ͘;ϮϬϭϯͿůĞĐƚƌŽĚŝĂŐŶŽƐŝƐŽĨĚŝƐŽƌĚĞƌƐŽĨŶĞƵƌŽŵƵƐĐƵůĂƌƚƌĂŶƐŵŝƐƐŝŽŶ͘WŚǇƐŝĐĂů
ŵĞĚŝĐŝŶĞĂŶĚƌĞŚĂďŝůŝƚĂƚŝŽŶĐůŝŶŝĐƐŽĨEŽƌƚŚŵĞƌŝĐĂϮϰ͗ϭϲϵͲϭϵϮ
ϳϵ͘ ,ŽǁĂƌĚ:&͕:ƌ͕͘ĂƌŽŚŶZ:͕ƵƚƚĞƌ'Z͕&ƌĞŝŵĞƌD͕:ƵĞůs͕DŽǌĂĨĨĂƌd͕DĞůůŝŽŶD>͕ĞŶĂƚĂƌ
D'͕&ĂƌƌƵŐŝĂD͕tĂŶŐ::͕DĂůŚŽƚƌĂ^^͕<ŝƐƐĞů:d͕'ƌŽƵƉD'^;ϮϬϭϯͿƌĂŶĚŽŵŝǌĞĚ͕ĚŽƵďůĞͲ
ďůŝŶĚ͕ƉůĂĐĞďŽͲĐŽŶƚƌŽůůĞĚƉŚĂƐĞ//ƐƚƵĚǇŽĨĞĐƵůŝǌƵŵĂďŝŶƉĂƚŝĞŶƚƐǁŝƚŚƌĞĨƌĂĐƚŽƌǇŐĞŶĞƌĂůŝǌĞĚ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘DƵƐĐůĞΘŶĞƌǀĞϰϴ͗ϳϲͲϴϰ
ϴϬ͘ /ŵĂŝd͕dƐƵĚĂ͕,ŽǌƵŬŝd͕zĂŵĂƵĐŚŝZ͕^ĂŝƚŽŚD͕,ŝƐĂŚĂƌĂ^͕zŽƐŚŝŬĂǁĂ,͕DŽƚŽŵƵƌĂD͕
<ĂǁĂŵĂƚĂ:͕^ŚŝŵŽŚĂŵĂ^;ϮϬϭϮͿĂƌůǇĞĨĨĞĐƚŽĨƚĂĐƌŽůŝŵƵƐŝŶŝŵƉƌŽǀŝŶŐĞǆĐŝƚĂƚŝŽŶͲ
ĐŽŶƚƌĂĐƚŝŽŶĐŽƵƉůŝŶŐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ůŝŶŝĐĂůŶĞƵƌŽƉŚǇƐŝŽůŽŐǇ͗ŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞ
/ŶƚĞƌŶĂƚŝŽŶĂů&ĞĚĞƌĂƚŝŽŶŽĨůŝŶŝĐĂůEĞƵƌŽƉŚǇƐŝŽůŽŐǇϭϮϯ͗ϭϴϴϲͲϭϴϵϬ
ϴϭ͘ /ŵĂŝd͕dƐƵĚĂ͕,ŽǌƵŬŝd͕zŽƐŚŝŬĂǁĂ,͕zĂŵĂƵĐŚŝZ͕^ĂŝƚŽŚD͕,ŝƐĂŚĂƌĂ^͕DŽƚŽŵƵƌĂD͕
<ĂǁĂŵĂƚĂ:͕^ŚŝŵŽŚĂŵĂ^;ϮϬϭϮͿŽŶƚƌŝďƵƚŝŽŶŽĨĂŶƚŝͲƌǇĂŶŽĚŝŶĞƌĞĐĞƉƚŽƌĂŶƚŝďŽĚǇƚŽ
ŝŵƉĂŝƌŵĞŶƚŽĨĞǆĐŝƚĂƚŝŽŶͲĐŽŶƚƌĂĐƚŝŽŶĐŽƵƉůŝŶŐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ůŝŶŝĐĂůŶĞƵƌŽƉŚǇƐŝŽůŽŐǇ
͗ŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞ/ŶƚĞƌŶĂƚŝŽŶĂů&ĞĚĞƌĂƚŝŽŶŽĨůŝŶŝĐĂůEĞƵƌŽƉŚǇƐŝŽůŽŐǇϭϮϯ͗ϭϮϰϮͲϭϮϰϳ
ϴϮ͘ /ŵĂŝd͕dƐƵĚĂ͕dŽǇŽƐŚŝŵĂd͕zŽƐŚŝŬĂǁĂ,͕DŽƚŽŵƵƌĂD͕^ŚŝŵŽŚĂŵĂ^;ϮϬϭϭͿŶƚŝͲ
ƌǇĂŶŽĚŝŶĞƌĞĐĞƉƚŽƌͲƉŽƐŝƚŝǀĞĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌͲŶĞŐĂƚŝǀĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĞǀŝĚĞŶĐĞŽĨ
ŝŵƉĂŝƌĞĚĞǆĐŝƚĂƚŝŽŶͲĐŽŶƚƌĂĐƚŝŽŶĐŽƵƉůŝŶŐ͘DƵƐĐůĞΘŶĞƌǀĞϰϯ͗ϮϵϰͲϮϵϱ
79 
ϴϯ͘ /ŶƚĞƌŶĂƚŝŽŶĂůDƵůƚŝƉůĞ^ĐůĞƌŽƐŝƐ'ĞŶĞƚŝĐƐ͕tĞůůĐŽŵĞdƌƵƐƚĂƐĞŽŶƚƌŽů͕^ĂǁĐĞƌ^͕
,ĞůůĞŶƚŚĂů'͕WŝƌŝŶĞŶD͕^ƉĞŶĐĞƌ͕WĂƚƐŽƉŽƵůŽƐE͕DŽƵƚƐŝĂŶĂƐ>͕ŝůƚŚĞǇ͕^Ƶ͕&ƌĞĞŵĂŶ
͕,ƵŶƚ^͕ĚŬŝŶƐ^͕'ƌĂǇ͕ŽŽƚŚZ͕WŽƚƚĞƌ^͕'ŽƌŝƐ͕ĂŶĚ'͕KƚƵƌĂŝ͕^ƚƌĂŶŐĞ͕
^ĂĂƌĞůĂ:͕ĞůůĞŶŐƵĞǌ͕&ŽŶƚĂŝŶĞ͕'ŝůůŵĂŶD͕,ĞŵŵĞƌ͕'ǁŝůůŝĂŵZ͕ŝƉƉ&͕:ĂǇĂŬƵŵĂƌ͕
DĂƌƚŝŶZ͕>ĞƐůŝĞ^͕,ĂǁŬŝŶƐ^͕'ŝĂŶŶŽƵůĂƚŽƵ͕ΖůĨŽŶƐŽ^͕ůĂĐŬďƵƌŶ,͕DĂƌƚŝŶĞůůŝŽŶĞƐĐŚŝ
&͕>ŝĚĚůĞ:͕,ĂƌďŽ,&͕WĞƌĞǌD>͕^ƉƵƌŬůĂŶĚ͕tĂůůĞƌD:͕DǇĐŬŽDW͕ZŝĐŬĞƚƚƐD͕ŽŵĂďĞůůĂ
D͕,ĂŵŵŽŶĚE͕<ŽĐŬƵŵ/͕DĐĂŶŶKd͕ĂŶD͕tŚŝƚƚĂŬĞƌW͕<ĞŵƉƉŝŶĞŶ͕tĞƐƚŽŶW͕
,ĂǁŬŝŶƐ͕tŝĚĂĂ^͕ĂũŝĐĞŬ:͕ƌŽŶŽǀ^͕ZŽďĞƌƚƐŽŶE͕ƵŵƉƐƚĞĂĚ^:͕ĂƌĐĞůůŽƐ>&͕
ZĂǀŝŶĚƌĂƌĂũĂŚZ͕ďƌĂŚĂŵZ͕ůĨƌĞĚƐƐŽŶ>͕ƌĚůŝĞ<͕ƵďŝŶ͕ĂŬĞƌ͕ĂŬĞƌ<͕ĂƌĂŶǌŝŶŝ^͕
ĞƌŐĂŵĂƐĐŚŝ>͕ĞƌŐĂŵĂƐĐŚŝZ͕ĞƌŶƐƚĞŝŶ͕ĞƌƚŚĞůĞ͕ŽŐŐŝůĚD͕ƌĂĚĨŝĞůĚ:W͕ƌĂƐƐĂƚ͕
ƌŽĂĚůĞǇ^͕ƵĐŬ͕ƵƚǌŬƵĞǀĞŶ,͕ĂƉƌĂZ͕ĂƌƌŽůůtD͕ĂǀĂůůĂW͕ĞůŝƵƐ'͕ĞƉŽŬ^͕
ŚŝĂǀĂĐĐŝZ͕ůĞƌŐĞƚͲĂƌƉŽƵǆ&͕ůǇƐƚĞƌƐ<͕Žŵŝ'͕ŽƐƐďƵƌŶD͕ŽƵƌŶƵͲZĞďĞŝǆ/͕ŽǆD͕
ŽǌĞŶt͕ƌĞĞ͕ƌŽƐƐ,͕ƵƐŝ͕ĂůǇD:͕ĂǀŝƐ͕ĚĞĂŬŬĞƌW/͕ĞďŽƵǀĞƌŝĞD͕Ζ,ŽŽŐŚĞ
D͕ŝǆŽŶ<͕ŽďŽƐŝZ͕ƵďŽŝƐ͕ůůŝŶŐŚĂƵƐ͕ůŽǀĂĂƌĂ/͕ƐƉŽƐŝƚŽ&͕&ŽŶƚĞŶŝůůĞ͕&ŽŽƚĞ^͕
&ƌĂŶŬĞ͕'ĂůŝŵďĞƌƚŝ͕'ŚĞǌǌŝ͕'ůĞƐƐŶĞƌ:͕'ŽŵĞǌZ͕'ŽƵƚK͕'ƌĂŚĂŵ͕'ƌĂŶƚ^&͕'ƵĞƌŝŶŝ
&Z͕,ĂŬŽŶĂƌƐŽŶ,͕,ĂůůW͕,ĂŵƐƚĞŶ͕,ĂƌƚƵŶŐ,W͕,ĞĂƌĚZE͕,ĞĂƚŚ^͕,ŽďĂƌƚ:͕,ŽƐŚŝD͕
/ŶĨĂŶƚĞͲƵĂƌƚĞ͕/ŶŐƌĂŵ'͕/ŶŐƌĂŵt͕/ƐůĂŵd͕:ĂŐŽĚŝĐD͕<ĂďĞƐĐŚD͕<ĞƌŵŽĚĞ'͕
<ŝůƉĂƚƌŝĐŬd:͕<ŝŵ͕<ůŽƉƉE͕<ŽŝǀŝƐƚŽ<͕>ĂƌƐƐŽŶD͕>ĂƚŚƌŽƉD͕>ĞĐŚŶĞƌͲ^ĐŽƚƚ:^͕>ĞŽŶĞD͕
>ĞƉƉĂs͕>ŝůũĞĚĂŚůh͕ŽŵĨŝŵ/>͕>ŝŶĐŽůŶZZ͕>ŝŶŬ:͕>ŝƵ:͕>ŽƌĞŶƚǌĞŶZ͕>ƵƉŽůŝ^͕DĂĐĐŝĂƌĚŝ&͕
DĂĐŬd͕DĂƌƌŝŽƚƚD͕DĂƌƚŝŶĞůůŝs͕DĂƐŽŶ͕DĐĂƵůĞǇ:>͕DĞŶƚĐŚ&͕DĞƌŽ/>͕DŝŚĂůŽǀĂd͕
DŽŶƚĂůďĂŶy͕DŽƚƚĞƌƐŚĞĂĚ:͕DǇŚƌ<D͕EĂůĚŝW͕KůůŝĞƌt͕WĂŐĞ͕WĂůŽƚŝĞ͕WĞůůĞƚŝĞƌ:͕WŝĐĐŝŽ
>͕WŝĐŬĞƌƐŐŝůůd͕WŝĞŚů&͕WŽďǇǁĂũůŽ^͕YƵĂĐŚ,>͕ZĂŵƐĂǇWW͕ZĞƵŶĂŶĞŶD͕ZĞǇŶŽůĚƐZ͕ZŝŽƵǆ
:͕ZŽĚĞŐŚĞƌD͕ZŽĞƐŶĞƌ^͕ZƵďŝŽ:W͕ZƵĐŬĞƌƚ/D͕^ĂůǀĞƚƚŝD͕^Ăůǀŝ͕^ĂŶƚĂŶŝĞůůŽ͕^ĐŚĂĞĨĞƌ
͕^ĐŚƌĞŝďĞƌ^͕^ĐŚƵůǌĞ͕^ĐŽƚƚZ:͕^ĞůůĞďũĞƌŐ&͕^ĞůŵĂũ<t͕^ĞǆƚŽŶ͕^ŚĞŶ>͕^ŝŵŵƐͲĐƵŶĂ
͕^ŬŝĚŵŽƌĞ^͕^ůĞŝŵĂŶWD͕^ŵĞƐƚĂĚ͕^ŽƌĞŶƐĞŶW^͕^ŽŶĚĞƌŐĂĂƌĚ,͕^ƚĂŶŬŽǀŝĐŚ:͕^ƚƌĂŶŐĞ
Z͕^ƵůŽŶĞŶD͕^ƵŶĚƋǀŝƐƚ͕^ǇǀĂŶĞŶ͕dĂĚĚĞŽ&͕dĂǇůŽƌ͕ůĂĐŬǁĞůů:D͕dŝĞŶĂƌŝW͕
ƌĂŵŽŶ͕dŽƵƌďĂŚ͕ƌŽǁŶD͕dƌŽŶĐǌǇŶƐŬĂ͕ĂƐĂƐ:W͕dƵďƌŝĚǇE͕ŽƌǀŝŶ͕sŝĐŬĞƌǇ:͕
:ĂŶŬŽǁƐŬŝ:͕sŝůůŽƐůĂĚĂW͕DĂƌŬƵƐ,^͕tĂŶŐ<͕DĂƚŚĞǁ'͕tĂƐŽŶ:͕WĂůŵĞƌE͕tŝĐŚŵĂŶŶ
,͕WůŽŵŝŶZ͕tŝůůŽƵŐŚďǇ͕ZĂƵƚĂŶĞŶ͕tŝŶŬĞůŵĂŶŶ:͕tŝƚƚŝŐD͕dƌĞŵďĂƚŚZ͕zĂŽƵĂŶƋ:͕
sŝƐǁĂŶĂƚŚĂŶ͕ŚĂŶŐ,͕tŽŽĚEt͕ƵǀŝĐŚZ͕ĞůŽƵŬĂƐW͕>ĂŶŐĨŽƌĚ͕ƵŶĐĂŶƐŽŶ͕
KŬƐĞŶďĞƌŐ:Z͕WĞƌŝĐĂŬͲsĂŶĐĞD͕,ĂŝŶĞƐ:>͕KůƐƐŽŶd͕,ŝůůĞƌƚ:͕/ǀŝŶƐŽŶ:͕Ğ:ĂŐĞƌW>͕
WĞůƚŽŶĞŶ>͕^ƚĞǁĂƌƚ':͕,ĂĨůĞƌ͕,ĂƵƐĞƌ^>͕DĐsĞĂŶ'͕ŽŶŶĞůůǇW͕ŽŵƉƐƚŽŶ;ϮϬϭϭͿ
'ĞŶĞƚŝĐƌŝƐŬĂŶĚĂƉƌŝŵĂƌǇƌŽůĞĨŽƌĐĞůůͲŵĞĚŝĂƚĞĚŝŵŵƵŶĞŵĞĐŚĂŶŝƐŵƐŝŶŵƵůƚŝƉůĞƐĐůĞƌŽƐŝƐ͘
EĂƚƵƌĞϰϳϲ͗ϮϭϰͲϮϭϵ
ϴϰ͘ :ĂĐŽďƐŽŶ>͕ĞĞƐŽŶ͕dǌĂƌƚŽƐ^͕sŝŶĐĞŶƚ;ϭϵϵϵͿDŽŶŽĐůŽŶĂůĂŶƚŝďŽĚŝĞƐƌĂŝƐĞĚĂŐĂŝŶƐƚ
ŚƵŵĂŶĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌďŝŶĚƚŽĂůůĨŝǀĞƐƵďƵŶŝƚƐŽĨƚŚĞĨĞƚĂůŝƐŽĨŽƌŵ͘:ŽƵƌŶĂůŽĨ
ŶĞƵƌŽŝŵŵƵŶŽůŽŐǇϵϴ͗ϭϭϮͲϭϮϬ
ϴϱ͘ :ĂŶŝͲĐƐĂĚŝ͕>ŝƐĂŬZW;ϮϬϬϳͿDǇĂƐƚŚĞŶŝĐĐƌŝƐŝƐ͗ŐƵŝĚĞůŝŶĞƐĨŽƌƉƌĞǀĞŶƚŝŽŶĂŶĚƚƌĞĂƚŵĞŶƚ͘
:ŽƵƌŶĂůŽĨƚŚĞŶĞƵƌŽůŽŐŝĐĂůƐĐŝĞŶĐĞƐϮϲϭ͗ϭϮϳͲϭϯϯ
ϴϲ͘ :ĂƌĞƚǌŬŝ͕ϯƌĚ͕ĂƌŽŚŶZ:͕ƌŶƐƚŽĨĨZD͕<ĂŵŝŶƐŬŝ,:͕<ĞĞƐĞǇ:͕WĞŶŶ^͕^ĂŶĚĞƌƐ;ϮϬϬϬͿ
DǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐĨŽƌĐůŝŶŝĐĂůƌĞƐĞĂƌĐŚƐƚĂŶĚĂƌĚƐ͘dĂƐŬ&ŽƌĐĞŽĨƚŚĞ
DĞĚŝĐĂů^ĐŝĞŶƚŝĨŝĐĚǀŝƐŽƌǇŽĂƌĚŽĨƚŚĞDǇĂƐƚŚĞŶŝĂ'ƌĂǀŝƐ&ŽƵŶĚĂƚŝŽŶŽĨŵĞƌŝĐĂ͘dŚĞ
ŶŶĂůƐŽĨƚŚŽƌĂĐŝĐƐƵƌŐĞƌǇϳϬ͗ϯϮϳͲϯϯϰ
ϴϳ͘ :ĂǇĂŵdƌŽƵƚŚ͕Ăďŝ͕^ŽůŝĞŵĂŶE͕<ƵƌƵŬƵŵďŝD͕<ĂůǇĂŶĂŵ:;ϮϬϭϮͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗Ă
ƌĞǀŝĞǁ͘ƵƚŽŝŵŵƵŶĞĚŝƐĞĂƐĞƐϮϬϭϮ͗ϴϳϰϲϴϬ
ϴϴ͘ :ĂǇĂǁĂŶƚ^͕WĂƌƌ:͕sŝŶĐĞŶƚ;ϮϬϭϯͿƵƚŽŝŵŵƵŶĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘,ĂŶĚďŽŽŬŽĨĐůŝŶŝĐĂů
ŶĞƵƌŽůŽŐǇϭϭϯ͗ϭϰϲϱͲϭϰϲϴ
ϴϵ͘ :ŽƌĚĞZ͕^ŶĞǀĞD͕,ƵƚĐŚŝŶƐŽŶD͕ŵĂƵƐE͕&ŝŐĞŶƐĐŚĂƵz͕'ƌŝŵŶĞƐ';ϮϬϭϬͿdƌĂĐŬŝŶŐŽĨ
ƐĞƌƵŵϮϱͲŚǇĚƌŽǆǇǀŝƚĂŵŝŶůĞǀĞůƐĚƵƌŝŶŐϭϰǇĞĂƌƐŝŶĂƉŽƉƵůĂƚŝŽŶͲďĂƐĞĚƐƚƵĚǇĂŶĚĚƵƌŝŶŐϭϮ
ŵŽŶƚŚƐŝŶĂŶŝŶƚĞƌǀĞŶƚŝŽŶƐƚƵĚǇ͘ŵĞƌŝĐĂŶũŽƵƌŶĂůŽĨĞƉŝĚĞŵŝŽůŽŐǇϭϳϭ͗ϵϬϯͲϵϬϴ
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ϵϬ͘ <ĞĞƐĞǇ:;ϮϬϬϮͿΗƌŝƐŝƐΗŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĂŶŚŝƐƚŽƌŝĐĂůƉĞƌƐƉĞĐƚŝǀĞ͘DƵƐĐůĞΘŶĞƌǀĞ
Ϯϲ͗ϭͲϯ
ϵϭ͘ <ĞƵŶŐ͕ZŽďĞƐŽŶ<Z͕ŝĂƉƵĂ͕ZŽƐĞŶ:͕KΖŽŶŶŽƌ<͕'ŽůĚƐƚĞŝŶ:D͕EŽǁĂŬZ:;ϮϬϭϯͿ
>ŽŶŐͲƚĞƌŵďĞŶĞĨŝƚŽĨƌŝƚƵǆŝŵĂďŝŶDƵ^<ĂƵƚŽĂŶƚŝďŽĚǇŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐƉĂƚŝĞŶƚƐ͘:ŽƵƌŶĂůŽĨ
ŶĞƵƌŽůŽŐǇ͕ŶĞƵƌŽƐƵƌŐĞƌǇ͕ĂŶĚƉƐǇĐŚŝĂƚƌǇϴϰ͗ϭϰϬϳͲϭϰϬϵ
ϵϮ͘ <ŚŽƵƌǇ^͕^ŚĂƉŝƌĂ^͕ŝůďĞƌŵĂŶd͕DĞŬŽƌŝz͕,ĞƌƐŚŬŽz;ϮϬϭϯͿWƌŽŐƌĞƐƐŝǀĞŵƵůƚŝĨŽĐĂů
ůĞƵŬŽĞŶĐĞƉŚĂůŽƉĂƚŚǇŝŶĂŶ,/sͲŶĞŐĂƚŝǀĞƉĂƚŝĞŶƚĨŽůůŽǁŝŶŐƚƌĞĂƚŵĞŶƚǁŝƚŚƌŝƚƵǆŝŵĂď͘dŚĞ
/ƐƌĂĞůDĞĚŝĐĂůƐƐŽĐŝĂƚŝŽŶũŽƵƌŶĂů͗/D:ϭϱ͗ϯϮϭͲϯϮϮ
ϵϯ͘ <ŝƌĐŚŶĞƌd͕^ĐŚĂůŬĞ͕DĂƌǆ͕DƵůůĞƌͲ,ĞƌŵĞůŝŶŬ,<;ϭϵϴϵͿǀĂůƵĂƚŝŽŶŽĨƉƌŽŐŶŽƐƚŝĐĨĞĂƚƵƌĞƐ
ŝŶƚŚǇŵŝĐĞƉŝƚŚĞůŝĂůƚƵŵŽƌƐ͘dŚǇŵƵƐϭϰ͗ϭϵϱͲϮϬϯ
ϵϰ͘ <ŝƚƚŝǁĂƚĂŶĂƉĂŝƐĂŶt͕'ĂƵƚŚŝĞƌ<͕tŝůůŝĂŵƐD͕KŚ^:;ϮϬϬϯͿ&ĂƚŝŐƵĞŝŶDǇĂƐƚŚĞŶŝĂ'ƌĂǀŝƐ
ƉĂƚŝĞŶƚƐ͘dŚĞ:ŽƵƌŶĂůŽĨŶĞƵƌŽƐĐŝĞŶĐĞŶƵƌƐŝŶŐ͗ũŽƵƌŶĂůŽĨƚŚĞŵĞƌŝĐĂŶƐƐŽĐŝĂƚŝŽŶŽĨ
EĞƵƌŽƐĐŝĞŶĐĞEƵƌƐĞƐϯϱ͗ϴϳͲϵϯ͕ϭϬϲ
ϵϱ͘ <ůĞŝŶZ͕DĂƌǆ͕^ƚƌŽďĞůW͕^ĐŚĂůŬĞ͕Eŝǆt͕tŝůůĐŽǆE;ϮϬϭϯͿƵƚŽŝŵŵƵŶĞĂƐƐŽĐŝĂƚŝŽŶƐĂŶĚ
ĂƵƚŽĂŶƚŝďŽĚǇƐĐƌĞĞŶŝŶŐƐŚŽǁĨŽĐƵƐĞĚƌĞĐŽŐŶŝƚŝŽŶŝŶƉĂƚŝĞŶƚƐƵďŐƌŽƵƉƐǁŝƚŚŐĞŶĞƌĂůŝǌĞĚ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘,ƵŵĂŶŝŵŵƵŶŽůŽŐǇϳϰ͗ϭϭϴϰͲϭϭϵϯ
ϵϲ͘ <ŽŶĚŽ<;ϮϬϬϴͿKƉƚŝŵĂůƚŚĞƌĂƉǇĨŽƌƚŚǇŵŽŵĂ͘dŚĞũŽƵƌŶĂůŽĨŵĞĚŝĐĂůŝŶǀĞƐƚŝŐĂƚŝŽŶ͗:D/
ϱϱ͗ϭϳͲϮϴ
ϵϳ͘ <ŽƐƚĞƌĂͲWƌƵƐǌĐǌǇŬ͕<ĂŵŝŶƐŬĂ͕ƵƚŬŝĞǁŝĐǌD͕ŵĞƌǇŬͲ^ǌĂũĞǁƐŬĂ͕^ƚƌƵŐĂůƐŬĂͲǇŶŽǁƐŬĂ
D,͕sŝŶĐĞŶƚ͕<ǁŝĞĐŝŶƐŬŝ,;ϮϬϬϴͿDƵ^<ͲƉŽƐŝƚŝǀĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝƐƌĂƌĞŝŶƚŚĞWŽůŝƐŚ
ƉŽƉƵůĂƚŝŽŶ͘ƵƌŽƉĞĂŶũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͗ƚŚĞŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞƵƌŽƉĞĂŶ&ĞĚĞƌĂƚŝŽŶŽĨ
EĞƵƌŽůŽŐŝĐĂů^ŽĐŝĞƚŝĞƐϭϱ͗ϳϮϬͲϳϮϰ
ϵϴ͘ <ƵŵĂƌs͕<ĂŵŝŶƐŬŝ,:;ϮϬϭϭͿdƌĞĂƚŵĞŶƚŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ƵƌƌĞŶƚŶĞƵƌŽůŽŐǇĂŶĚ
ŶĞƵƌŽƐĐŝĞŶĐĞƌĞƉŽƌƚƐϭϭ͗ϴϵͲϵϲ
ϵϵ͘ <ƵƉĞƌƐŵŝƚŚD:;ϮϬϬϵͿKĐƵůĂƌŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ƚƌĞĂƚŵĞŶƚƐƵĐĐĞƐƐĞƐĂŶĚĨĂŝůƵƌĞƐŝŶƉĂƚŝĞŶƚƐ
ǁŝƚŚůŽŶŐͲƚĞƌŵĨŽůůŽǁͲƵƉ͘:ŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇϮϱϲ͗ϭϯϭϰͲϭϯϮϬ
ϭϬϬ͘ >Ăŝ,͕dƐĞŶŐ,&;ϮϬϭϬͿEĂƚŝŽŶǁŝĚĞƉŽƉƵůĂƚŝŽŶͲďĂƐĞĚĞƉŝĚĞŵŝŽůŽŐŝĐĂůƐƚƵĚǇŽĨŵǇĂƐƚŚĞŶŝĂ
ŐƌĂǀŝƐŝŶƚĂŝǁĂŶ͘EĞƵƌŽĞƉŝĚĞŵŝŽůŽŐǇϯϱ͗ϲϲͲϳϭ
ϭϬϭ͘ >ĂƌŽƐĞd>͕ŚĞŶz͕ĂŵĂƌŐŽ͕:ƌ͕͘>ĂŶŐŚĂŵŵĞƌ͕ZŽŵƵŶĚƐƚĂĚW͕DĂŝyD;ϮϬϭϯͿ&ĂĐƚŽƌƐ
ĂƐƐŽĐŝĂƚĞĚǁŝƚŚǀŝƚĂŵŝŶĚĞĨŝĐŝĞŶĐǇŝŶĂEŽƌǁĞŐŝĂŶƉŽƉƵůĂƚŝŽŶ͗ƚŚĞ,hEd^ƚƵĚǇ͘:ŽƵƌŶĂůŽĨ
ĞƉŝĚĞŵŝŽůŽŐǇĂŶĚĐŽŵŵƵŶŝƚǇŚĞĂůƚŚ
ϭϬϮ͘ >ĞWĂŶƐĞZ͕ĞƌƌŝŚͲŬŶŝŶ^;ϮϬϭϯͿƵƚŽŝŵŵƵŶĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĂƵƚŽĂŶƚŝďŽĚǇŵĞĐŚĂŶŝƐŵƐ
ĂŶĚŶĞǁĚĞǀĞůŽƉŵĞŶƚƐŽŶŝŵŵƵŶĞƌĞŐƵůĂƚŝŽŶ͘ƵƌƌĞŶƚŽƉŝŶŝŽŶŝŶŶĞƵƌŽůŽŐǇϮϲ͗ϱϲϵͲϱϳϲ
ϭϬϯ͘ >ĞĨǀĞƌƚ<͕ũŽƌŬŚŽůŵD;ϭϵϴϳͿŶƚŝďŽĚŝĞƐĂŐĂŝŶƐƚƚŚĞĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌŝŶŚĞŵĂƚŽůŽŐŝĐ
ĚŝƐŽƌĚĞƌƐ͗ŝŵƉůŝĐĂƚŝŽŶƐĨŽƌƚŚĞĚĞǀĞůŽƉŵĞŶƚŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐĂĨƚĞƌďŽŶĞŵĂƌƌŽǁ
ŐƌĂĨƚŝŶŐ͘dŚĞEĞǁŶŐůĂŶĚũŽƵƌŶĂůŽĨŵĞĚŝĐŝŶĞϯϭϳ͗ϭϳϬ
ϭϬϰ͘ >ĞŝƚĞD/͕:ĂĐŽď^͕sŝĞŐĂƐ^͕ŽƐƐŝŶƐ:͕ůŽǀĞƌ>͕DŽƌŐĂŶW͕ĞĞƐŽŶ͕tŝůůĐŽǆE͕sŝŶĐĞŶƚ
;ϮϬϬϴͿ/Ő'ϭĂŶƚŝďŽĚŝĞƐƚŽĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌƐŝŶΖƐĞƌŽŶĞŐĂƚŝǀĞΖŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ƌĂŝŶ͗
ĂũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇϭϯϭ͗ϭϵϰϬͲϭϵϱϮ
ϭϬϱ͘ >ĞŝƚĞD/͕^ƚƌŽďĞůW͕:ŽŶĞƐD͕DŝĐŬůĞŵ<͕DŽƌŝƚǌZ͕'ŽůĚZ͕EŝŬƐ,͕ĞƌƌŝŚͲŬŶŝŶ^͕^ĐĂƌĂǀŝůůŝ&͕
ĂŶĞůŚĂƐ͕DĂƌǆ͕EĞǁƐŽŵͲĂǀŝƐ:͕tŝůůĐŽǆE͕sŝŶĐĞŶƚ;ϮϬϬϱͿ&ĞǁĞƌƚŚǇŵŝĐĐŚĂŶŐĞƐŝŶ
DƵ^<ĂŶƚŝďŽĚǇͲƉŽƐŝƚŝǀĞƚŚĂŶŝŶDƵ^<ĂŶƚŝďŽĚǇͲŶĞŐĂƚŝǀĞD'͘ŶŶĂůƐŽĨŶĞƵƌŽůŽŐǇϱϳ͗ϰϰϰͲ
ϰϰϴ
ϭϬϲ͘ >ĞǁŝƐZ;ϮϬϭϯͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗EĞǁƚŚĞƌĂƉĞƵƚŝĐĂƉƉƌŽĂĐŚĞƐďĂƐĞĚŽŶƉĂƚŚŽƉŚǇƐŝŽůŽŐǇ͘
:ŽƵƌŶĂůŽĨƚŚĞŶĞƵƌŽůŽŐŝĐĂůƐĐŝĞŶĐĞƐϯϯϯ͗ϵϯͲϵϴ
ϭϬϳ͘ >ŝďŵĂŶZ͕ĞŶƐŽŶZ͕ŝŶďĞƌŐ<;ϮϬϬϮͿDǇĂƐƚŚĞŶŝĂŵŝŵŝĐŬŝŶŐǀĞƌƚĞďƌŽďĂƐŝůĂƌƐƚƌŽŬĞ͘:ŽƵƌŶĂů
ŽĨŶĞƵƌŽůŽŐǇϮϰϵ͗ϭϱϭϮͲϭϱϭϰ
ϭϬϴ͘ >ŝŶĚƐƚƌŽŵ:;ϭϵϳϳͿŶĂƐƐĂǇĨŽƌĂŶƚŝďŽĚŝĞƐƚŽŚƵŵĂŶĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌŝŶƐĞƌƵŵĨƌŽŵ
ƉĂƚŝĞŶƚƐǁŝƚŚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ůŝŶŝĐĂůŝŵŵƵŶŽůŽŐǇĂŶĚŝŵŵƵŶŽƉĂƚŚŽůŽŐǇϳ͗ϯϲͲϰϯ
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ϭϬϵ͘ >ŝŶĚƐƚƌŽŵ:;ϭϵϴϱͿ/ŵŵƵŶŽďŝŽůŽŐǇŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͕ĞǆƉĞƌŝŵĞŶƚĂůĂƵƚŽŝŵŵƵŶĞ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͕ĂŶĚ>ĂŵďĞƌƚͲĂƚŽŶƐǇŶĚƌŽŵĞ͘ŶŶƵĂůƌĞǀŝĞǁŽĨŝŵŵƵŶŽůŽŐǇϯ͗ϭϬϵͲϭϯϭ
ϭϭϬ͘ >ŝŶĚƐƚƌŽŵ:D͕ŝŶĂƌƐŽŶ>͕>ĞŶŶŽŶs͕^ĞǇďŽůĚD;ϭϵϳϲͿWĂƚŚŽůŽŐŝĐĂůŵĞĐŚĂŶŝƐŵƐŝŶ
ĞǆƉĞƌŝŵĞŶƚĂůĂƵƚŽŝŵŵƵŶĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘/͘/ŵŵƵŶŽŐĞŶŝĐŝƚǇŽĨƐǇŶŐĞŶĞŝĐŵƵƐĐůĞ
ĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌĂŶĚƋƵĂŶƚŝƚĂƚŝǀĞĞǆƚƌĂĐƚŝŽŶŽĨƌĞĐĞƉƚŽƌĂŶĚĂŶƚŝďŽĚǇͲƌĞĐĞƉƚŽƌ
ĐŽŵƉůĞǆĞƐĨƌŽŵŵƵƐĐůĞƐŽĨƌĂƚƐǁŝƚŚĞǆƉĞƌŝŵĞŶƚĂůĂƵƚŽŵŝŵŵƵŶĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘dŚĞ
:ŽƵƌŶĂůŽĨĞǆƉĞƌŝŵĞŶƚĂůŵĞĚŝĐŝŶĞϭϰϰ͗ϳϮϲͲϳϯϴ
ϭϭϭ͘ >ŝŶĚƐƚƌŽŵ:D͕^ĞǇďŽůĚD͕>ĞŶŶŽŶs͕tŚŝƚƚŝŶŐŚĂŵ^͕ƵĂŶĞ;ϭϵϳϲͿŶƚŝďŽĚǇƚŽ
ĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘WƌĞǀĂůĞŶĐĞ͕ĐůŝŶŝĐĂůĐŽƌƌĞůĂƚĞƐ͕ĂŶĚĚŝĂŐŶŽƐƚŝĐ
ǀĂůƵĞ͘EĞƵƌŽůŽŐǇϮϲ͗ϭϬϱϰͲϭϬϱϵ
ϭϭϮ͘ >ŽďŽ>:͕ZĞǇŶŽůĚƐ:D͕^ŶǇĚĞƌ>;ϮϬϭϯͿZŝƚƵǆŝŵĂďͲĂƐƐŽĐŝĂƚĞĚƉƌŽŐƌĞƐƐŝǀĞŵƵůƚŝĨŽĐĂů
ůĞƵŬŽĞŶĐĞƉŚĂůŽƉĂƚŚǇĂĨƚĞƌůƵŶŐƚƌĂŶƐƉůĂŶƚĂƚŝŽŶ͘dŚĞ:ŽƵƌŶĂůŽĨŚĞĂƌƚĂŶĚůƵŶŐ
ƚƌĂŶƐƉůĂŶƚĂƚŝŽŶ͗ƚŚĞŽĨĨŝĐŝĂůƉƵďůŝĐĂƚŝŽŶŽĨƚŚĞ/ŶƚĞƌŶĂƚŝŽŶĂů^ŽĐŝĞƚǇĨŽƌ,ĞĂƌƚdƌĂŶƐƉůĂŶƚĂƚŝŽŶ
ϯϮ͗ϳϱϮͲϳϱϯ
ϭϭϯ͘ >ŽǇĂŐĂͲZĞŶĚŽŶZz͕dĂǇůŽƌK͕<ŽǀĂů;ϮϬϭϯͿWƌŽŐƌĞƐƐŝǀĞŵƵůƚŝĨŽĐĂůůĞƵŬŽĞŶĐĞƉŚĂůŽƉĂƚŚǇ
ŝŶĂŚĞĂƌƚƚƌĂŶƐƉůĂŶƚƌĞĐŝƉŝĞŶƚĨŽůůŽǁŝŶŐƌŝƚƵǆŝŵĂďƚŚĞƌĂƉǇĨŽƌĂŶƚŝďŽĚǇͲŵĞĚŝĂƚĞĚƌĞũĞĐƚŝŽŶ͘
ŵĞƌŝĐĂŶũŽƵƌŶĂůŽĨƚƌĂŶƐƉůĂŶƚĂƚŝŽŶ͗ŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞŵĞƌŝĐĂŶ^ŽĐŝĞƚǇŽĨ
dƌĂŶƐƉůĂŶƚĂƚŝŽŶĂŶĚƚŚĞŵĞƌŝĐĂŶ^ŽĐŝĞƚǇŽĨdƌĂŶƐƉůĂŶƚ^ƵƌŐĞŽŶƐϭϯ͗ϭϬϳϱͲϭϬϳϵ
ϭϭϰ͘ >ƵĐĂƐZD͕WŽŶƐŽŶďǇ>͕ĞĂƌ<͕sĂůĞƌǇW͕WĞŶĚĞƌDW͕dĂǇůŽƌs͕<ŝůƉĂƚƌŝĐŬd:͕ǁǇĞƌd͕
ŽƵůƚŚĂƌĚ͕ŚĂƉŵĂŶ͕ǀĂŶĚĞƌDĞŝ/͕tŝůůŝĂŵƐ͕DĐDŝĐŚĂĞů:;ϮϬϭϭͿ^ƵŶĞǆƉŽƐƵƌĞĂŶĚ
ǀŝƚĂŵŝŶĂƌĞŝŶĚĞƉĞŶĚĞŶƚƌŝƐŬĨĂĐƚŽƌƐĨŽƌE^ĚĞŵǇĞůŝŶĂƚŝŽŶ͘EĞƵƌŽůŽŐǇϳϲ͗ϱϰϬͲϱϰϴ
ϭϭϱ͘ >ƵŽ:͕>ŝŶĚƐƚƌŽŵ:;ϮϬϭϮͿDǇĂƐƚŚĞŶŽŐĞŶŝĐŝƚǇŽĨƚŚĞŵĂŝŶŝŵŵƵŶŽŐĞŶŝĐƌĞŐŝŽŶĂŶĚ
ĞŶĚŽŐĞŶŽƵƐŵƵƐĐůĞŶŝĐŽƚŝŶŝĐĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌƐ͘ƵƚŽŝŵŵƵŶŝƚǇϰϱ͗ϮϰϱͲϮϱϮ
ϭϭϲ͘ DĂŚĞƌDD͕^ŚĞƉĂƌĚ:;ϮϬϬϱͿ/ŵĂŐŝŶŐŽĨƚŚǇŵŽŵĂ͘^ĞŵŝŶĂƌƐŝŶƚŚŽƌĂĐŝĐĂŶĚĐĂƌĚŝŽǀĂƐĐƵůĂƌ
ƐƵƌŐĞƌǇϭϳ͗ϭϮͲϭϵ
ϭϭϳ͘ DĂŶŝĂŽů,͕ůƐĂŝƐ͕>ŽƌĞŶƚǌĞŶZ͕KǁĞ:&͕sŝŬĞŶD<͕^ĂĞƚŚĞƌ,͕&ůĂŵ^d͕ƌĂƚŚĞŶ'͕
<ĂŵƉŵĂŶDd͕DŝĚŐĂƌĚZ͕ŚƌŝƐƚĞŶƐĞŶD͕ZŽŐŶĞƌƵĚ͕<ĞƌƚǇ͕'ŝůŚƵƐE͕dĂůůĂŬƐĞŶD͕>ŝĞ
͕,ĂƌďŽ,&;ϮϬϭϮͿ>ĂƚĞŽŶƐĞƚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚ,>ZϭΎϭϱ͗ϬϭŝŶƚŚĞ
EŽƌǁĞŐŝĂŶƉŽƉƵůĂƚŝŽŶ͘WůŽ^ŽŶĞϳ͗ĞϯϲϲϬϯ
ϭϭϴ͘ DĂƌǆ͕WĨŝƐƚĞƌ&͕^ĐŚĂůŬĞ͕^ĂƌƵŚĂŶͲŝƌĞƐŬĞŶĞůŝ'͕DĞůŵƐ͕^ƚƌŽďĞůW;ϮϬϭϯͿdŚĞĚŝĨĨĞƌĞŶƚ
ƌŽůĞƐŽĨƚŚĞƚŚǇŵƵƐŝŶƚŚĞƉĂƚŚŽŐĞŶĞƐŝƐŽĨƚŚĞǀĂƌŝŽƵƐŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐƐƵďƚǇƉĞƐ͘
ƵƚŽŝŵŵƵŶŝƚǇƌĞǀŝĞǁƐϭϮ͗ϴϳϱͲϴϴϰ
ϭϭϵ͘ DĞƌŝŐŐŝŽůŝDE͕ŝĂĨĂůŽŶŝ͕ůͲ,ĂǇŬ<͕ZŽǁŝŶ:͕dƵĐŬĞƌͲ>ŝƉƐĐŽŵď͕DĂƐƐĞǇ:D͕^ĂŶĚĞƌƐ
;ϮϬϬϯͿDǇĐŽƉŚĞŶŽůĂƚĞŵŽĨĞƚŝůĨŽƌŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĂŶĂŶĂůǇƐŝƐŽĨĞĨĨŝĐĂĐǇ͕ƐĂĨĞƚǇ͕ĂŶĚ
ƚŽůĞƌĂďŝůŝƚǇ͘EĞƵƌŽůŽŐǇϲϭ͗ϭϰϯϴͲϭϰϰϬ
ϭϮϬ͘ DĞƌŝŐŐŝŽůŝDE͕^ĂŶĚĞƌƐ;ϮϬϬϵͿƵƚŽŝŵŵƵŶĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĞŵĞƌŐŝŶŐĐůŝŶŝĐĂůĂŶĚ
ďŝŽůŽŐŝĐĂůŚĞƚĞƌŽŐĞŶĞŝƚǇ͘>ĂŶĐĞƚŶĞƵƌŽůŽŐǇϴ͗ϰϳϱͲϰϵϬ
ϭϮϭ͘ DŝĚŐĂƌĚZ;ϮϬϭϮͿ/ŶĐŝĚĞŶĐĞĂŶĚƉƌĞǀĂůĞŶĐĞŽĨŵƵůƚŝƉůĞƐĐůĞƌŽƐŝƐŝŶEŽƌǁĂǇ͘ĐƚĂŶĞƵƌŽůŽŐŝĐĂ
^ĐĂŶĚŝŶĂǀŝĐĂ^ƵƉƉůĞŵĞŶƚƵŵ͗ϯϲͲϰϮ
ϭϮϮ͘ DŽŶƚĞƌŽͲKĚĂƐƐŽD;ϮϬϬϲͿǇƐƉŚŽŶŝĂĂƐĨŝƌƐƚƐǇŵƉƚŽŵŽĨůĂƚĞͲŽŶƐĞƚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘
:ŽƵƌŶĂůŽĨŐĞŶĞƌĂůŝŶƚĞƌŶĂůŵĞĚŝĐŝŶĞϮϭ͗ϰͲϲ
ϭϮϯ͘ DŽŶƚŽŵŽůŝ͕ŝƚƚĞƌŝŽ͕WŝĐĐŽůŽ'͕ŝŽĐĐĂůĞZ͕&ĞƌƌĞƚƚŝss͕&ƌĂƚƚŝ͕ĞƌŐĂŵĂƐĐŚŝZ͕ŽƐŝs
;ϮϬϭϮͿƉŝĚĞŵŝŽůŽŐǇĂŶĚŐĞŽŐƌĂƉŚŝĐĂůǀĂƌŝĂƚŝŽŶŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶƚŚĞƉƌŽǀŝŶĐĞŽĨ
WĂǀŝĂ͕/ƚĂůǇ͘EĞƵƌŽĞƉŝĚĞŵŝŽůŽŐǇϯϴ͗ϭϬϬͲϭϬϱ
ϭϮϰ͘ DŽƌĞů͕&ĞƵŝůůĞƚͲ&ŝĞƵǆDE͕sĞƌŶĞƚͲĚĞƌ'ĂƌĂďĞĚŝĂŶ͕ZĂŝŵŽŶĚ&͕ΖŶŐůĞũĂŶ:͕ĂƚĂŝůůĞZ͕
^ĂŶǇ:͕ĂĐŚ:&;ϭϵϵϭͿƵƚŽĂŶƚŝďŽĚŝĞƐŝŶͲƉĞŶŝĐŝůůĂŵŝŶĞͲŝŶĚƵĐĞĚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗Ă
ĐŽŵƉĂƌŝƐŽŶǁŝƚŚŝĚŝŽƉĂƚŚŝĐŵǇĂƐƚŚĞŶŝĂĂŶĚƌŚĞƵŵĂƚŽŝĚĂƌƚŚƌŝƚŝƐ͘ůŝŶŝĐĂůŝŵŵƵŶŽůŽŐǇĂŶĚ
ŝŵŵƵŶŽƉĂƚŚŽůŽŐǇϱϴ͗ϯϭϴͲϯϯϬ
ϭϮϱ͘ DƵůůĞƌͲ,ĞƌŵĞůŝŶŬ,<͕DĂƌǆ;ϮϬϬϬͿdŚǇŵŽŵĂ͘ƵƌƌĞŶƚŽƉŝŶŝŽŶŝŶŽŶĐŽůŽŐǇϭϮ͗ϰϮϲͲϰϯϯ
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ϭϮϲ͘ DƵƐĐůĞ^ƚƵĚǇ';ϮϬϬϴͿƚƌŝĂůŽĨŵǇĐŽƉŚĞŶŽůĂƚĞŵŽĨĞƚŝůǁŝƚŚƉƌĞĚŶŝƐŽŶĞĂƐŝŶŝƚŝĂů
ŝŵŵƵŶŽƚŚĞƌĂƉǇŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘EĞƵƌŽůŽŐǇϳϭ͗ϯϵϰͲϯϵϵ
ϭϮϳ͘ DǇŐůĂŶĚ͕Ăƌůŝ:͕,ŽĨƐƚĂĚ,͕'ŝůŚƵƐE;ϭϵϵϭͿ,ĞĂƌƚŵƵƐĐůĞĂŶƚŝďŽĚŝĞƐŝŶŵǇĂƐƚŚĞŶŝĂ
ŐƌĂǀŝƐ͘ƵƚŽŝŵŵƵŶŝƚǇϭϬ͗ϮϲϯͲϮϲϳ
ϭϮϴ͘ DǇŐůĂŶĚ͕dǇƐŶĞƐK͕DĂƚƌĞZ͕sŽůƉĞW͕Ăƌůŝ:͕'ŝůŚƵƐE;ϭϵϵϮͿZǇĂŶŽĚŝŶĞƌĞĐĞƉƚŽƌ
ĂƵƚŽĂŶƚŝďŽĚŝĞƐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐƉĂƚŝĞŶƚƐǁŝƚŚĂƚŚǇŵŽŵĂ͘ŶŶĂůƐŽĨŶĞƵƌŽůŽŐǇϯϮ͗ϱϴϵͲ
ϱϵϭ
ϭϮϵ͘ EĂŐĂŶĞz͕^ƵǌƵŬŝ^͕^ƵǌƵŬŝE͕hƚƐƵŐŝƐĂǁĂ<;ϮϬϭϭͿĂƌůǇĂŐŐƌĞƐƐŝǀĞƚƌĞĂƚŵĞŶƚƐƚƌĂƚĞŐǇĂŐĂŝŶƐƚ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ƵƌŽƉĞĂŶŶĞƵƌŽůŽŐǇϲϱ͗ϭϲͲϮϮ
ϭϯϬ͘ EĂŐĂŶĞz͕^ƵǌƵŬŝ^͕^ƵǌƵŬŝE͕hƚƐƵŐŝƐĂǁĂ<;ϮϬϭϬͿdǁŽͲǇĞĂƌƚƌĞĂƚŵĞŶƚǁŝƚŚĐǇĐůŽƐƉŽƌŝŶĞ
ŵŝĐƌŽĞŵƵůƐŝŽŶĨŽƌƌĞƐƉŽŶĚĞƌŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐƉĂƚŝĞŶƚƐ͘ƵƌŽƉĞĂŶŶĞƵƌŽůŽŐǇϲϰ͗ϭϴϲͲϭϵϬ
ϭϯϭ͘ EĂŬĂŵƵƌĂ^͕<ĂŶĞŬŽ^͕^ŚŝŶĚĞ͕DŽƌŝƚĂ:͕&ƵũŝƚĂ<͕EĂŬĂŶŽ^͕<ƵƐĂŬĂ,;ϮϬϭϯͿWƌĞĚŶŝƐŽůŽŶĞͲ
ƐƉĂƌŝŶŐĞĨĨĞĐƚŽĨĐǇĐůŽƐƉŽƌŝŶƚŚĞƌĂƉǇĨŽƌǀĞƌǇĞůĚĞƌůǇƉĂƚŝĞŶƚƐǁŝƚŚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘
EĞƵƌŽŵƵƐĐƵůĂƌĚŝƐŽƌĚĞƌƐ͗EDϮϯ͗ϭϳϲͲϭϳϵ
ϭϯϮ͘ EŽƌǁŽŽĚ&͕ŚĂŶũĂůD͕,ŝůůD͕:ĂŵĞƐE͕:ƵŶŐďůƵƚŚ,͕<ǇůĞW͕KΖ^ƵůůŝǀĂŶ'͕WĂůĂĐĞ:͕ZŽďď^͕
tŝůůŝĂŵƐŽŶ͕,ŝůƚŽŶͲ:ŽŶĞƐ͕EĞůƐŽŶͲWŝĞƌĐǇ;ϮϬϭϯͿDǇĂƐƚŚĞŶŝĂŝŶƉƌĞŐŶĂŶĐǇ͗ďĞƐƚƉƌĂĐƚŝĐĞ
ŐƵŝĚĞůŝŶĞƐĨƌŽŵĂh<ŵƵůƚŝƐƉĞĐŝĂůƚǇǁŽƌŬŝŶŐŐƌŽƵƉ͘:ŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͕ŶĞƵƌŽƐƵƌŐĞƌǇ͕ĂŶĚ
ƉƐǇĐŚŝĂƚƌǇ
ϭϯϯ͘ EŽǁĂŬZ:͕ŝĐĂƉƵĂ͕ĞďĂƌĚĂƐƚE͕'ŽůĚƐƚĞŝŶ:D;ϮϬϭϭͿZĞƐƉŽŶƐĞŽĨƉĂƚŝĞŶƚƐǁŝƚŚ
ƌĞĨƌĂĐƚŽƌǇŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐƚŽƌŝƚƵǆŝŵĂď͗ĂƌĞƚƌŽƐƉĞĐƚŝǀĞƐƚƵĚǇ͘dŚĞƌĂƉĞƵƚŝĐĂĚǀĂŶĐĞƐŝŶ
ŶĞƵƌŽůŽŐŝĐĂůĚŝƐŽƌĚĞƌƐϰ͗ϮϱϵͲϮϲϲ
ϭϯϰ͘ KƐƐĞƌŵĂŶ<͕<ĂƉůĂŶ>/;ϭϵϱϮͿZĂƉŝĚĚŝĂŐŶŽƐƚŝĐƚĞƐƚĨŽƌŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ŝŶĐƌĞĂƐĞĚŵƵƐĐůĞ
ƐƚƌĞŶŐƚŚ͕ǁŝƚŚŽƵƚĨĂƐĐŝĐƵůĂƚŝŽŶƐ͕ĂĨƚĞƌŝŶƚƌĂǀĞŶŽƵƐĂĚŵŝŶŝƐƚƌĂƚŝŽŶŽĨĞĚƌŽƉŚŽŶŝƵŵ;ƚĞŶƐŝůŽŶͿ
ĐŚůŽƌŝĚĞ͘:ŽƵƌŶĂůŽĨƚŚĞŵĞƌŝĐĂŶDĞĚŝĐĂůƐƐŽĐŝĂƚŝŽŶϭϱϬ͗ϮϲϱͲϮϲϴ
ϭϯϱ͘ KǁĞ:&͕ĂůƚǀĞŝƚ<͕'ŝůŚƵƐE;ϮϬϬϲͿĂƵƐĞƐŽĨĚĞĂƚŚĂŵŽŶŐƉĂƚŝĞŶƚƐǁŝƚŚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ
ŝŶEŽƌǁĂǇďĞƚǁĞĞŶϭϵϱϭĂŶĚϮϬϬϭ͘:ŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͕ŶĞƵƌŽƐƵƌŐĞƌǇ͕ĂŶĚƉƐǇĐŚŝĂƚƌǇ
ϳϳ͗ϮϬϯͲϮϬϳ
ϭϯϲ͘ WĂůĂĐĞ:͕EĞǁƐŽŵͲĂǀŝƐ:͕>ĞĐŬǇ;ϭϵϵϴͿƌĂŶĚŽŵŝǌĞĚĚŽƵďůĞͲďůŝŶĚƚƌŝĂůŽĨƉƌĞĚŶŝƐŽůŽŶĞ
ĂůŽŶĞŽƌǁŝƚŚĂǌĂƚŚŝŽƉƌŝŶĞŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘DǇĂƐƚŚĞŶŝĂ'ƌĂǀŝƐ^ƚƵĚǇ'ƌŽƵƉ͘EĞƵƌŽůŽŐǇ
ϱϬ͗ϭϳϳϴͲϭϳϴϯ
ϭϯϳ͘ WĂůůĂǀĞƌ&͕ZŝǀŝĞƌĂW͕WŝĨĨĞƌ^͕ZŝĐĐŝĂƌĚŝZ͕ZŽŶŝZ͕KƌƌŝĐŽ͕ŽŶŝĨĂƚŝD;ϮϬϭϭͿŚĂŶŐĞŝŶ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐĞƉŝĚĞŵŝŽůŽŐǇŝŶdƌĞŶƚŽ͕/ƚĂůǇ͕ĂĨƚĞƌƚǁĞŶƚǇǇĞĂƌƐ͘EĞƵƌŽĞƉŝĚĞŵŝŽůŽŐǇ
ϯϲ͗ϮϴϮͲϮϴϳ
ϭϯϴ͘ WĂƐŶŽŽƌD͕tŽůĨĞ'/͕EĂƚŝŽŶƐ^͕dƌŝǀĞĚŝ:͕ĂƌŽŚŶZ:͕,ĞƌďĞůŝŶ>͕DĐsĞǇ͕ŝŵĂĐŚŬŝĞD͕
<ŝƐƐĞů:͕tĂůƐŚZ͕ŵĂƚŽ͕DŽǌĂĨĨĂƌd͕,ƵŶŐƐD͕ŚƵŝ>͕'ŽůĚƐƚĞŝŶ:͕EŽǀĞůůĂ^͕ƵƌŶƐd͕
WŚŝůůŝƉƐ>͕ůĂƵƐƐĞŶ'͕zŽƵŶŐ͕ĞƌƚŽƌŝŶŝd͕KŚ^;ϮϬϭϬͿůŝŶŝĐĂůĨŝŶĚŝŶŐƐŝŶDƵ^<ͲĂŶƚŝďŽĚǇ
ƉŽƐŝƚŝǀĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗Ăh͘^͘ĞǆƉĞƌŝĞŶĐĞ͘DƵƐĐůĞΘŶĞƌǀĞϰϭ͗ϯϳϬͲϯϳϰ
ϭϯϵ͘ WĂƚǁĂ,^͕ŚĂƵĚŚƌǇs͕<ĂƚǌďĞƌŐ,͕ZĂĞͲ'ƌĂŶƚ͕^Žzd;ϮϬϭϮͿǀŝĚĞŶĐĞͲďĂƐĞĚŐƵŝĚĞůŝŶĞ͗
ŝŶƚƌĂǀĞŶŽƵƐŝŵŵƵŶŽŐůŽďƵůŝŶŝŶƚŚĞƚƌĞĂƚŵĞŶƚŽĨŶĞƵƌŽŵƵƐĐƵůĂƌĚŝƐŽƌĚĞƌƐ͗ƌĞƉŽƌƚŽĨƚŚĞ
dŚĞƌĂƉĞƵƚŝĐƐĂŶĚdĞĐŚŶŽůŽŐǇƐƐĞƐƐŵĞŶƚ^ƵďĐŽŵŵŝƚƚĞĞŽĨƚŚĞŵĞƌŝĐĂŶĐĂĚĞŵǇŽĨ
EĞƵƌŽůŽŐǇ͘EĞƵƌŽůŽŐǇϳϴ͗ϭϬϬϵͲϭϬϭϱ
ϭϰϬ͘ WĞĚĞƌƐĞŶ'͕,ĂůůĂƐ:͕,ĂŶƐĞŶ<͕:ĞŶƐĞŶW͕'ĂŝƐƚ;ϮϬϭϯͿ>ĂƚĞͲŽŶƐĞƚŵǇĂƐƚŚĞŶŝĂŶŽƚŽŶƚŚĞ
ŝŶĐƌĞĂƐĞ͗ĂŶĂƚŝŽŶǁŝĚĞƌĞŐŝƐƚĞƌƐƚƵĚǇŝŶĞŶŵĂƌŬ͕ϭϵϵϲͲϮϬϬϵ͘ƵƌŽƉĞĂŶũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ
͗ƚŚĞŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞƵƌŽƉĞĂŶ&ĞĚĞƌĂƚŝŽŶŽĨEĞƵƌŽůŽŐŝĐĂů^ŽĐŝĞƚŝĞƐϮϬ͗ϯϬϵͲϯϭϰ
ϭϰϭ͘ WŚŝůůŝƉƐ>,͕ϮŶĚ͕dŽƌŶĞƌ:;ϭϵϵϲͿƉŝĚĞŵŝŽůŽŐŝĐĞǀŝĚĞŶĐĞĨŽƌĂĐŚĂŶŐŝŶŐŶĂƚƵƌĂůŚŝƐƚŽƌǇŽĨ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘EĞƵƌŽůŽŐǇϰϳ͗ϭϮϯϯͲϭϮϯϴ
ϭϰϮ͘ WŝƌƌŽŶƚŝd͕ZŝŶĂůĚŝW͕ĂƚŽĐĐŚŝW͕ǀŽůŝ͕ŝ^ĐŚŝŶŽ͕DĂƌĂŶŽW;ϮϬϬϮͿdŚǇŵŝĐůĞƐŝŽŶƐĂŶĚ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ŝĂŐŶŽƐŝƐďĂƐĞĚŽŶŵĞĚŝĂƐƚŝŶĂůŝŵĂŐŝŶŐĂŶĚƉĂƚŚŽůŽŐŝĐĂůĨŝŶĚŝŶŐƐ͘ĐƚĂ
ƌĂĚŝŽůŽŐŝĐĂϰϯ͗ϯϴϬͲϯϴϰ
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ϭϰϯ͘ WůŽŵƉ::͕,ƵŝũďĞƌƐD'͕ǀĂŶĚĞƌDĂĂƌĞů^D͕sĞƌƐĐŚƵƵƌĞŶ::;ϮϬϭϮͿWĂƚŚŽŐĞŶŝĐ/Ő'ϰƐƵďĐůĂƐƐ
ĂƵƚŽĂŶƚŝďŽĚŝĞƐŝŶDƵ^<ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ŶŶĂůƐŽĨƚŚĞEĞǁzŽƌŬĐĂĚĞŵǇŽĨ^ĐŝĞŶĐĞƐ
ϭϮϳϱ͗ϭϭϰͲϭϮϮ
ϭϰϰ͘ WŽŚĂŶŬĂD;ϮϬϭϮͿĐĞƚǇůĐŚŽůŝŶĞƐƚĞƌĂƐĞŝŶŚŝďŝƚŽƌƐ͗ĂƉĂƚĞŶƚƌĞǀŝĞǁ;ϮϬϬϴͲƉƌĞƐĞŶƚͿ͘ǆƉĞƌƚ
ŽƉŝŶŝŽŶŽŶƚŚĞƌĂƉĞƵƚŝĐƉĂƚĞŶƚƐϮϮ͗ϴϳϭͲϴϴϲ
ϭϰϱ͘ WŽůŝǌǌŝ͕,ƵƐŽŶ^D͕sŝŶĐĞŶƚ;ϮϬϬϬͿdĞƌĂƚŽŐĞŶƵƉĚĂƚĞ͗ŵĂƚĞƌŶĂůŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐĂƐĂ
ĐĂƵƐĞŽĨĐŽŶŐĞŶŝƚĂůĂƌƚŚƌŽŐƌǇƉŽƐŝƐ͘dĞƌĂƚŽůŽŐǇϲϮ͗ϯϯϮͲϯϰϭ
ϭϰϲ͘ WŽƐĂĚĂĚĞůĂWĂǌD͕'ƌŽĨƚ^;ϮϬϭϬͿZĂƌĞĚŝƐĞĂƐĞƐĞƉŝĚĞŵŝŽůŽŐǇ͘^ƉƌŝŶŐĞƌ͕ŽƌĚƌĞĐŚƚ͖EĞǁ
zŽƌŬ
ϭϰϳ͘ WŽƵůĂƐ<͕dƐŝďƌŝ͕<ŽŬůĂ͕WĂƉĂŶĂƐƚĂƐŝŽƵ͕dƐŽƵůŽƵĨŝƐd͕DĂƌŝŶŽƵD͕dƐĂŶƚŝůŝW͕
WĂƉĂƉĞƚƌŽƉŽƵůŽƐd͕dǌĂƌƚŽƐ^:;ϮϬϬϭͿƉŝĚĞŵŝŽůŽŐǇŽĨƐĞƌŽƉŽƐŝƚŝǀĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶ
'ƌĞĞĐĞ͘:ŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͕ŶĞƵƌŽƐƵƌŐĞƌǇ͕ĂŶĚƉƐǇĐŚŝĂƚƌǇϳϭ͗ϯϱϮͲϯϱϲ
ϭϰϴ͘ WƵŶŐĂZ͕^ĂǁĂĚĂD͕^ƚĂůďĞƌŐs;ϮϬϬϴͿůĞĐƚƌŽƉŚǇƐŝŽůŽŐŝĐĂůƐŝŐŶƐĂŶĚƚŚĞƉƌĞǀĂůĞŶĐĞŽĨ
ĂĚǀĞƌƐĞĞĨĨĞĐƚƐŽĨĂĐĞƚǇůĐŚŽůŝŶĞƐƚĞƌĂƐĞŝŶŚŝďŝƚŽƌƐŝŶƉĂƚŝĞŶƚƐǁŝƚŚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘DƵƐĐůĞ
ΘŶĞƌǀĞϯϳ͗ϯϬϬͲϯϬϳ
ϭϰϵ͘ YƵƌĞƐŚŝ/͕ŚŽƵĚŚƌǇD͕ŬďĂƌD^͕DŽŚĂŵŵĂĚz͕ŚƵĂ,͕zĂŚŝĂD͕hůĂƚŽǁƐŬŝ:͕
<ƌĞŶĚĞů͕>ĞƐŚŶĞƌZd;ϭϵϵϵͿWůĂƐŵĂĞǆĐŚĂŶŐĞǀĞƌƐƵƐŝŶƚƌĂǀĞŶŽƵƐŝŵŵƵŶŽŐůŽďƵůŝŶ
ƚƌĞĂƚŵĞŶƚŝŶŵǇĂƐƚŚĞŶŝĐĐƌŝƐŝƐ͘EĞƵƌŽůŽŐǇϱϮ͗ϲϮϵͲϲϯϮ
ϭϱϬ͘ ZĂƐƐůĞƌ͕DĂƌǆ'͕,ĂůůĞďĂĐŚ^͕<ĂůŝƐĐŚĞǁƐŬŝW͕ĂƵŵĂŶŶ/;ϮϬϭϭͿ>ŽŶŐͲƚĞƌŵƌĞƐƉŝƌĂƚŽƌǇ
ŵƵƐĐůĞĞŶĚƵƌĂŶĐĞƚƌĂŝŶŝŶŐŝŶƉĂƚŝĞŶƚƐǁŝƚŚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĨŝƌƐƚƌĞƐƵůƚƐĂĨƚĞƌĨŽƵƌŵŽŶƚŚƐ
ŽĨƚƌĂŝŶŝŶŐ͘ƵƚŽŝŵŵƵŶĞĚŝƐĞĂƐĞƐϮϬϭϭ͗ϴϬϴϲϬϳ
ϭϱϭ͘ ZĂǌĂǌŝĂŶE͕^ŚŽŬƌŝĂŶE͕ŽƐƚĂŶŝ͕DŽƌĂĚŝĂŶE͕dĂŚŵĂƐĞďŝ^;ϮϬϭϰͿ^ƚƵĚǇŽĨĨĂƚŝŐƵĞ
ĨƌĞƋƵĞŶĐǇĂŶĚŝƚƐĂƐƐŽĐŝĂƚŝŽŶǁŝƚŚƐŽĐŝŽĚĞŵŽŐƌĂƉŚŝĐĂŶĚĐůŝŶŝĐĂůǀĂƌŝĂďůĞƐŝŶƉĂƚŝĞŶƚƐǁŝƚŚ
ŵƵůƚŝƉůĞƐĐůĞƌŽƐŝƐ͘EĞƵƌŽƐĐŝĞŶĐĞƐϭϵ͗ϯϴͲϰϮ
ϭϱϮ͘ ZŝĐŚŵĂŶW͕ŐŝƵƐD;ϭϵϵϰͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ƉĂƚŚŽŐĞŶĞƐŝƐĂŶĚƚƌĞĂƚŵĞŶƚ͘^ĞŵŝŶĂƌƐŝŶ
ŶĞƵƌŽůŽŐǇϭϰ͗ϭϬϲͲϭϭϬ
ϭϱϯ͘ ZŽĚŐĂĂƌĚ͕EŝĞůƐĞŶ&͕ũƵƌƵƉZ͕^ŽŵŶŝĞƌ&͕'ĂŵŵĞůƚŽĨƚ^;ϭϵϴϳͿĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌ
ĂŶƚŝďŽĚǇŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ƉƌĞĚŽŵŝŶĂŶĐĞŽĨ/Ő'ƐƵďĐůĂƐƐĞƐϭĂŶĚϯ͘ůŝŶŝĐĂůĂŶĚ
ĞǆƉĞƌŝŵĞŶƚĂůŝŵŵƵŶŽůŽŐǇϲϳ͗ϴϮͲϴϴ
ϭϱϰ͘ ZŽŵŝ&͕Ăƌůŝ:͕'ŝůŚƵƐE;ϮϬϬϳͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐƉĂƚŝĞŶƚƐǁŝƚŚƌǇĂŶŽĚŝŶĞƌĞĐĞƉƚŽƌ
ĂŶƚŝďŽĚŝĞƐŚĂǀĞĚŝƐƚŝŶĐƚŝǀĞĐůŝŶŝĐĂůĨĞĂƚƵƌĞƐ͘ƵƌŽƉĞĂŶũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͗ƚŚĞŽĨĨŝĐŝĂů
ũŽƵƌŶĂůŽĨƚŚĞƵƌŽƉĞĂŶ&ĞĚĞƌĂƚŝŽŶŽĨEĞƵƌŽůŽŐŝĐĂů^ŽĐŝĞƚŝĞƐϭϰ͗ϲϭϳͲϲϮϬ
ϭϱϱ͘ ZŽŵŝ&͕'ŝůŚƵƐE͕Ăƌůŝ:;ϮϬϬϱͿDǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĐůŝŶŝĐĂů͕ŝŵŵƵŶŽůŽŐŝĐĂů͕ĂŶĚƚŚĞƌĂƉĞƵƚŝĐ
ĂĚǀĂŶĐĞƐ͘ĐƚĂŶĞƵƌŽůŽŐŝĐĂ^ĐĂŶĚŝŶĂǀŝĐĂϭϭϭ͗ϭϯϰͲϭϰϭ
ϭϱϲ͘ ZŽŵŝ&͕'ŝůŚƵƐE͕sĂƌŚĂƵŐ:͕DǇŬŝŶŐ͕Ăƌůŝ:;ϮϬϬϯͿdŚǇŵĞĐƚŽŵǇŝŶŶŽŶƚŚǇŵŽŵĂĞĂƌůǇͲ
ŽŶƐĞƚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶĐŽƌƌĞůĂƚŝŽŶǁŝƚŚĚŝƐĞĂƐĞƐĞǀĞƌŝƚǇĂŶĚŵƵƐĐůĞĂƵƚŽĂŶƚŝďŽĚŝĞƐ͘
ƵƌŽƉĞĂŶŶĞƵƌŽůŽŐǇϰϵ͗ϮϭϬͲϮϭϳ
ϭϱϳ͘ ZŽŵŝ&͕'ŝůŚƵƐE͕sĂƌŚĂƵŐ:͕DǇŬŝŶŐ͕^ŬĞŝĞ'K͕Ăƌůŝ:;ϮϬϬϯͿdŚǇŵĞĐƚŽŵǇĂŶĚ
ĂŶƚŝŵƵƐĐůĞĂŶƚŝďŽĚŝĞƐŝŶŶŽŶƚŚǇŵŽŵĂƚŽƵƐŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ŶŶĂůƐŽĨƚŚĞEĞǁzŽƌŬ
ĐĂĚĞŵǇŽĨ^ĐŝĞŶĐĞƐϵϵϴ͗ϰϴϭͲϰϵϬ
ϭϱϴ͘ ZŽŵŝ&͕<ƌŝƐƚŽĨĨĞƌƐĞŶ<͕Ăƌůŝ:͕'ŝůŚƵƐE;ϮϬϬϱͿdŚĞƌŽůĞŽĨĐŽŵƉůĞŵĞŶƚŝŶŵǇĂƐƚŚĞŶŝĂ
ŐƌĂǀŝƐ͗ƐĞƌŽůŽŐŝĐĂůĞǀŝĚĞŶĐĞŽĨĐŽŵƉůĞŵĞŶƚĐŽŶƐƵŵƉƚŝŽŶŝŶǀŝǀŽ͘:ŽƵƌŶĂůŽĨ
ŶĞƵƌŽŝŵŵƵŶŽůŽŐǇϭϱϴ͗ϭϵϭͲϭϵϰ
ϭϱϵ͘ ZŽŵŝ&͕^ŬĞŝĞ'K͕Ăƌůŝ:͕'ŝůŚƵƐE;ϮϬϬϬͿDƵƐĐůĞĂƵƚŽĂŶƚŝďŽĚŝĞƐŝŶƐƵďŐƌŽƵƉƐŽĨ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐƉĂƚŝĞŶƚƐ͘:ŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇϮϰϳ͗ϯϲϵͲϯϳϱ
ϭϲϬ͘ ZŽŵŝ&͕^ŬĞŝĞ'K͕'ŝůŚƵƐE͕Ăƌůŝ:;ϮϬϬϱͿ^ƚƌŝĂƚŝŽŶĂůĂŶƚŝďŽĚŝĞƐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗
ƌĞĂĐƚŝǀŝƚǇĂŶĚƉŽƐƐŝďůĞĐůŝŶŝĐĂůƐŝŐŶŝĨŝĐĂŶĐĞ͘ƌĐŚŝǀĞƐŽĨŶĞƵƌŽůŽŐǇϲϮ͗ϰϰϮͲϰϰϲ
ϭϲϭ͘ ZŽƚŚŵĂŶ<:;ϮϬϬϮͿƉŝĚĞŵŝŽůŽŐǇ͗ĂŶŝŶƚƌŽĚƵĐƚŝŽŶ͘KǆĨŽƌĚhŶŝǀĞƌƐŝƚǇWƌĞƐƐ͕EĞǁzŽƌŬ͕E͘z͘
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ϭϲϮ͘ ^ĂŬĂŐƵĐŚŝ,͕zĂŵĂƐŚŝƚĂ^͕,ŝƌĂŶŽd͕EĂŬĂũŝŵĂD͕<ŝŵƵƌĂ͕DĂĞĚĂz͕hĐŚŝŶŽD;ϮϬϭϮͿ
DǇĂƐƚŚĞŶŝĐĐƌŝƐŝƐƉĂƚŝĞŶƚƐǁŚŽƌĞƋƵŝƌĞŝŶƚĞŶƐŝǀĞĐĂƌĞƵŶŝƚŵĂŶĂŐĞŵĞŶƚ͘DƵƐĐůĞΘŶĞƌǀĞ
ϰϲ͗ϰϰϬͲϰϰϮ
ϭϲϯ͘ ^ĂŶĚĞƌƐ͕ůͲ^ĂůĞŵ<͕DĂƐƐĞǇ:D͕DĐŽŶǀŝůůĞ:͕sŝŶĐĞŶƚ;ϮϬϬϯͿůŝŶŝĐĂůĂƐƉĞĐƚƐŽĨDƵ^<
ĂŶƚŝďŽĚǇƉŽƐŝƚŝǀĞƐĞƌŽŶĞŐĂƚŝǀĞD'͘EĞƵƌŽůŽŐǇϲϬ͗ϭϵϳϴͲϭϵϴϬ
ϭϲϰ͘ ^ĂŶĚĞƌƐ͕ǀŽůŝ;ϮϬϭϬͿ/ŵŵƵŶŽƐƵƉƉƌĞƐƐŝǀĞƚŚĞƌĂƉŝĞƐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘
ƵƚŽŝŵŵƵŶŝƚǇϰϯ͗ϰϮϴͲϰϯϱ
ϭϲϱ͘ ^ĂŶĚĞƌƐ͕,Ăƌƚ/<͕DĂŶƚĞŐĂǌǌĂZ͕^ŚƵŬůĂ^^͕^ŝĚĚŝƋŝ͕ĞĂĞƚƐD,͕DĞůŵƐ͕EŝĐŽůůĞ
Dt͕^ŽůŽŵŽŶƐE͕ZŝĐŚŵĂŶW;ϮϬϬϴͿŶŝŶƚĞƌŶĂƚŝŽŶĂů͕ƉŚĂƐĞ///͕ƌĂŶĚŽŵŝǌĞĚƚƌŝĂůŽĨ
ŵǇĐŽƉŚĞŶŽůĂƚĞŵŽĨĞƚŝůŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘EĞƵƌŽůŽŐǇϳϭ͗ϰϬϬͲϰϬϲ
ϭϲϲ͘ ^ĂŶĚĞƌƐ͕^ŝĚĚŝƋŝ;ϮϬϬϴͿ>ĞƐƐŽŶƐĨƌŽŵƚǁŽƚƌŝĂůƐŽĨŵǇĐŽƉŚĞŶŽůĂƚĞŵŽĨĞƚŝůŝŶ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ŶŶĂůƐŽĨƚŚĞEĞǁzŽƌŬĐĂĚĞŵǇŽĨ^ĐŝĞŶĐĞƐϭϭϯϮ͗ϮϰϵͲϮϱϯ
ϭϲϳ͘ ^ĂŶƚĂŶĂ>͕'ŝǀŝĐĂ͕ĂŵĂĐŚŽ͕ƌŵĞĚ&ŽƌĐĞƐ/ŶƐƚŝƚƵƚĞŽĨW;ϮϬϬϮͿĞƐƚĐĂƐĞƐĨƌŽŵƚŚĞ&/W͗
ƚŚǇŵŽŵĂ͘ZĂĚŝŽŐƌĂƉŚŝĐƐ͗ĂƌĞǀŝĞǁƉƵďůŝĐĂƚŝŽŶŽĨƚŚĞZĂĚŝŽůŽŐŝĐĂů^ŽĐŝĞƚǇŽĨEŽƌƚŚŵĞƌŝĐĂ͕
/ŶĐϮϮ^ƉĞĐEŽ͗^ϵϱͲ^ϭϬϮ
ϭϲϴ͘ ^ĂƌƵŚĂŶͲŝƌĞƐŬĞŶĞůŝ'͕<ŝůŝĐ͕WĂƌŵĂŶz͕^ĞƌĚĂƌŽŐůƵW͕ĞǇŵĞĞƌ&;ϮϬϬϲͿ,>ͲY
ƉŽůǇŵŽƌƉŚŝƐŵŝŶdƵƌŬŝƐŚƉĂƚŝĞŶƚƐǁŝƚŚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘,ƵŵĂŶŝŵŵƵŶŽůŽŐǇϲϳ͗ϯϱϮͲϯϱϴ
ϭϲϵ͘ ^ĐŚůĞƐƐĞůŵĂŶ::͕^ƚŽůůĞǇW;ϭϵϴϮͿĂƐĞͲĐŽŶƚƌŽůƐƚƵĚŝĞƐ͗ĚĞƐŝŐŶ͕ĐŽŶĚƵĐƚ͕ĂŶĂůǇƐŝƐ͘KǆĨŽƌĚ
hŶŝǀĞƌƐŝƚǇWƌĞƐƐ͕EĞǁzŽƌŬ
ϭϳϬ͘ ^ĐŚŶĞŝĚĞƌͲ'ŽůĚ͕'ĂũĚŽƐW͕dŽǇŬĂ<s͕,ŽŚůĨĞůĚZZ;ϮϬϬϱͿŽƌƚŝĐŽƐƚĞƌŽŝĚƐĨŽƌŵǇĂƐƚŚĞŶŝĂ
ŐƌĂǀŝƐ͘dŚĞŽĐŚƌĂŶĞĚĂƚĂďĂƐĞŽĨƐǇƐƚĞŵĂƚŝĐƌĞǀŝĞǁƐ͗ϬϬϮϴϮϴ
ϭϳϭ͘ ^ĐŚŶĞŝĚĞƌͲ'ŽůĚ͕,ĂƌƚƵŶŐ,W͕'ŽůĚZ;ϮϬϬϲͿDǇĐŽƉŚĞŶŽůĂƚĞŵŽĨĞƚŝůĂŶĚƚĂĐƌŽůŝŵƵƐ͗ŶĞǁ
ƚŚĞƌĂƉĞƵƚŝĐŽƉƚŝŽŶƐŝŶŶĞƵƌŽŝŵŵƵŶŽůŽŐŝĐĂůĚŝƐĞĂƐĞƐ͘DƵƐĐůĞΘŶĞƌǀĞϯϰ͗ϮϴϰͲϮϵϭ
ϭϳϮ͘ ^ĐƵĚĞƌŝ&͕DĂƌŝŶŽD͕ŽůŽŶŶĂ>͕DĂŶŶĞůůĂ&͕ǀŽůŝ͕WƌŽǀĞŶǌĂŶŽ͕ĂƌƚŽĐĐŝŽŶŝ;ϮϬϬϮͿŶƚŝͲ
ƉϭϭϬĂƵƚŽĂŶƚŝďŽĚŝĞƐŝĚĞŶƚŝĨǇĂƐƵďƚǇƉĞŽĨΗƐĞƌŽŶĞŐĂƚŝǀĞΗŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐǁŝƚŚƉƌŽŵŝŶĞŶƚ
ŽĐƵůŽďƵůďĂƌŝŶǀŽůǀĞŵĞŶƚ͘>ĂďŽƌĂƚŽƌǇŝŶǀĞƐƚŝŐĂƚŝŽŶ͖ĂũŽƵƌŶĂůŽĨƚĞĐŚŶŝĐĂůŵĞƚŚŽĚƐĂŶĚ
ƉĂƚŚŽůŽŐǇϴϮ͗ϭϭϯϵͲϭϭϰϲ
ϭϳϯ͘ ^ŝŵƉƐŽŶ^͕:ƌ͕͘ůŝǌǌĂƌĚ>͕KƚĂŚĂůW͕sĂŶĚĞƌDĞŝ/͕dĂǇůŽƌ;ϮϬϭϭͿ>ĂƚŝƚƵĚĞŝƐƐŝŐŶŝĨŝĐĂŶƚůǇ
ĂƐƐŽĐŝĂƚĞĚǁŝƚŚƚŚĞƉƌĞǀĂůĞŶĐĞŽĨŵƵůƚŝƉůĞƐĐůĞƌŽƐŝƐ͗ĂŵĞƚĂͲĂŶĂůǇƐŝƐ͘:ŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͕
ŶĞƵƌŽƐƵƌŐĞƌǇ͕ĂŶĚƉƐǇĐŚŝĂƚƌǇϴϮ͗ϭϭϯϮͲϭϭϰϭ
ϭϳϰ͘ ^ŝŵƐ'W͕^ŚŝŽŶŽ,͕tŝůůĐŽǆE͕^ƚŽƚƚ/;ϮϬϬϭͿ^ŽŵĂƚŝĐŚǇƉĞƌŵƵƚĂƚŝŽŶĂŶĚƐĞůĞĐƚŝŽŶŽĨĐĞůůƐ
ŝŶƚŚǇŵŝĐŐĞƌŵŝŶĂůĐĞŶƚĞƌƐƌĞƐƉŽŶĚŝŶŐƚŽĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘:ŽƵƌŶĂů
ŽĨŝŵŵƵŶŽůŽŐǇϭϲϳ͗ϭϵϯϱͲϭϵϰϰ
ϭϳϱ͘ ^ŬĞŝĞ'K͕ƉŽƐƚŽůƐŬŝ^͕ǀŽůŝ͕'ŝůŚƵƐE͕/ůůĂ/͕,ĂƌŵƐ>͕,ŝůƚŽŶͲ:ŽŶĞƐ͕DĞůŵƐ͕
sĞƌƐĐŚƵƵƌĞŶ:͕,ŽƌŐĞ,t͕ƵƌŽƉĞĂŶ&ĞĚĞƌĂƚŝŽŶŽĨEĞƵƌŽůŽŐŝĐĂů^;ϮϬϭϬͿ'ƵŝĚĞůŝŶĞƐĨŽƌ
ƚƌĞĂƚŵĞŶƚŽĨĂƵƚŽŝŵŵƵŶĞŶĞƵƌŽŵƵƐĐƵůĂƌƚƌĂŶƐŵŝƐƐŝŽŶĚŝƐŽƌĚĞƌƐ͘ƵƌŽƉĞĂŶũŽƵƌŶĂůŽĨ
ŶĞƵƌŽůŽŐǇ͗ƚŚĞŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞƵƌŽƉĞĂŶ&ĞĚĞƌĂƚŝŽŶŽĨEĞƵƌŽůŽŐŝĐĂů^ŽĐŝĞƚŝĞƐϭϳ͗ϴϵϯͲ
ϵϬϮ
ϭϳϲ͘ ^ŬĞŝĞ'K͕DǇŐůĂŶĚ͕Ăƌůŝ:͕'ŝůŚƵƐE;ϭϵϵϱͿdŝƚŝŶĂŶƚŝďŽĚŝĞƐŝŶƉĂƚŝĞŶƚƐǁŝƚŚůĂƚĞŽŶƐĞƚ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĐůŝŶŝĐĂůĐŽƌƌĞůĂƚŝŽŶƐ͘ƵƚŽŝŵŵƵŶŝƚǇϮϬ͗ϵϵͲϭϬϰ
ϭϳϳ͘ ^ŽůĞŝŵĂŶŝ͕DŽĂǇǇĞƌŝ͕ŬŚŽŶĚǌĂĚĞŚ^͕^ĂĚĂƚƐĂĨĂǀŝD͕dĂǀĂŬŽůŝ^ŚĂůŵĂŶŝ,͕^ŽůƚĂŶǌĂĚĞŚ
;ϮϬϬϰͿ&ƌĞƋƵĞŶĐǇŽĨŵǇĂƐƚŚĞŶŝĐĐƌŝƐŝƐŝŶƌĞůĂƚŝŽŶƚŽƚŚǇŵĞĐƚŽŵǇŝŶŐĞŶĞƌĂůŝǌĞĚŵǇĂƐƚŚĞŶŝĂ
ŐƌĂǀŝƐ͗ĂϭϳͲǇĞĂƌĞǆƉĞƌŝĞŶĐĞ͘DŶĞƵƌŽůŽŐǇϰ͗ϭϮ
ϭϳϴ͘ ^ŽŵŵĞƌE͕^ŝŐŐ͕DĞůŵƐ͕tĞůůĞƌD͕^ĐŚĞƉĞůŵĂŶŶ<͕,ĞƌǌĂƵs͕ŝĐŚŐĂŶƐ:;ϭϵϵϳͿKĐƵůĂƌ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ƌĞƐƉŽŶƐĞƚŽůŽŶŐͲƚĞƌŵŝŵŵƵŶŽƐƵƉƉƌĞƐƐŝǀĞƚƌĞĂƚŵĞŶƚ͘:ŽƵƌŶĂůŽĨ
ŶĞƵƌŽůŽŐǇ͕ŶĞƵƌŽƐƵƌŐĞƌǇ͕ĂŶĚƉƐǇĐŚŝĂƚƌǇϲϮ͗ϭϱϲͲϭϲϮ
ϭϳϵ͘ ^ŽŵŶŝĞƌ&;ϭϵϵϯͿůŝŶŝĐĂůŝŵƉůĞŵĞŶƚĂƚŝŽŶŽĨĂŶƚŝͲĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌĂŶƚŝďŽĚŝĞƐ͘:ŽƵƌŶĂů
ŽĨŶĞƵƌŽůŽŐǇ͕ŶĞƵƌŽƐƵƌŐĞƌǇ͕ĂŶĚƉƐǇĐŚŝĂƚƌǇϱϲ͗ϰϵϲͲϱϬϰ
ϭϴϬ͘ ^ŽŵŶŝĞƌ&͕<ĞŝĚŝŶŐE͕WĂƵůƐŽŶK;ϭϵϵϭͿƉŝĚĞŵŝŽůŽŐǇŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶĞŶŵĂƌŬ͘
ůŽŶŐŝƚƵĚŝŶĂůĂŶĚĐŽŵƉƌĞŚĞŶƐŝǀĞƉŽƉƵůĂƚŝŽŶƐƵƌǀĞǇ͘ƌĐŚŝǀĞƐŽĨŶĞƵƌŽůŽŐǇϰϴ͗ϳϯϯͲϳϯϵ
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ϭϴϭ͘ ^ƉŝůůĂŶĞ:͕,ĂǇǁĂƌĚD͕,ŝƌƐĐŚEW͕dĂǇůŽƌ͕<ƵůůŵĂŶŶD͕,ŽǁĂƌĚZ^;ϮϬϭϯͿdŚǇŵĞĐƚŽŵǇ͗
ƌŽůĞŝŶƚŚĞƚƌĞĂƚŵĞŶƚŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘:ŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇϮϲϬ͗ϭϳϵϴͲϭϴϬϭ
ϭϴϮ͘ ^ƚĂŶŐŚĞůůŝŶŝs͕ŽŐůŝĂŶĚƌŽZ&͕ĚĞ'ŝŽƌŐŝŽZ͕ĂƌďĂƌĂ'͕^ĂůǀŝŽůŝ͕ŽƌŝŶĂůĚĞƐŝZ;ϮϬϬϳͿŚƌŽŶŝĐ
ŝŶƚĞƐƚŝŶĂůƉƐĞƵĚŽͲŽďƐƚƌƵĐƚŝŽŶ͗ŵĂŶŝĨĞƐƚĂƚŝŽŶƐ͕ŶĂƚƵƌĂůŚŝƐƚŽƌǇĂŶĚŵĂŶĂŐĞŵĞŶƚ͘
EĞƵƌŽŐĂƐƚƌŽĞŶƚĞƌŽůŽŐǇĂŶĚŵŽƚŝůŝƚǇ͗ƚŚĞŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞƵƌŽƉĞĂŶ'ĂƐƚƌŽŝŶƚĞƐƚŝŶĂů
DŽƚŝůŝƚǇ^ŽĐŝĞƚǇϭϵ͗ϰϰϬͲϰϱϮ
ϭϴϯ͘ ^ƚŽƌŵͲDĂƚŚŝƐĞŶ;ϭϵϲϲͿƉŝĚĞŵŝŽůŽŐŝĐĂůĂŶĚƉƌŽŐŶŽƐƚŝĐĂůĂƐƉĞĐƚƐŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶ
EŽƌǁĂǇ͘ŶŶĂůƐŽĨƚŚĞEĞǁzŽƌŬĐĂĚĞŵǇŽĨ^ĐŝĞŶĐĞƐϭϯϱ͗ϰϯϭͲϰϯϱ
ϭϴϰ͘ ^ƚŽƌŵͲDĂƚŚŝƐĞŶ;ϭϵϴϰͿƉŝĚĞŵŝŽůŽŐǇŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶEŽƌǁĂǇ͘ĐƚĂŶĞƵƌŽůŽŐŝĐĂ
^ĐĂŶĚŝŶĂǀŝĐĂϳϬ͗ϮϳϰͲϮϴϰ
ϭϴϱ͘ ^ƵǌƵŬŝ^͕ĂďĂ͕<ĂŝĚĂ<͕hƚƐƵŐŝƐĂǁĂ<͕<ŝƚĂz͕dƐƵŐĂǁĂ:͕KŐĂǁĂ'͕EĂŐĂŶĞz͕<ƵǁĂŶĂD͕
^ƵǌƵŬŝE;ϮϬϭϯͿĂƌĚŝĂĐŝŶǀŽůǀĞŵĞŶƚƐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐĂƐƐŽĐŝĂƚĞĚǁŝƚŚĂŶƚŝͲ<ǀϭ͘ϰ
ĂŶƚŝďŽĚŝĞƐ͘ƵƌŽƉĞĂŶũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͗ƚŚĞŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞƵƌŽƉĞĂŶ&ĞĚĞƌĂƚŝŽŶŽĨ
EĞƵƌŽůŽŐŝĐĂů^ŽĐŝĞƚŝĞƐ
ϭϴϲ͘ ^ƵǌƵŬŝ^͕^ĂƚŽŚd͕zĂƐƵŽŬĂ,͕,ĂŵĂŐƵĐŚŝz͕dĂŶĂŬĂ<͕<ĂǁĂŬĂŵŝz͕^ƵǌƵŬŝE͕<ƵǁĂŶĂD
;ϮϬϬϱͿEŽǀĞůĂƵƚŽĂŶƚŝďŽĚŝĞƐƚŽĂǀŽůƚĂŐĞͲŐĂƚĞĚƉŽƚĂƐƐŝƵŵĐŚĂŶŶĞů<ǀϭ͘ϰŝŶĂƐĞǀĞƌĞĨŽƌŵŽĨ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘:ŽƵƌŶĂůŽĨŶĞƵƌŽŝŵŵƵŶŽůŽŐǇϭϳϬ͗ϭϰϭͲϭϰϵ
ϭϴϳ͘ ^ƵǌƵŬŝ^͕hƚƐƵŐŝƐĂǁĂ<͕EĂŐĂŶĞz͕^ĂƚŽŚd͕<ƵǁĂŶĂD͕^ƵǌƵŬŝE;ϮϬϭϭͿůŝŶŝĐĂůĂŶĚ
ŝŵŵƵŶŽůŽŐŝĐĂůĚŝĨĨĞƌĞŶĐĞƐďĞƚǁĞĞŶĞĂƌůǇĂŶĚůĂƚĞͲŽŶƐĞƚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶ:ĂƉĂŶ͘:ŽƵƌŶĂů
ŽĨŶĞƵƌŽŝŵŵƵŶŽůŽŐǇϮϯϬ͗ϭϰϴͲϭϱϮ
ϭϴϴ͘ ^ƵǌƵŬŝ^͕hƚƐƵŐŝƐĂǁĂ<͕EĂŐĂŶĞz͕^ƵǌƵŬŝE;ϮϬϭϭͿdŚƌĞĞƚǇƉĞƐŽĨƐƚƌŝĂƚŝŽŶĂůĂŶƚŝďŽĚŝĞƐŝŶ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ƵƚŽŝŵŵƵŶĞĚŝƐĞĂƐĞƐϮϬϭϭ͗ϳϰϬϱϴϯ
ϭϴϵ͘ ^ƵǌƵŬŝ^͕hƚƐƵŐŝƐĂǁĂ<͕^ƵǌƵŬŝE;ϮϬϭϯͿKǀĞƌůŽŽŬĞĚŶŽŶͲŵŽƚŽƌƐǇŵƉƚŽŵƐŝŶŵǇĂƐƚŚĞŶŝĂ
ŐƌĂǀŝƐ͘:ŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͕ŶĞƵƌŽƐƵƌŐĞƌǇ͕ĂŶĚƉƐǇĐŚŝĂƚƌǇϴϰ͗ϵϴϵͲϵϵϰ
ϭϵϬ͘ ^ƵǌƵŬŝ^͕hƚƐƵŐŝƐĂǁĂ<͕zŽƐŚŝŬĂǁĂ,͕DŽƚŽŵƵƌĂD͕DĂƚƐƵďĂƌĂ^͕zŽŬŽǇĂŵĂ<͕EĂŐĂŶĞz͕
DĂƌƵƚĂd͕^ĂƚŽŚd͕^ĂƚŽ,͕<ƵǁĂŶĂD͕^ƵǌƵŬŝE;ϮϬϬϵͿƵƚŽŝŵŵƵŶĞƚĂƌŐĞƚƐŽĨŚĞĂƌƚĂŶĚ
ƐŬĞůĞƚĂůŵƵƐĐůĞƐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ƌĐŚŝǀĞƐŽĨŶĞƵƌŽůŽŐǇϲϲ͗ϭϯϯϰͲϭϯϯϴ
ϭϵϭ͘ dĂŬĂŵŽƌŝD͕DŽƚŽŵƵƌĂD͕&ƵŬƵĚŽŵĞd͕zŽƐŚŝŬĂǁĂ,;ϮϬϬϳͿƵƚŽĂŶƚŝďŽĚŝĞƐĂŐĂŝŶƐƚDϭ
ŵƵƐĐĂƌŝŶŝĐĂĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌŝŶŵǇĂƐƚŚĞŶŝĐĚŝƐŽƌĚĞƌƐ͘ƵƌŽƉĞĂŶũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͗
ƚŚĞŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞƵƌŽƉĞĂŶ&ĞĚĞƌĂƚŝŽŶŽĨEĞƵƌŽůŽŐŝĐĂů^ŽĐŝĞƚŝĞƐϭϰ͗ϭϮϯϬͲϭϮϯϱ
ϭϵϮ͘ dĞůůĞǌͲĞŶƚĞŶŽ:&͕ZĞŵĞƐͲdƌŽĐŚĞ:D͕'ĂƌĐŝĂͲZĂŵŽƐ'͕ƐƚĂŶŽů͕'ĂƌĚƵŶŽͲƐƉŝŶŽǌĂ:;ϮϬϬϭͿ
WƌŽŐŶŽƐƚŝĐĨĂĐƚŽƌƐŽĨƚŚǇŵĞĐƚŽŵǇŝŶƉĂƚŝĞŶƚƐǁŝƚŚŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĂĐŽŚŽƌƚŽĨϭϯϮ
ƉĂƚŝĞŶƚƐ͘ƵƌŽƉĞĂŶŶĞƵƌŽůŽŐǇϰϲ͗ϭϳϭͲϭϳϳ
ϭϵϯ͘ dĞƌŵƐĂƌĂƐĂďW͕<Ăƚŝƌũŝ;ϮϬϭϮͿKƉƉŽƌƚƵŶŝƐƚŝĐŝŶĨĞĐƚŝŽŶƐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐƚƌĞĂƚĞĚǁŝƚŚ
ŵǇĐŽƉŚĞŶŽůĂƚĞŵŽĨĞƚŝů͘:ŽƵƌŶĂůŽĨŶĞƵƌŽŝŵŵƵŶŽůŽŐǇϮϰϵ͗ϴϯͲϴϱ
ϭϵϰ͘ dŚŽŵĂƐ͕DĂǇĞƌ^͕'ƵŶŐŽƌz͕^ǁĂƌƵƉZ͕tĞďƐƚĞƌ͕ŚĂŶŐ/͕ƌĂŶŶĂŐĂŶd,͕&ŝŶŬD͕
ZŽǁůĂŶĚ>W;ϭϵϵϳͿDǇĂƐƚŚĞŶŝĐĐƌŝƐŝƐ͗ĐůŝŶŝĐĂůĨĞĂƚƵƌĞƐ͕ŵŽƌƚĂůŝƚǇ͕ĐŽŵƉůŝĐĂƚŝŽŶƐ͕ĂŶĚƌŝƐŬ
ĨĂĐƚŽƌƐĨŽƌƉƌŽůŽŶŐĞĚŝŶƚƵďĂƚŝŽŶ͘EĞƵƌŽůŽŐǇϰϴ͗ϭϮϱϯͲϭϮϲϬ
ϭϵϱ͘ dŚŽƌůĂĐŝƵƐ^͕Ăƌůŝ:͕ZŝŝƐĞd͕DĂƚƌĞZ͕:ŽŚŶƐĞŶ,:;ϭϵϴϵͿƐƐŽĐŝĂƚĞĚĚŝƐŽƌĚĞƌƐŝŶŵǇĂƐƚŚĞŶŝĂ
ŐƌĂǀŝƐ͗ĂƵƚŽŝŵŵƵŶĞĚŝƐĞĂƐĞƐĂŶĚƚŚĞŝƌƌĞůĂƚŝŽŶƚŽƚŚǇŵĞĐƚŽŵǇ͘ĐƚĂŶĞƵƌŽůŽŐŝĐĂ
^ĐĂŶĚŝŶĂǀŝĐĂϴϬ͗ϮϵϬͲϮϵϱ
ϭϵϲ͘ dŽŵŝǇĂŵĂE͕,ŽŶĚĂK͕dƐƵďĂŵŽƚŽD͕/ŶŽƵĞ͕^ƵŵŝŬĂǁĂ,͕<ƵƌŝǇĂŵĂ<͕<ƵƐƵŵŽƚŽD͕
:ŽŚŬŽŚd͕EĂŬĂŵƵƌĂ,;ϮϬϬϵͿŶƚĞƌŝŽƌŵĞĚŝĂƐƚŝŶĂůƚƵŵŽƌƐ͗ĚŝĂŐŶŽƐƚŝĐĂĐĐƵƌĂĐǇŽĨdĂŶĚ
DZ/͘ƵƌŽƉĞĂŶũŽƵƌŶĂůŽĨƌĂĚŝŽůŽŐǇϲϵ͗ϮϴϬͲϮϴϴ
ϭϵϳ͘ dŽƌŬŝůĚƐĞŶK͕'ƌǇƚƚĞŶE͕ĂƌƐĞƚŚ:͕DǇŚƌ<D͕<ĂŵƉŵĂŶDd;ϮϬϭϮͿDŽŶƚŚŽĨďŝƌƚŚĂƐĂƌŝƐŬ
ĨĂĐƚŽƌĨŽƌŵƵůƚŝƉůĞƐĐůĞƌŽƐŝƐ͗ĂŶƵƉĚĂƚĞ͘ĐƚĂŶĞƵƌŽůŽŐŝĐĂ^ĐĂŶĚŝŶĂǀŝĐĂ^ƵƉƉůĞŵĞŶƚƵŵ͗ϱϴͲϲϮ
ϭϵϴ͘ dŽƌŵŽĞŚůĞŶ>D͕WĂƐĐƵǌǌŝZD;ϮϬϬϴͿdŚǇŵŽŵĂ͕ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͕ĂŶĚŽƚŚĞƌƉĂƌĂŶĞŽƉůĂƐƚŝĐ
ƐǇŶĚƌŽŵĞƐ͘,ĞŵĂƚŽůŽŐǇͬŽŶĐŽůŽŐǇĐůŝŶŝĐƐŽĨEŽƌƚŚŵĞƌŝĐĂϮϮ͗ϱϬϵͲϱϮϲ
ϭϵϵ͘ dƌŝƉĞƉŝ'͕:ĂŐĞƌ<:͕ĞŬŬĞƌ&t͕ŽĐĐĂůŝ;ϮϬϭϬͿ^ĞůĞĐƚŝŽŶďŝĂƐĂŶĚŝŶĨŽƌŵĂƚŝŽŶďŝĂƐŝŶĐůŝŶŝĐĂů
ƌĞƐĞĂƌĐŚ͘EĞƉŚƌŽŶůŝŶŝĐĂůƉƌĂĐƚŝĐĞϭϭϱ͗ĐϵϰͲϵϵ
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ϮϬϬ͘ dƌŝƉĞƉŝ'͕:ĂŐĞƌ<:͕ĞŬŬĞƌ&t͕ŽĐĐĂůŝ;ϮϬϭϬͿ^ƚƌĂƚŝĨŝĐĂƚŝŽŶĨŽƌĐŽŶĨŽƵŶĚŝŶŐͲͲƉĂƌƚϭ͗ƚŚĞ
DĂŶƚĞůͲ,ĂĞŶƐǌĞůĨŽƌŵƵůĂ͘EĞƉŚƌŽŶůŝŶŝĐĂůƉƌĂĐƚŝĐĞϭϭϲ͗ĐϯϭϳͲϯϮϭ
ϮϬϭ͘ dƐŝĂŵĂůŽƐW͕<ŽƌĚĂƐ'͕<ŽŬůĂ͕WŽƵůĂƐ<͕dǌĂƌƚŽƐ^:;ϮϬϬϵͿƉŝĚĞŵŝŽůŽŐŝĐĂůĂŶĚ
ŝŵŵƵŶŽůŽŐŝĐĂůƉƌŽĨŝůĞŽĨŵƵƐĐůĞͲƐƉĞĐŝĨŝĐŬŝŶĂƐĞŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶ'ƌĞĞĐĞ͘ƵƌŽƉĞĂŶ
ũŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͗ƚŚĞŽĨĨŝĐŝĂůũŽƵƌŶĂůŽĨƚŚĞƵƌŽƉĞĂŶ&ĞĚĞƌĂƚŝŽŶŽĨEĞƵƌŽůŽŐŝĐĂů
^ŽĐŝĞƚŝĞƐϭϲ͗ϵϮϱͲϵϯϬ
ϮϬϮ͘ ǀĂŶĂƌƚĞů^͕ZĞƉƉŝŶŐͲtƵƚƐ:t͕ǀĂŶ,ŽŽŐŵŽĞĚ͕ůĞŝũĞŶďĞƌŐ'͕ǀĂŶZŝĞůW>͕&ƌĂŶƐĞŶ:
;ϮϬϭϯͿƐƐŽĐŝĂƚŝŽŶďĞƚǁĞĞŶĨĂƚŝŐƵĞĂŶĚƉĂŝŶŝŶƌŚĞƵŵĂƚŽŝĚĂƌƚŚƌŝƚŝƐ͗ĚŽĞƐƉĂŝŶƉƌĞĐĞĚĞ
ĨĂƚŝŐƵĞŽƌĚŽĞƐĨĂƚŝŐƵĞƉƌĞĐĞĚĞƉĂŝŶ͍ƌƚŚƌŝƚŝƐĐĂƌĞΘƌĞƐĞĂƌĐŚϲϱ͗ϴϲϮͲϴϲϵ
ϮϬϯ͘ sĂƉŚŝĂĚĞƐD^͕ŚĂƚƚŝDd͕>ĞƐƐĞƌZ>;ϮϬϭϮͿKĐƵůĂƌŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͘ƵƌƌĞŶƚŽƉŝŶŝŽŶŝŶ
ŽƉŚƚŚĂůŵŽůŽŐǇϮϯ͗ϱϯϳͲϱϰϮ
ϮϬϰ͘ sŝŶĐĞŶƚ;ϮϬϬϴͿƵƚŽĂŶƚŝďŽĚŝĞƐŝŶŶĞƵƌŽŵƵƐĐƵůĂƌƚƌĂŶƐŵŝƐƐŝŽŶĚŝƐŽƌĚĞƌƐ͘ŶŶĂůƐŽĨ/ŶĚŝĂŶ
ĐĂĚĞŵǇŽĨEĞƵƌŽůŽŐǇϭϭ͗ϭϰϬͲϭϰϱ
ϮϬϱ͘ sŝŶĐĞŶƚ͕ůŽǀĞƌ>͕ƵĐŬůĞǇ͕'ƌŝŵůĞǇǀĂŶƐ:͕ZŽƚŚǁĞůůWD͕^ƵƌǀĞǇh<D';ϮϬϬϯͿǀŝĚĞŶĐĞ
ŽĨƵŶĚĞƌĚŝĂŐŶŽƐŝƐŽĨŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐŝŶŽůĚĞƌƉĞŽƉůĞ͘:ŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ͕ŶĞƵƌŽƐƵƌŐĞƌǇ͕
ĂŶĚƉƐǇĐŚŝĂƚƌǇϳϰ͗ϭϭϬϱͲϭϭϬϴ
ϮϬϲ͘ sŝŶĐĞŶƚ͕EĞǁƐŽŵͲĂǀŝƐ:;ϭϵϴϱͿĐĞƚǇůĐŚŽůŝŶĞƌĞĐĞƉƚŽƌĂŶƚŝďŽĚǇĂƐĂĚŝĂŐŶŽƐƚŝĐƚĞƐƚĨŽƌ
ŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ƌĞƐƵůƚƐŝŶϭϱϯǀĂůŝĚĂƚĞĚĐĂƐĞƐĂŶĚϮϵϲϳĚŝĂŐŶŽƐƚŝĐĂƐƐĂǇƐ͘:ŽƵƌŶĂůŽĨ
ŶĞƵƌŽůŽŐǇ͕ŶĞƵƌŽƐƵƌŐĞƌǇ͕ĂŶĚƉƐǇĐŚŝĂƚƌǇϰϴ͗ϭϮϰϲͲϭϮϱϮ
ϮϬϳ͘ sŝŶĐĞŶƚ͕tĂƚĞƌƐW͕>ĞŝƚĞD/͕:ĂĐŽďƐŽŶ>͕<ŽŶĞĐǌŶǇ/͕ŽƐƐŝŶƐ:͕ĞĞƐŽŶ;ϮϬϭϮͿŶƚŝďŽĚŝĞƐ
ŝĚĞŶƚŝĨŝĞĚďǇĐĞůůͲďĂƐĞĚĂƐƐĂǇƐŝŶŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐĂŶĚĂƐƐŽĐŝĂƚĞĚĚŝƐĞĂƐĞƐ͘ŶŶĂůƐŽĨƚŚĞ
EĞǁzŽƌŬĐĂĚĞŵǇŽĨ^ĐŝĞŶĐĞƐϭϮϳϰ͗ϵϮͲϵϴ
ϮϬϴ͘ tĞďĞƌ<W͕^ƚƌĂƵŵĂŶŶ;ϮϬϭϯͿEĞƵƌŽͲŽƉŚƚŚĂůŵŽůŽŐǇƵƉĚĂƚĞ͘:ŽƵƌŶĂůŽĨŶĞƵƌŽůŽŐǇ
ϮϬϵ͘ tĞŶĚĞůů>͕>ĞǀŝŶĞ:D;ϮϬϭϭͿDǇĂƐƚŚĞŶŝĐĐƌŝƐŝƐ͘dŚĞEĞƵƌŽŚŽƐƉŝƚĂůŝƐƚϭ͗ϭϲͲϮϮ
ϮϭϬ͘ tŽŶŐ^,͕,ƵĚĂ^͕sŝŶĐĞŶƚ͕WůĂŶƚ'd;ϮϬϭϰͿKĐƵůĂƌŵǇĂƐƚŚĞŶŝĂŐƌĂǀŝƐ͗ĐŽŶƚƌŽǀĞƌƐŝĞƐĂŶĚ
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